Bibliografía Seleccionada


Bibliografía Basica de Bioética

• Aristóteles: Etica a Nicómano.
• Apel, K-O- Teoría de la verdad y ética del discurso. Paidós. 1991.
• Bankowski Z. y Levine R.J., Ethics and Research on Human Subjects International Guidelines: Proceedings of he XXVII CIOMS Conference Geneva, Switzerland. 7-9 November 1990. CIOMS.1991.
• Bankowski Z. y Bryant J.H., Health Policy, Ethics and Human Values:An international Dialogue XVIIIth .CIOMS Round Table Conference. CIOMS. 1985.
• Bankowski Z. y Howard Jones, Human Experimentation and Medical Ethics: XVth CIOMS Round Table Conference. CIOMS.1982.
• Beauchamp, Tom L. y Childress, James F.; Principles of Biomedical Ethics. Oxford University Press. 1994.
• Beauchamp, Tom L. y Walters LeRoy; Contemporary Issues in Bioethics. Wadsworth Publishing Company. 1994.
• Beauchamp, Tom; Philosophical Ethics. An Introduction to Moral Philosophy. Mc. Graw-Hill, Inc. 1991.
• Bióetica y Legislación Tomo 1 y 2. Nordan Comunidad. 1993.
• Bondolfi, Alberto y otros; Vent anni di Bioética. Fondazione Lanza, Gregoriana Librería Editrice. 1990.
• Brock Dan W.; Life and Death. Philosophical Essays in Biomedical Ethics. Cambridge University Press. 1993.
• Buchanan, James M.; Cálculo del consenso. Editorial Espasa-Calpe, S.A. 1993.
• Callahan Sidney y Callahan Daniel; Abortion Understanding Differences. Plenum Press. 1984.
• Castillo Valery y Mugarra Torca; Etica, política, derecho y situaciones de muerte; Ediciones rectorado de la Universidad Central de Venezuela. 1991.
• CIOMS y otros; Medical Ethics and Medical Education. CIOMS. 1981.
• Cortina, Adela; Etica Mínima, Editorial Technos. 1992.
• Council of Europe; Ethics and Human Genetics. Council of Europe. 1994.
• Drane , James F.; Becoming a Good Doctor: the Place of Virtue and Character in Medical Ethics. Sheed & Ward. 1988.
• Drane, James; Clinical Biothics: Theory and Practice in Medical-Ethical Decision Making. Sheed & Ward. 1994.
• Engelhardt, Tristram; The Foundations of Bioethics. Oxford University Press. 1986.
• Engelhardt, Tristam; The Foundations of Bioethics: Second Edition. Oxford University Press. 1996.
• Etique et Recherche Biomédicale: Rapport 1992-1993. La Documentation Francaise.
• Federación Internacional de Universidades Católicas; La vida humana origen y desarrollo: Reflexiones bioéticas de científicos y Moralistas. Instituto Borja de Bioética. 1989.
• Frondizi, Risieri; ¿Qué son los valores?. Introducción a la axiología. Fondo de Cultura Económica. Breviarios. 1993.
• Fuenzalida Puelma Hernán y otros; Aportes de la ética y el desarrollo del SIDA. Organización Panamericana de la Salud. 1991.
• Gafo, Javier; Dilemas éticos de la medicina actual – Volumen 1,2, 3, 4, 5, 6 y 7 . Publicaciones de la Universidad Pontificia Comillas. Madrid. 1989.
• Gracia, Diego; Primum non nocere. El principio de no maleficencia como fundamento de la ética médica. Discurso para la recepción pública de Académico electo,Madrid. 1990.
• Gracia, Diego; Fundamentos de Bioética. Eudema Universidad, Manuales. 1989.
• Gracia, Diego; Procedimientos de decisión clínica. Eudema Universidad, Textos de Apoyo. 1991.
• Instituto de Bioética; Fundación de Ciencias de la Salud. Informe sobre clonación: En las Fronteras de la vida. Madrid, Ediciones Doce Calles S.L., 1999.
• Jonas, Hans; El Principio de responsabilidad. Ensayo de una ética para la civilización tecnológica. Editorial Herder. 1995.
• Jonas Howard y Bankowski Z.; Medical Experimentation and The Protection of Human Rights: XIIth CIOMS Round Table Conference. CIOMS. 1979.
• Kant, Immanuel; Fundamentación de la Metafísica de las Costumbres. Espasa-Calpe.1989.
• Levine, Robert; Ethics and Regulation of Clinical Research. Yaler University Press. 1988.
• Lolas S., Fernando; Notas al margen. ensayos. Editorial Cuatro Vientos, Santiago, Chile. 1985.
• Lolas S., Fernando(Editor); Vejez y envejecimiento en América Latina y el Caribe- Aspectos demográficos y bioéticos. Universidad de Chile. Vicerrectoría Académica, Santiago, 1996.
• Lolas S., Fernando; Más allá del cuerpo . Editorial Andrés Bello, Santiago, Chile. 1997.
• Lolas S., Fernando; Bioética/Bioethics: el diálogo moral en las ciencias de la vida. Editorial Universitaria, Santiago, Chile. 1998.
• Lolas S., Fernando; Bioética y antropología médica. Editorial Mediterráneo, Santiago, Chile. 1999.
• Mac-Intyre, Alasdair; After Virtue. University of Notre Dame Press. 1984.
•Mac- Intire, Alasdair; Historia de la ética. Editorial Paidós Básica. 1991.
• Organización Panamericana de la Salud; Bioética. Temas y perspectivas. 1990.
• Pellegrino Edmund y Thomasma David; For The Patient´s Good: The Restoration of Beneficence in Health Care. Oxford University Press. 1988.
• Pessini, Leocir; Eutanasia e América Latina: Teología Moral na América Latina. Editora Santuário. 1990.
• Proyecto Genoma Humano. Fundación BBV. 1991.
• Rawls, J.; Sobre las libertades. Editorial Paidós Ibérica. 1990.
• Rawls, J. ; Justicia como equidad y otros ensayos. Editorial Tecnos. 1986.
• Romeo Casabona, Carlos María; Genética Humana. Fundamentos para el estudio de los efectos sociales de las investigaciones sobre el genoma humano. Universidad de Deusto. Fundación BBv. 1995.
• Sen, Amartya; Sobre ética y economía. Alianza Editorial. 1989.
• Singer, Peter; Applied Ethics. Oxford Readings in Philosophy. 1986.
• Sosa, Nicolás M. Etica Ecológica: necesidad, posibilidad, justificación y debate. Madrid, Universidad Libertarius, 1990.
• Veatch, Robert; Cross Cultural Perpectives in Medical Ethics: Readings. Jones and Barlett Publishers. 1989.
• Weber, Max; Etica protestante y espíritu del capitalismo, Traducción de Luis Legaz Lacambra. Ediciones Península. 1994.
• Wittgenstein, Ludwing; Conferencia sobre ética: con dos comentarios sobre la teoría del valor Introducción de Manuel Cruz. Paidós/I.C.E. – U.A.B. 1989

Volver


Etica y Envejecimiento

•Bedell, S., Pelle, D., Maher, P., & Clearly, P. (1986). Do-not-resuscitate orders for critically ill patients in the hospital: How are they used and what is their impact? Journal of the American Medical Association, 256(2), 233-237.
• Bermel, J. (1983). Guidelines for nursing homes raise some questions. Hastings Center Report. Dec; 13(6): 3.
• Binstock, R.H., Post, S.G. & Whitehouse, P.J. (Eds.), Dementia and aging: Ethics, values, and policy choices (pp. 153-170). Baltimore:Johns Hopkins University Press.
• Blasszauer, B. (1994). Institutional care of the elderly. Hastings Center Report.
• Brock, I.G., et al; (1994). Age and organ transplantation (letter, comment). CMAJ, Jan.
• Burgess, M. (1993). The medicalization of dying. The Journal of Medicine and Philosophy, 18, 269-279.
• Callahan, D. (1987). Setting limits: Medical goals in an aging society. New York:Simon & Schuster.
• Callahan, D. (1987). Terminating treatment: age as a standard. [Excerpt from his book, Setting Limits: Medical Goals in an Aging Society, Simon and Schuster; 1987]. Hastings Center Report. Oct/Nov; 17(5): 21-25.
• Callahan, D. (1990). Rationing medical progress: The way to affordable health care. The New England Journal of Medicine, 332(25), 1810-1813.
• Callahan, D. (1990). What kind of life? The limits of medical progress. New York:Simon & Schuster.
• Callahan, D. (1990). Why we must set limits. In P. Homer & M. Holstein (Eds.), A good old age: The paradox of setting limits (pp.23-36). New York:Simon and Schuster.
• Callahan, D.; Topinkova, E.; ter Meulen, R. (1994). Caring for an aging world: allocating scarce resources. Hastings Center Report. Sep-Oct; 24(5): 3.
• Callahan, D. (1994). Setting limits: a response. Gerontologist, Jun.
• Christiansen, D. (1974). Dignity in aging. Hastings Center Report 4(1): 6-8, Feb.
• Cofer, M.J. (1998). How to avoid age bias. Nurs. Manage, Nov.
• Coleman, D. (1999). Home services or euthanasia: at the heart of the debate. Caring. Jul;18(7):16-8, 20-1.
• Creedon, M.A. (1985). Ethical perspectives on health policy for an aging society. Thought. Jun; 60(237): 196-204.
• Daniels, N. (1988). Am I my parents´ keeper? An essay on justice between the young and the old. New York:Oxford University Press.
• DeRenzo, E. (1994). Surrogate decision making for severely cognitively impaired research subjects: the continuing debate. Cambridge Quarterly of Healthcare Ethic, Fall; 3(4): 539-548.
• Dixon, K.M. (1994). Oppressive limits: Callahan's foundation myth. Journal of Medicine and Philosophy. Dec; 19(6): 613-617.
• Doolittle, N.O.; Herrick, C.A. (1992). Ethics in aging: a decision-making paradigm. Educational Gerontology, Jun; 18(4): 395-408.
• Dubler, N. (1994). Current ethical issues in aging: introduction. Generations (American Society on Aging), Winter; 18(4): 5-8.
• Emanuel, L., Barry, M., Stoeckle, J., Ettelson, L., & Emmanuel, E. (1991). Advance directives for medical care: A case for greater use. The New England Journal of Medicine, 314(1), 14-20.
• High, D.M. (1992). Research with Alzheimer´s disease subjects: informed consent and proxy deision making. Journal of the American Geriatrics Society, Sep.
• Hope, T. (1997). Aging, research and families. [Editorial]. Journal of Medical Ethics. Oct; 23(5): 267-268.
• Jackson, R.; Carlos, A. (1991). Getting ready for the PSDA: what are hospitals and nursing homes doing? Journal of Clinical Ethics. Fall; 2(3): 177-181.
• Jennings, B.; Callahan, D.; Caplan, A.L. (1988). Ethical challenges of chronic illness. Hastings Center Report. Feb/Mar; 18(1): S1-S16.
• Johnson, P.R. (1988). Allocation and aging: a review and response to Callahan's Setting Limits. Linacre Quarterly. Nov; 55(4): 57-63.
• Kapp, M.S. (1990). Law and aging: special persons, special treatment? [Book review essay]. Law, Medicine and Health Care. Fall; 18(3): 290-292.
• Kaufman, S.R. (1995). Decision making, responsibility, and advocacy in geriatric medicine: physician dilemmas with elderly in the community. Gerontologist, Aug.
• King, Nancy (1996). Making Sense of Advance Directives (rev. ed.), Georgetown University Press: Washington, DC (1996).
• Koop, C.E. Ethical imperatives: responding to the aging patient. Saint Louis University Law Journal. Spring; 33(3): 569-573.
• Lo. B. (1995). Improving care near the end of life. Journal of the American Medical Association, 274 1634-35.
• Lonergan, E.T.; Krevans, J.R. A national agenda for research on aging. New England Journal of Medicine. Jun 20; 324(25): 1825-1828.
• Macklin, R. (1994). Ethical principles in the conduct of menopause research. Exp Gerontol, May.
• Mezey, M.; Kluger, M.; Maislin, G.; Mittelman, M. (1996). Life-sustaining treatment decisions by spouses of patients with Alzheimer's disease. Journal of the American Geriatrics Society. Feb; 44(2): 144-150.
• Moody, H.R. (1994). Four scenarios for an aging society. Hastings Center Report. Sep-Oct; 24(5): 32-35.
• Muller, MT, et al; (1998). Euthanasia and assisted suicide: facts, figures and fancies with special regard to old age. Drugs Aging, Sep.
• Murphy, T.F. (1986). A cure for aging? Journal of Medicine and Philosophy. Aug; 11(3): 237-255.
• Paulson, R.J., et al; (1994). Pregnancies in post-menopausal women. Oocyte donation to women of advanced reproductive age: "How old is too old?". Hum Reprod, Apr.
• Post, S.G.; Whitehouse, P.J. (1995). Fairhill guidelines on ethics of the care of people with Alzheimer's disease: a clinical summary. Journal of the American Geriatrics Society. Dec; 43(12): 1423-1429.
• Quill, T. (1991). Death and dignity: A case of individualized decision-making. The New England Journal of Medicine, 324(10), 691-694.
• Quill, T. (1993). Doctor, I want to die. Will you help me? Journal of the American Medical Association, 270(7), 870-873.
• Rich, B. (1997). Prospective autonomy and critical interests: A narrative defense of the moral authority of advanced directives. Cambrige Quarterly of Healthcare Ethics 6 (2), 138-147.
• Rikkert, Marcel G.M. Olde; ten Have, Henk A.M.J.; Hoefnagels, Willibrord H.L. (1996). Informed consent in biomedical studies on aging: survey of four journals. BMJ (British Medical Journal). Nov 2; 313(7065): 1117.
• Rowland, A.B. (1983). Age discrimination in retirement: In search of an alternative. American Journal of Law and Medicine, 8(4), 433-480.
• Schark, S., et al; (1996). Age as a basis for healthcare rationing. Arguments against agism. Drugs Aging, Dec.
• Schneiderman, L.J. (1994). Medical futility and aging: ethical implications. Generations (American Society on Aging), Winter; 18(4): 61-65.
• Schwartz, R.L. (1989). Setting limits on autonomy: saving money in an aging society. Saint Louis University Law Journal. Spring; 33(3): 617-630.
• Sikula, A Sr., et al; (1994). Are age and ethics related? J. Psychol, Nov.
• Solomon, M.Z. et.al. (1993). Decision near the end of life: Professional views on life sustaining treatments. American Journal of Public Health 83. 14-23.
• van den Boer van den Berg JM; (1997). [Towards a more humane care for the elderly. Ethical reflection] (Tijdschr Gerontol Geriatr, Oct.
• Veatch, R.M. (1988). Justice and the economics of terminal illness. Hastings Center Report, 18(4), 34-40.
• Vidalis, A., et al; (1998). Euthanasia in Greece: moral and ethical dilemmas. Aging (Milano), Apr.
• Wicclair, M.R. (1993). Ethics and the elderly. New York:Oxford University Press.

Volver


Clonación

 

1) Forum (Genova) 1999 Jul-Dec;9(3 Suppl 3):99-105

Bioethics, biotechnology products and humans: europe between the skilled theseus and the labyrinth-MinotaurOs syndrome.

Frati P

Facolt di Legge, Universit di Macerata, e IRCCS Neuromed, Pozzilli, Isernia.

Following the approval on May 1998 of the European Union Common position no. 19/98 regarding the legal protection of biotechnological inventions, the debate on bioethical aspects of biotechnologies is increased. The European Union document clearly protects the patentability of inventions (that concerns more than a particular plant or animal variety or a single procedure if they are of industrial interest), but not the finding or discovery of that is in the nature, e.g. a gene. Some safeguards (the dignity and integrity of the person and of the human embryo, the plant diversity, etc.) and exclusions from patentability (plant and animal varieties, processes for the production of plants or animals, the human body at any stage of growth, cloning of human beings, modifications of germ line, use of human embryos for industrial or commercial purposes as well as the inventions whose publication or exploitation would offend against public policy or morality, according to the Article 53a of the European Patenting Convention) are also indicated. Ethical issues discussed include the nature of human life and its protection, the safeguard of plant-animal biological diversity, the safeguard of human dignity and nature, whereas on several aspects (e. g. limits of the use of genetic material, xenotransplantation, etc.) the Parliament Assembly of the Council of Europe has requested a discussion or a moratorium (April, 1999). In this case an evaluation on the basis of the ethical beneficial principles should be performed and society should decide whether to master technologies and emulate the positive action of the hero Theseus against the Labyrinth-Minotaur syndrome or to renounce or OmisuseO technologies like Daedalus and Icarus, who met a tragic end.

2) Nat Med 1999 Sep;5(9):975-7

Human therapeutic cloning.

Lanza RP, Cibelli JB, West MD

Tissue Engineering and Transplant Medicine, Advanced Cell Technology, One Innovation Drive, Worcester, Massachusetts 01605, USA. rlanza@advancedcell.com

Somatic cell nuclear 'reprogramming' in livestock species is now routine in many laboratories. Here, Robert Lanza, Jose Cibelli and Michael West discuss how these techniques may soon be used to clone genetically matched cells and tissues for transplantation into patients suffering from a wide range of disorders that result from tissue loss or dysfunction.

3) Nature 1999 Jul 8;400(6740):103

European embryology experts offer to advise on ethics of cloning.

Abbott A

4) Nature 1999 May 27;399(6734):297

Guidelines point the way on genetics ethics.

Wertz DC

  • Comment on: Nature 1999 Mar 18;398(6724):175
  • Comment on: Nature 1999 Mar 18;398(6724):179

5) Law Hum Genome Rev 1998 Jul-Dec;(9):251-3

[An additional protocol to the Convention for the Protection of Human Rights and Human Dignity with regard to the Application of Biology and Medicine on the prohibition of the cloning of human beings, 6 November 1997].

6) Law Hum Genome Rev 1998 Jul-Dec;(9):91-110

[Human cloning. The biological fundamentals and an ethical-legal assessment].

Eser A, Fruhwald W, Honnefelder L, Markl H, Reiter J, Tanner W, Winnacker EL

Following a description of the cloning process and how this might be used in humans, the authors examine the possibility of human cloning in the light of recognised ethical principles. They also address the question of whether current national and international laws are sufficient to prevent such practices.

7) Hum Reprod Update 1998 Nov-Dec;4(6):791-811

How identical would cloned children be? An understanding essential to the ethical debate.

Edwards RG, Beard HK

Human Reproduction Journals, Moor Barns Farm, Coton, Cambridge, UK.

The ban on human cloning in many countries worldwide is founded on an assumption that cloned children will be identical to each other and to their nuclear donor. This paper explores the scientific basis for this assumption, considering both the principles and practice of cloning in animals and comparing genetic and epigenetic variation in potential human clones with that in monozygotic twins.

8) Hum Reprod Update 1998 Nov-Dec;4(6):787-90

Is cloning the absolute evil?

Hottois G

Universite Libre de Bruxelles, CRIB, Brussels, Belgium.

9) Cad Saude Publica 1999;15 Suppl 1:51-64

The Dolly case, the Polly drug, and the morality of human cloning.

Schramm FR

Departamento de Ciencias Sociais, Escola Nacional de Saude Publica, Fundacao Oswaldo Cruz, Rua Leopoldo Bulhoes, 1480, Rio de Janeiro, RJ 21041-210, Brasil.

The year 1996 witnessed the cloning of the lamb Dolly, based on the revolutionary somatic cell nuclear transfer (SCNT) technique, developed by researchers from the Roslin Institute in Edinburgh, Scotland. This fact marked a relevant biotechnoscientific innovation, with probable significant consequences in the field of public health, since in principle it allows for expanding possibilities for the reproductive autonomy of infertile couples and carriers of diseases of mitochondrial origin. This article expounds on 1) the experiment's technical data and the theoretical implications for the biological sciences; 2) the public's perception thereof and the main international documents aimed at the legal and moral regulation of the technique; and 3) the moral arguments for and against cloning, from the point of view of consequentialist moral theory. We conclude that in the current stage of the debate on the morality of cloning, in which there are no cogent deontological arguments either for or against, weighing the probability of risks and benefits is the only reasonable way of dealing with the issue in societies that consider themselves democratic, pluralistic, and tolerant.

10) Issues Law Med 1998 Fall;14(2):217-22

Executive summary of cloning human beings: report and recommendations of the National Bioethics Advisory Commission.

11) N Engl J Med 1999 Feb 11;340(6):471-5

Would cloned humans really be like sheep?

Eisenberg L

Harvard Medical School, Boston, MA 02115-6019, USA.

12) Science 1998 Dec 18;282(5397):2167-8

Britain urged to expand embryo studies.

Marshall E

13) Harefuah 1998 Oct;135(7-8):319-21

[The role of bioethics in mammalian and human cloning].

Ishay R

14) Science 1998 Dec 4;282(5395):1824-5

Human cloning.

Nader C, Newman SA

15) C R Seances Soc Biol Fil 1998;192(5):869-82

[Ethical problems connected with developmental biology].

Le Douarin NM

16) Science 1998 Oct 16;282(5388):413

Regulating human cloning.

Berg P, Singer M

17) N Engl J Med 1998 Nov 19;339(21):1558-9

Human cloning.

Gilbert SF

18) Ann Ist Super Sanita 1998;34(2):213-9

[Ethical problems of research on medical-assisted reproduction].

Frontali N, Zucco F

Gia Laboratorio di Igiene Ambientale, Istituto Superiore di Sanita, Roma.

Research in the field of assisted reproduction technologies (ART) is today very active internationally and is aimed both at improving success chances of already consolidated techniques (in fact these chances are still considerably low), and at elaborating new methods like ICSI (intracytoplasmic sperm injection), oocyte cryoconservation, ovary tissue cultures. Some other techniques, connected to ART, are here considered, like preimplantation diagnosis, early sex determination, gene therapy in utero and cloning. All these subjects of research are here briefly mentioned in relation to the ethical debate which they have stirred or which they should stir according to the authors. These debates are in part mirrored in the different legislations.

19) Arch Neurol 1998 Oct;55(10):1287-90
The Human Genome Project: applications in the diagnosis and treatment of neurologic disease.

Evans GA

McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas 75235, USA.

The Human Genome Project (HGP), an international program to decode the entire DNA sequence of the human genome in 15 years, represents the largest biological experiment ever conducted. This set of information will contain the blueprint for the construction and operation of a human being. While the primary driving force behind the genome project is the potential to vastly expand the amount of genetic information available for biomedical research, the ramifications for other fields of study in biological research, the biotechnology and pharmaceutical industry, our understanding of evolution, effects on agriculture, and implications for bioethics are likely to be profound.

20) Presse Med 1998 Mar 28;27(12):573-8
[Prohibition of human cloning. The status 1 year after the Scottish experience].

Pellissier V, Antoniotti S, Gentile S, Manuel C

Laboratoire de Sante Publique, Marseille.

21) J Med Philos 1998 Jun;23(3):227-33

Introduction: why protect the human genome?

Sass HM

Ruhr University, Bochum, Germany.

22) Nature 1998 Jul 30;394(6692):408-9

Cloned mice fail to rekindle ethics debate.

Wadman M

23) Qual Assur 1997 Oct-Dec;5(4):265-78

Legal issues pertaining to cloning.

Fersko RS

Gordan Altman Butowsky Weitzen Shalov & Wein, New York, New York, USA.

24) N Engl J Med 1998 Jul 9;339(2):122-5

Why we should ban human cloning.

Annas GJ

Boston University Schools of Medicine and Public Health, MA 02118, USA.

25) N Engl J Med 1998 Jul 9;339(2):119-22

Human cloning and the challenge of regulation.

Robertson JA

University of Texas School of Law, Austin 78705, USA.

26) Acta Genet Med Gemellol (Roma) 1997;46(3):135-7

Bioethical considerations on cloning and twinning.

Milani-Comparetti M

27) Health Aff (Millwood) 1998 May-Jun;17(3):264-7

Dealing with Dolly: inside the National Bioethics Advisory Commission.

Miller FG, Caplan AL, Fletcher JC

University of Virginia, Charlottesville, USA.

28) N Engl J Med 1998 Jun 11;338(24):1770; discussion 1771

Human cloning research.

Soldini M

Publication Types:

Comment on: N Engl J Med 1998 Mar 26;338(13):905-6

29) Circulation 1998 May 19;97(19):1889

Legislation of human cloning in the United States.

ORelle R

30) Hum Reprod Update 1997 Nov-Dec;3(6):629-41

Report on cloning by the US Bioethics Advisory Commission: ethical considerations

31) Rev Infirm 1998 Jan;(34):60-3

[The pretty story of Dolly and Polly, the lambs of the transgenic revolution].

Khan A

32) Camb Q Healthc Ethics 1998 Spring;7(2):194-6; discussion 196-8

Ethical aspects of genetic modification of animals: opinion of the Group of Advisers on the Ethical Implications of Biotechnology of the European Commission.

33) Camb Q Healthc Ethics 1998 Spring;7(2):121-40

Voices from Roslin: the creators of Dolly discuss science, ethics, and social responsibility.

Bulfield G, Campbell K, James R, Wilmut I

34) Rev Med Chil 1997 Jun;125(6):740-1

[Ethical contribution from Dolly].

Valenzuela CYS

35) Science 1998 Feb 20;279(5354):1123-4

Biomedical groups derail fast-track anticloning bill.

Marshall E

36) J Assist Reprod Genet 1998 Jan;15(1):1-9

Reproductive health care policies around the world. Is human cloning justified?

Tanos V, Schenker JG

Department of Obstetrics and Gynecology, Hadassah Medical Center, Hebrew University Hospital, Ein-Kerem, Jerusalem, Israel.

37) Adv Pract Nurs Q 1997 Fall;3(2):82-4

An ethical defense against the plague of cloning.

Husted GL, Husted JH

School of Nursing, Duquesne University, Pittsburgh, Pennsylvania, USA.

38) Science 1997 Oct 31;278(5339):798

First Dolly, now headless tadpoles.

Morton O, Williams N

Comment in: Science 1997 Nov 28;278(5343):1547-8

39) Science 1998 Jan 16;279(5349):315

Cloning plan spawns ethics debate.

Kestenbaum D

40) Nature 1998 Jan 22;391(6665):313

Japan gears up to debate brake on human cloning.

Saegusa A

41) Lancet 1998 Jan 17;351(9097):151

Cooling down over cloning.l

Comment in: Lancet 1999 Jan 9;353(9147):81

42) Nat Biotechnol 1998 Jan;16(1):6

Arrogance on human cloning may pose a threat to biotechnology.

Hoyle R

43) Nature 1998 Jan 15;391(6664):219

Unesco declaration lacks legal teeth.

Wadman M, Butler D

1)Forum (Genova) 1999 Jul-Dec;9(3 Suppl 3):99-105
Bioethics, biotechnology products and humans: Europe between the skilled Theseus and the Labyrinth-Minotaur's syndrome.

Frati P

Facolt di Legge, Universit di Macerata, e IRCCS Neuromed, Pozzilli, Isernia.

Following the approval on May 1998 of the European Union Common position no. 19/98 regarding the legal protection of biotechnological inventions, the debate on bioethical aspects of biotechnologies is increased. The European Union document clearly protects the patentability of inventions (that concerns more than a particular plant or animal variety or a single procedure if they are of industrial interest), but not the finding or discovery of that is in the nature, e.g. a gene. Some safeguards (the dignity and integrity of the person and of the human embryo, the plant diversity, etc.) and exclusions from patentability (plant and animal varieties, processes for the production of plants or animals, the human body at any stage of growth, cloning of human beings, modifications of germ line, use of human embryos for industrial or commercial purposes as well as the inventions whose publication or exploitation would offend against public policy or morality, according to the Article 53a of the European Patenting Convention) are also indicated. Ethical issues discussed include the nature of human life and its protection, the safeguard of plant-animal biological diversity, the safeguard of human dignity and nature, whereas on several aspects (e. g. limits of the use of genetic material, xenotransplantation, etc.) the Parliament Assembly of the Council of Europe has requested a discussion or a moratorium (April, 1999). In this case an evaluation on the basis of the ethical beneficial principles should be performed and society should decide whether to master technologies and emulate the positive action of the hero Theseus against the Labyrinth-Minotaur syndrome or to renounce or "misuse" technologies like Daedalus and Icarus, who met a tragic end.

2)Nat Med 1999 Sep;5(9):975-7
Human therapeutic cloning.

Lanza RP, Cibelli JB, West MD

Tissue Engineering and Transplant Medicine, Advanced Cell Technology, One Innovation Drive, Worcester, Massachusetts 01605, USA. rlanza@advancedcell.com

Somatic cell nuclear 'reprogramming' in livestock species is now routine in many laboratories. Here, Robert Lanza, Jose Cibelli and Michael West discuss how these techniques may soon be used to clone genetically matched cells and tissues for transplantation into patients suffering from a wide range of disorders that result from tissue loss or dysfunction.

Volver


Tecnología Reproductiva

FERTILIZACION IN VITRO

1) Lamb DJ, et al.          
Bioethics and law forum.
J Androl. 1999 Jul-Aug;20(4):454-5. No abstract available.
2) Djerassi C.        
Sex in an age of mechanical reproduction.
Science. 1999 Jul 2;285(5424):53-4. No abstract available.
3) Mastroianni L Jr.          
Swimming upstream: views on the ethics of preconception gender selection.
J Androl. 1999 May-Jun;20(3):332-5. No abstract available.
4) Belker AM.        
Bioethics and Law Forum.
J Androl. 1999 May-Jun;20(3):331. No abstract available.
5) Berkowitz JM.          
Sexism and racism in preconceptive trait selection.
Fertil Steril. 1999 Mar;71(3):415-7. No abstract available.
6) Schotsmans PT.          
In vitro fertilisation: the ethics of illicitness? A personalist Catholic approach.
Eur J Obstet Gynecol Reprod Biol. 1998 Dec;81(2):235-41. Review.
7) Frontali N, et al.           
[Ethical problems of research on medical-assisted reproduction].
Ann Ist Super Sanita. 1998;34(2):213-9. Italian.
8) Kopfensteiner TR.          
Ethical aspects of in vitro fertilization and embryo transfer.
Biomed Pharmacother. 1998;52(5):204-7.
9) Eisenberg VH, et al.           
Pre-embryo donation: ethical and legal aspects.
Int J Gynaecol Obstet. 1998 Jan;60(1):51-7. Review.
10) Verlinsky Y, et al.           
Progress in preimplantation genetics.
J Assist Reprod Genet. 1998 Jan;15(1):9-11. No abstract available.
11) Berner LS.         
Legal contracts in oocyte donation and surrogacy: don't put all your eggs in one basket!
J Womens Health. 1997 Dec;6(6):605-7. No abstract available.


1)Hum Reprod 2000 Feb;15(2):319-24
Experience with the elective transfer of two embryos under the conditions of the german embryo protection law: results of a retrospective data analysis of 2573 transfer cycles.

Ludwig M, Schopper B, Katalinic A, Sturm R, Al-Hasani S, Diedrich K

Department of Gynecology and Obstetrics, Medical University of Lubeck, Germany.

The German embryo protection law (Embryonenschutzgesetz, ESchG) does not allow embryo selection. Therefore, only as many oocytes at the pronuclear stage (PN), as are planned to be transferred, are allowed to be cultured. It is not known whether, under these conditions, it is possible to reduce the number of embryos for transfer without a corresponding reduction of the overall pregnancy rate (PR). We retrospectively analysed 2573 consecutive transfer cycles following either in-vitro fertilization (IVF) or IVF/intracytoplasmic sperm injection. Out of these cycles, 234, 329 and 792 were performed with one, two, and three embryos respectively, because only that number was available (non-elective transfer). Another 123 and 1095 transfer cycles were performed with two and three embryos, respectively, which were selected from a higher number of PN oocytes (elective transfer). The clinical ongoing PR were 3.9, 9.1 and 17.7% respectively for the groups with non-elective transfer of 1, 2 and 3 embryos, and 22.0 and 22.5% for the groups with elective transfers with two and three embryos, respectively. There was no statistically significant difference in PR between the two elective embryo transfer groups up to the age of 40 years. The multiple pregnancy rate was reduced by 7.9%. The reduction of the number of embryos transferred from three to two can be performed even under the conditions of the ESchG without an effect on the overall PR.

 

2)Br J Nurs 1999 Sep 9-22;8(16):1108-9
Confidentiality. 7: Human fertilization and embryology issues.

Dimond B

University of Glamorgan.

A woman who was having in-vitro fertilization (IVF) treatment was involved in a road accident. Her sister, a nurse, who was with her at the time, knew the drugs which she was taking as part of the IVF treatment and passed this information on to those caring for her in the accident and emergency department. Subsequently, the patient complained that this information should not have been passed on. She did not want anyone else to know that she was receiving fertility treatment. What is the law?

3)Hum Reprod 2000 Mar;15(3):604-607
Incidence of cancer in children born after in-vitro fertilization.

Bruinsma F, Venn A, Lancaster P, Speirs A, Healy D

Centre for the Study of Mothers' and Children's Health, La Trobe University, 251 Faraday Street, Carlton, 3053, Victoria, Australian Institute of Health and Welfare National Perinatal Statistics Unit, University of New South Wales, Sydney, 2031, NSW, Reproductive Biology Unit, Royal Women's Hospital, Carlton, 3053, Victoria and Monash IVF & Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre, Clayton, 3168, Victoria, Australia. Evaluation of the long-term health of children born using in-vitro fertilization (IVF) provides important information to clinicians and consumers. Until very recently, there have been no published data on the incidence of cancer in children conceived as a result of IVF, despite a number of case reports of neuroblastoma in children conceived using fertility drugs. This study used a record-linkage cohort design to investigate the incidence of cancer in children born after IVF. The study included all conceptions using assisted reproductive technologies between 1979 and 1995 at two clinics in Victoria, Australia that resulted in a live birth. Data on births were linked with a population-based cancer registry to determine the number of cases of cancer that occurred. The standardized incidence ratio (SIR) was calculated by comparing the observed number of cases to the expected number of cases. The final cohort included 5249 births. The median length of follow-up was 3 years, 9 months (range 0-15 years). In all, 4.33 cases of cancer were expected and six were observed, giving a SIR of 1.39 (95% CI 0.62-3.09). This study found that children conceived using IVF and related procedures did not have a significantly increased incidence of cancer in comparison to the general population.

 

4)Fertil Steril 2000 Feb;73(2):215-20
Embryo donation programs and policies in North America: survey results and implications for health and mental health professionals.

Kingsberg SA, Applegarth LD, Janata JW

Department of Reproductive Biology, Case Western Reserve University, Cleveland, Ohio 44106, USA. sak5@po.cwru.edu

OBJECTIVE: To use survey results from Society of Assisted Reproductive Technology to describe program policies regarding embryo donation, report protocols used for the disposition of cryopreserved embryos, and discuss clarification of guidelines governing ethical and psychosocially informed embryo donation. METHOD(S): A 66-item questionnaire was sent to the 312 Society of Assisted Reproductive Technology programs, generating 108 responses. RESULT(S): Seventy-eight (72%) of 108 programs offer embryo donation. Forty (37%) have actually performed donation, with 246 cycles completed and 53 "take-home babies." Disposition agreements for donors address divorce (92%) and death (90%). Only 28% require that potential donors undergo psychologic evaluation. Ninety-five percent of programs do not compensate donors. Seventy-one percent require a complete medical and psychologic history and 10% require genetic karyotyping. Three percent limit the number of donations. Eligible recipients include married couples (100%), unmarried couples (61%), lesbian couples (55%), and single women (59%). Sixty-four percent of programs require psychologic screening. Storage limits range from 2-10 years. Forty-nine percent of programs have unclaimed embryos in storage. CONCLUSION(S): Embryo donation is more often contemplated than performed. Variability in program procedures and policies suggests that guidelines need to be clarified. The complexity of the psychosocial and ethical issues underscores the importance of a routine, comprehensive psychologic assessment.

 

5)Gynecol Endocrinol 1999 Dec;13(6):420-40

A historical perspective of the clinical evolution of the assisted reproductive technologies.

Fasouliotis SJ, Schenker JG

Department of Obstetrics and Gynecology, Hadassah Medical Center-Hebrew University, Jerusalem, Israel.

The practice of assisted reproduction technology today is the result of the dedicated patient care, observation, research, and experimentation undertaken by previous generations of physicians. The building blocks of progress have been assembled over past decades, by scientists whose primary objective has been to push forward the frontiers of knowledge, in order to offer more effective methods of infertility treatment. And fortunately that process continues today. Amongst the many scientific developments that have led to the modern practice in assisted reproductive technology, a small number stand out as having had a unique importance. This historical review redraws the path through which in vitro fertilization went from an experimental to an accepted infertility treatment.

 

6)Gynecol Endocrinol 1999 Dec;13(6):371-4
Does female age affect embryo morphology?

Bar-Hava I, Ferber A, Ashkenazi J, Orvieto R, Kaplan B, Bar J, Peleg D, Ben-Rafael Z

Department of Obstetrics and Gynecology, Rabin Medical Center, Petah Tiqva, Israel.

[Medline record in process]

Deteriorating oocyte quality is commonly believed to be the primary determinant of the decreased implantation potential in older women. We assessed the influence of age on embryo morphology in standard in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) modalities. All 6350 consecutive embryos (2990 IVF, 3360 ICSI) obtained in our Assisted Reproductive Technology Unit from January 1996 through June 1997 were included. High quality embryos were defined as those with equal-sized blastomeres and < 10% fragmentations and a cleavage rate of four cells on day 2 or eight cells on day 3 transfers. The results were analyzed for the standard IVF group, the ICSI group, and the ICSI subgroup with severe male factor infertility (< or = 1 x 10(6) total motile spermotozoa in the ejaculate). For standard IVF, a positive association was observed between female age and increased proportion of good quality embryos. No such association was detected for the ICSI cycles (whole group or subgroup). We conclude that in standard IVF, embryo quality, as reflected by embryo morphology, does not deteriorate with increased maternal age.

 

7)Gesundheitswesen 1999 Dec;61(12):593-600
[Possibilities and limits of assisted reproduction].

Ludwig M, Diedrich K

Klinik fur Frauenheilkunde und Geburtshilfe, Medizinische Universitat zu Lubeck. Ludwig_M@t-online.de

The term assisted reproductive technologies (ART) describes all treatment procedures which include more than the natural intercourse to conceive. The most invasive procedure is intracytoplasmic sperm injection (ICSI), which was introduced in 1993. By ICSI the successful treatment of couples with severe male factor infertility, even in cases of azoospermia, became possible. In cases where only immature forms of spermatogenesis are present in the testicular tissue, pregnancies could also be achieved. The limiting factor with greatest influence on the success rate of ART procedures is the female's age. In this context the treatment of postmenopausal women by oocyte donation, as well as ooplasma donation to overcome the negative influence of the female's age on oocyte quality are extreme examples of ethically questionable ART procedures. Until now several 100,000 children worldwide have been born subsequent to ART and especially in vitro fertilisation. No increase in the malformation rate neither after IVF nor after IVF/ICSI have been reported so far. However, because of the lack of prospective controlled studies using standardised evaluation procedures and having enough statistical power to prove the security of ICSI for the newborn children, the German statutory health insurance bodies have ceased to pay ICSI costs as of July 1999. The data on the success of ICSI, the known data on the newborn and developing children and the decisions of the medical services of the German statutory health insurance bodies are presented in discussed in this paper.

8)Hum Reprod 2000 Feb;15(2):330-4
Public perception on infertility and its treatment: an international survey. The Bertarelli Foundation Scientific Board.

Adashi EY, Cohen J, Hamberger L, Jones HW Jr, de Kretser DM, Lunenfield B, Rosenwaks Z, Van Steirteghem A

Chemin de Bellevue, Case Postale 13, CH-1270 Trelex, Switzerland.

The first large survey on the public perception of infertility and its treatment was conducted in six European countries, the USA and Australia. A representative sample of 8194 adults was polled, using standard validated methodology. The results obtained highlighted the following major aspects: (i) infertility is perceived as a disease by less than half of the people surveyed (38%), in contrast to the accepted medical opinion; (ii) awareness about the definition and incidence of infertility is relatively low, despite the fact that half of the people polled claimed to know someone affected by infertility; (iii) close to 90% of the adults surveyed knew about in-vitro fertilization (IVF), but less than one-quarter of them knew about the chances of success of this assisted reproductive technology; and (iv) when confronted with the knowledge that the cost of three IVF cycles is roughly equivalent to the cost of a hip replacement (a commonly reimbursed procedure), a large majority (70%) of the individuals interviewed agreed that IVF should be reimbursable.

FERTILIZACION IN VITRO (Continuación)

12) Eur J Obstet Gynecol Reprod Biol 1998 Dec;81(2):235-41

In vitro fertilisation: the ethics of illicitness? A personalist Catholic approach.

Schotsmans PT

Centre of Biomedical Ethics and Law, Department of Public Health, School of Medicine, Leuven, Belgium. Paul.Schotsmans@med.kuleuven.ac.be

In line with Professor Brosens' work at the K.U. Leuven, the ethical integration of in vitro fertilisation (IVF) was made possible in the context of personalism, what we will present here in its anthropological and theological foundations. This presentation is necessary to make clear that personalism is always in the making of the clarification of its foundations. The three basic anthropological options are then applied to the ethical integration of IVF. They will lead to three concrete criteria for clinical practice: stable heterosexual infertile couple as indication; the respect for the human embryo and the qualitative social organization of infertility treatment. This position of Catholic personalists is in contradiction with the teaching of the Church, declaring that the IVF practice is in itself illicit. The third and fourth parts of this article are devoted to this statement. First, by debating the official magisterial position, and second, by referring to probably one of the most crucial issues for the ethical debate on IVF in the Church: the moral status of the embryo.

13) Ann Ist Super Sanita 1998;34(2):213-9

[Ethical problems of research on medical-assisted reproduction].

[Article in Italian]

Frontali N, Zucco F

Gia Laboratorio di Igiene Ambientale, Istituto Superiore di Sanita, Roma.

Research in the field of assisted reproduction technologies (ART) is today very active internationally and is aimed both at improving success chances of already consolidated techniques (in fact these chances are still considerably low), and at elaborating new methods like ICSI (intracytoplasmic sperm injection), oocyte cryoconservation, ovary tissue cultures. Some other techniques, connected to ART, are here considered, like preimplantation diagnosis, early sex determination, gene therapy in utero and cloning. All these subjects of research are here briefly mentioned in relation to the ethical debate which they have stirred or which they should stir according to the authors. These debates are in part mirrored in the different legislations.

14) Nature 1998 Oct 8;395(6702):532-3

Pressure grows for relaxation of French embryo research laws.

Butler D

15) Biomed Pharmacother 1998;52(5):204-7

Ethical aspects of in vitro fertilization and embryo transfer.

Kopfensteiner TR

Department of Theology, Fordham University, The Bronx, New York 10458, USA.

In vitro fertilization and embryo transfer (IVF-ET) confronts moral reflection with a wide range of concerns. Some are similar to those raised by artificial insemination such as the procurement of sperm, the goods of marriage and donor gametes. Others are unique to IVF-ET such as surrogacy, the status of the embryo and cryopreservation.

16) Int J Gynaecol Obstet 1998 Jan;60(1):51-7

Pre-embryo donation: ethical and legal aspects.

Eisenberg VH, Schenker JG

Department of Gynecology and Obstetrics, Hadassah University Medical Center, Jerusalem, Israel.

Genetic material donation has become an integral part of the management of infertility. Sperm, oocyte and pre-embryo donation are successful both medically and technically. The practice of genetic material donation raises ethical, legal, religious and social issues. The practice of pre-embryo donation raises several unique issues, such as the status of the pre-embryo and its well-being. Medical problems which need to be considered include selection of the donors, evaluation of the recipients and quality control of the genetic material. The relationship between the biological and social parents, and the safeguarding of the interests of the offspring, may be resolved by specific legislation pertaining to each country. Potential pre-embryo banks should be subjected to licensing and should not be run by a commercial system. By practicing pre-embryo donation, the medical profession and society should consider not only the interests of the infertile couple, but also the interests of the offspring.

17) J Assist Reprod Genet 1998 Jan;15(1):9-11

Progress in preimplantation genetics.

Verlinsky Y, Kuliev A

Reproductive Genetics Institute, Chicago, Illinois 60657, USA.

18) J Womens Health 1997 Dec;6(6):605-7

Legal contracts in oocyte donation and surrogacy: don't put all your eggs in one basket!

Berner LS

Cleveland Clinic Foundation, OH 44195, USA.

 

 

Volver


Derechos de los Animales

1) Science 1999 Nov 5;286(5442):1059

Animal rights. Booby-trapped letters sent to 87 researchers.

Kaiser J

2) Neth J Med 1999 Nov;55(5):206-8

Scientific progress versus reduction of animal experiments: weighing human and animal interests.

Joles JA, Vorstenbosch JM

Comment on: Neth J Med 1999 Nov;55(5):212-4

3) Arch Med Res 1999 Jul-Aug;30(4):341-2

Animal rights in the 1990s: a different species, but you're still the prey.

Brennan M

Foundation for Biomedical Research, Washington, D.C 20006, USA. mbrennan@fbresearch.org

4) Nature 1999 Nov 4;402(6757):7-8

Threats to US primate researchers.

Nadis S

5) JAMA 1999 Aug 18;282(7):619-21

Researchers urged to tell public how animal studies benefit human health.

Lamberg L

6) Trends Biotechnol 1999 Nov;17(11):428-9

Ethics and the clinical utility of animal organs.

Bramstedt KA

Biomedical and Research Ethics Program at the University of California Los Angeles, CHS 52-242, Los Angeles, CA 90095-7041, USA. kbramstedt@mednet.ucla.edu

7) Wiad Lek 1999;52(5-6):316-23

[Supporting experimental animals rights in medicine].

[Article in Polish]

Koplinski A

Katedry i Kliniki Anestezjologii, Intensywnej Terapii Slaskiej Akademii Medycznej w Katowicach.

The paper outlines the history of experiments on animals in medicine and biology. It also presents the sources of the notion and its evolution along with the roles played by Silesian Medical Academy representative in supporting experimental animals rights.

8) Zentralbl Chir 1999;124(7):636-40

[Xenotransplantation from the ethical viewpoint. An outline].

Beckmann JP

Institut fur Philosophie, Fern-Universitat Hagen.

The duty to save and to preserve lives on one hand, and the scarcity of human donor organs on the other hand call for a search for new organ sources, including xenogenic ones. Xenotransplantation, however, is not only in need of medical research, but also of ethical analysis. The latter is not to be considered a substitute for moral intuition, but rather a foundation of it by way of a critical evaluation of the ethical principles and reasons involved. This basically demands an analysis of the legitimacy of the aims and of the acceptability of the means for xenotransplantation. It includes safeguarding informed consent; risk assessment and the protection of not only the recipient, but also others; the question of limitation of personal rights; allocation problems; and last but not least animal protection. The aim is to clarify the ethical status of xenotransplantation in general and the question of a moratorium regarding clinical trials due to unsolved problems of infectivity and immunosuppression in particular by way of an integrative approach to both scientific developments and ethical analysis.

9) Nat Med 1999 Sep;5(9):973

Universities offer animal rights courses.

Ready T

10) Nature 1999 Aug 12;400(6745):606

Animal rights activists attack Gore over chemical screening.

Wadman M

11) Ugeskr Laeger 1999 Jul 26;161(30):4306-7

[Animal experiments in medical research].

Thorn NA, Beck-Nielsen H

12) J Bone Joint Surg Am 1999 Jun;81(6):751

Management of postoperative pain in animals used in research.

Cowell HR

13) Science 1999 Jun 4;284(5420):1604-6

European researchers grapple with animal rights.

Koenig R

Comment in: Science 1999 Jul 16;285(5426):337

14) Lakartidningen 1999 May 12;96(19):2378-80

[The proposal of the EU concerning experimental animals is a threat to biomedical research. The aim should be fewer animals used per project and not a general reduction].

Hagelin J, Hau J, Karlsson HE

Institutionen for fysiologi, Uppsala universitet.

15) Nature 1999 Jun 3;399(6735):397

US Senate gets tough on animal activists.

Wadman M

16) Nurs Ethics 1999 Mar;6(2):173

The use of animals in biomedical research.

Hagelin J, Carlsson HE, Hau J

17) Food Drug Law J 1998;53(2):353-84

Xenotransplantation: ethics and economics.

Kress JM

U.S. Department of Health and Human Services, U.S.A.

18) Eur Spine J 1999;8(2):85

Animal ethics in basic scientific research.

Olmarker K

19) Science 1999 Apr 16;284(5413):410-1

Animal rights. Activists ransack Minnesota labs.

Kaiser J

20) Cad Saude Publica 1999;15 Suppl 1:99-110

Ethics and animal experimentation: what is debated?

Paixao RL, Schramm FR

Departamento de Fisiologia, Instituto Biomedico, Universidade Federal Fluminense, Rua Hernani Melo, 101, Niteroi, RJ 24210-130, Brasil. mflrlpp@vm.uff.br

The purpose of this article is to raise some points for an understanding of the contemporary debate over the ethics of using animals in scientific experiments. We present the various positions from scientific and moral perspectives establishing different ways of viewing animals, as well as several concepts like 'animal ethics', 'animal rights', and 'animal welfare'. The paper thus aims to analyze the importance and growth of this debate, while proposing to expand the academic approach to this theme in the field of health.

21) Nature 1999 Feb 11;397(6719):461

German science fights animal rights bill.

Schiermeier Q

22) Science 1999 Jan 29;283(5402):639

Animal rights brochure.

Navar LG

Publication Types:

Comment on: Science 1998 Nov 20;282(5393):1417

23) Science 1999 Jan 15;283(5400):329

Animal rights.

Shannon TA

Comment on: Science 1998 Nov 20;282(5393):1417

24) Science 1999 Jan 15;283(5400):328-9

Animal rights.

Buckmaster CA

Comment on: Science 1998 Nov 20;282(5393):1417

25) Science 1999 Jan 15;283(5400):328

Animal rights.

Hunt HW

Comment on: Science 1998 Nov 20;282(5393):1406-7

Comment on: Science 1998 Nov 20;282(5393):1417

26) Science 1999 Jan 15;283(5400):327-8

Animal rights.

Davis LL

Comment on: Science 1998 Nov 20;282(5393):1417

27) Science 1999 Jan 15;283(5400):327

Animal rights.

Staddon JE

Comment on: Science 1998 Nov 20;282(5393):1417

28) Science 1999 Jan 15;283(5400):327

Animal rights.

Coalgate B, Coalgate J

Comment on: Science 1998 Nov 20;282(5393):1417

29) Camb Q Healthc Ethics 1999 Winter;8(1):64-72

The use of animals in biomedical research and teaching: searching for a common goal.

Silverman J

Laboratory Animal Science Program, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania, USA.

30) Camb Q Healthc Ethics 1999 Winter;8(1):23-34

The ethics of animal research: what are the prospects for agreement?

DeGrazia D

George Washington University, USA.

31) Science 1998 Nov 20;282(5393):1417

Animal rights: reaching the public.

Conn PM, Parker J

  • Comment in: Science 1999 Jan 15;283(5400):327
  • Comment in: Science 1999 Jan 15;283(5400):327-8
  • Comment in: Science 1999 Jan 15;283(5400):328
  • Comment in: Science 1999 Jan 15;283(5400):328-9
  • Comment in: Science 1999 Jan 15;283(5400):329
  • Comment in: Science 1999 Jan 29;283(5402):639
  • Comment in: Science 1999 Apr 2;284(5411):49-50

32) Nature 1998 Dec 10;396(6711):505

Animal rights activists turn the screw.

Schiermeier Q

33) Acad Med 1998 Nov;73(11):1180-1

Accrediting animal research programs: where science and responsible animal care connect.

Miller JG

Association for Assessment and Accreditation of Laboratory Animal Care International, Rockville, Maryland, USA.

34) J Oral Maxillofac Surg 1998 Oct;56(10):1224

The use of dogs for experimentation.

Silegy T

Comment on: J Oral Maxillofac Surg 1998 Mar;56(3):345-8

35) Oral Maxillofac Surg 1998 Oct;56(10):1224

The use of dogs for experimentation.

Colm SJ

Comment on: J Oral Maxillofac Surg 1998 Mar;56(3):330-8

36) DTW Dtsch Tierarztl Wochenschr 1998 Aug;105(8):313-21

[Animal rights and animal health on ecological farms].

Horning B

Fachgebiet Angewandte Nutztierethologie und Artgemasse Tierhaltung, Universitat GH Kassel in Witzenhausen.

Intensive animal husbandry is criticized in relation to the fulfillment of the animals needs. The guidelines of the organizations of organic agriculture offer the opportunity for better animal welfare. In this paper an overview is given concerning animal health and welfare on organic farms with dairy cows, fattening pigs and laying hens. On organic farms housing systems with the potential for a better animal welfare dominate. In field studies using scoring systems (animal welfare index) organic farms reach more points than conventional ones. However, animal health on average is not much better on organic farms. The health problems discussed in the paper are mainly caused by management problems. Therefore, improvements are possible.

37) Schweiz Med Wochenschr 1998 Jun 13;128(24):982-6

[Legal aspects of xenotransplantation].

Leroux T

Centre de recherche en droit public, Universite de Montreal. Quebec.

38) Schweiz Med Wochenschr 1998 Jun 13;128(24):973-4

[Ethical and philosophical aspects of xenotransplantation].

Engels EM

Lehrstuhl fur Ethik in den Biowissenschaften, Fakultat fur Biologie, Eberhard-Karls-Universitat, Tubingen.


39) Schweiz Med Wochenschr 1998 Jun 13;128(24):961-72

[Xenotransplantation: ethical and philosophical aspects].

Baertschi B

40) Acta Cient Venez 1997;48(3):125-6

[Ethics in scientific research].

Romero Vecchione E

41) Camb Q Healthc Ethics 1998 Spring;7(2):194-6; discussion 196-8

Ethical aspects of genetic modification of animals: opinion of the Group of Advisers on the Ethical Implications of Biotechnology of the European Commission.

42) Nature 1998 Feb 12;391(6668):624

Germany remains split on animal testing.

Miller B

43) Science 1997 Oct 24;278(5338):557; discussion 560

Animal rights.

Woolley M

Comment on: Science 1997 Sep 5;277(5331):1419

44) Science 1997 Oct 24;278(5338):557; discussion 560

Animal rights.

Cowley AW Jr, Schafer JA, Navar LG

Comment on: Science 1997 Sep 5;277(5331):1419

 

1)Nature 2000 Feb 10;403(6770):582
Austria taken to court for inadequate laws on animal welfare.

Nuthall K

2)Lancet 2000 Jan 29;355(9201):408
Xenotransplantation debate.

Orr C

3)J Am Vet Med Assoc 2000 Jan 15;216(2):153, 168
Skies could get friendlier for animals.

Nolen RS

4)Hastings Cent Rep 1999 Nov-Dec;29(6):22-5
A xenotransplantation protocol.

Hanson MJ, Russow LM, McCarthy CR

5)J Am Vet Med Assoc 2000 Jan 1;216(1):25-6
Emotional distress, punitive damages, and the veterinarian--some judicial responses.

Hannah HW

6)J Am Vet Med Assoc 2000 Jan 1;216(1):8-9

Delta Society to explore influence of animals on human health.

Nolen RS

7)Berl Munch Tierarztl Wochenschr 1999 Dec;112(12):422-9
[The impact of suboptimal animal husbandry practices on animal health and economic profitability using the example of tie-in and loose housing system of dairy cattle].

Platz S, Miller F, Unshelm J

Institut fur Tierhygiene, Verhaltenskunde und Tierschutz der Ludwig-Maximilians-Universitat Munchen.

In this study of two common housing systems of dairy cattle, the tie-in system and the loose housing system, check lists were created to evaluate whether these husbandry systems fulfill the needs of the animals. Furthermore, a combination of questionnaires and interviews were employed to assess the qualification of dairy stockmen to handle the animals. These checklists should provide a useful tool for those persons involved in the examination of husbandry systems, both by providing a written record and by providing a clear outline of all the points that need to be covered during such an examination. The study, done in the way of an explorative analysis of data, included 22 farms (14 with tie-in systems and 8 with loose housing systems) and a total of 802 animals. With regard to the economic effects of poor management and housing conditions, several interesting and statistically noteworthy correlations emerged. TIE-IN SYSTEM: Positive correlations were found between severity of behavioural abnormalities (behave)and number of injuries due to husbandry system (injury); injury and number of inseminations per pregnancy (preg); injury and age of cow (age); preg and cell count of milk (cell). Negative correlations were found between cell and milk yield (milk) as well as between the qualification of stockmen (equal) and inappropriate technical design of the housing environment (tech). LOOSE HOUSING SYSTEM: Positive correlations existed between behave and injury, and between tech and injury. Negative correlations were found between milk and cell, equal and tech, and milk and age. The magnitudes of these correlations were quantified by means of linear regression analysis. Comparison of the two husbandry systems revealed that while the loose housing systems is associated with significantly more problems related to tech, it is associated with significantly fewer problems related to injury. It seems that in this housing system cows are better able to avoid injury since they are allowed to move freely. No significant differences in behavior were found between the two husbandry systems. The present study shows the importance of proper technical design of housing environments, both in relation to animal welfare and to economic profitability.

Volver


Death and Dying

MORIR Y PROCESO DE MORIR

1) Hosp J 1999;14(2):49-63

Attitudes toward assisted suicide: a survey of hospice volunteers.

Zehnder PW, Royse D

College of Social Work, University of Kentucky, Lexington 40506-0027, USA.

Technological advances have lengthened our years and, often, the dying process as well. While studies have been conducted of physicians and dying patients concerning their views on assisted suicide, no prior studies have examined the attitudes of hospice volunteers. This survey of 277 hospice volunteers found that overall their attitudes were more supportive of assisted suicide than that of a convenience sample of the public. Thirty-seven percent of the volunteers endorsed the view that there are situations when assisting death may be morally acceptable; 4% had been asked to provide assistance to help a patient end his or her life.

2) Hosp J 1999;14(2):17-33

"What should I say?": qualitative findings on dilemmas in palliative care nursing.

McGrath P, Yates P, Clinton M, Hart G

Queensland University of Technology, Australia.

The nursing literature suggests that talking and listening to patients about issues associated with death and dying, is both important and difficult, and may be improved with training. This discussion presents the results of recent nursing research to confirm, and elaborate on, this theme. In this research participants touched on many central issues in communicating with patients that included articulating a sense of discomfort and inadequacy about the whole process, detailing the innumerable blocks to open communication [e.g., interference, denial, unrealistic optimism, resistance, collusion and anger] and sharing their sense of success and failure. The insights of nurses who participated in this research testify to the ongoing need to prioritize the development of nursing skills and support in this challenging but important area.

3) Palliat Med 1998 Nov;12(6):429-35

Why is the pain relief of dying patients often unsuccessful? The relatives' perspectives.

Miettinen TT, Tilvis RS, Karppi P, Arve S

Department of Nursing Sciences, University of Tampere, Finland.

In order to determine relatives' opinions of the pain relief of dying patients a postal questionnaire was sent to close relatives (n = 371) of aged patients (mean age 80.1 years) who had died one to two years earlier. In the relatives' opinions, 57% of the patients (n = 211) had suffered from moderate to severe pain and in 22% (n = 46) of these the pain relief was unsuccessful. Inadequate pain relief was associated with a feeling of helplessness in the patients (odds ratio 2.6), insufficient self-determination of analgesic use (9.4), unsatisfactory care of daily needs such as nutrition (8.3), and insufficient care of concomitant symptoms such as dry mouth (6.2). The pain relief was also evaluated as having been unsuccessful when the relatives received limited information about the forthcoming death (5.7), when it was difficult to discuss with the clinical staff (5.7), and when the relatives were not supported by, for example, comforting and heartening (7.9) or encouraging to participate in the care (7.2). In the multivariate analysis, the self-determination of the patients about their pain medication (5.7), difficulties of the relatives to discuss issues with the nursing staff (3.7) and poor atmosphere of the treatment environment (2.8) emerged as the most significant associates of unsuccessful pain relief. The results show that dissatisfaction with the pain management is associated with low appreciation of the treatment of other discomforts and complaints. Successful pain management therefore requires a holistic approach to the wider spectrum of problems in dying patients.

4) Palliat Med 1998 Nov;12(6):417-27

Specialist palliative care in nonmalignant disease.

Addington-Hall J, Fakhoury W, McCarthy M

Department of Palliative Care and Policy, Guy's, King's and St Thomas' School of Medicine/St Christopher's Hospice, London, UK.

The objective of this study was to investigate how many patients who die from causes other than cancer might benefit from specialist palliative care. This was achieved by secondary analysis of data from the Regional Study of Care for the Dying, a retrospective national population-based interview survey. The investigation involved 20 self-selected English health districts, nationally representative in terms of social deprivation and most aspects of health services provision. A total of 3696 patients were randomly selected from death registrations in the last quarter of 1990; an interview concerning the patient was completed 10 months after the death by bereaved family, friends or officials. The results show that a third (243/720) of cancer patients who were admitted to hospices or had domiciliary palliative care scored at or above the median on three measures of reported symptom experience in the last year of life. That is the number of symptoms (eight or more), the number of distressing symptoms (three or more) and the number of symptoms lasting more than six months (three or more). A total of 269 out of 1605 noncancer patients (16.8%) fulfilled these criteria. On this basis, it is estimated that 71,744 people who die from nonmalignant disease in England and Wales each year may require specialist palliative care. An increase of at least 79% in caseload would, therefore, be expected if specialist palliative care services were made fully available to noncancer patients. This is a conservative estimate, as non-cancer patients were matched to only one-third of cancer patients who had specialist palliative care. It is concluded that clinicians and patient groups caring for patients with advanced nonmalignant disease must work together with specialist palliative care services and with health commissioners to develop, fund and evaluate appropriate, cost-effective services which meet patient and family needs for symptom control and psychosocial support.

5) Nurs Forum 1999 Apr-Jun;34(2):5-14

Improving end-of-life care: gathering suggestions from family members.

Pierce SF

Department of Social and Administrative Nursing Systems, School of Nursing, University of North Carolina, Chapel Hill, USA. Juall46@bellatlantic.net

Tertiary care centers are criticized for not providing a peaceful death experience. This qualitative study was undertaken to ascertain suggestions family members (N = 29) might have to improve the situation. Family members made three major suggestions where the negative effects of the complex hospital system might be ameliorated when caring for dying patients: facilitate improved interaction between the dying patient and the family; improve interactions between caregivers and patients/families; and create a setting, or milieu, more conducive to these interactions. Further, family members related an overwhelming need to be close physically to their dying loved one; to be given permission, instruction, and opportunities to touch their loved one; to receive more information from caregivers; and to have their and their loved one's personhood acknowledged and respected. Thus, nurses should engage in respectful, personalized conversations with patients and families that allow them to define the dying experience they desire.

6) Drugs Aging 1999 Nov;15(5):335-40

Drugs used in physician-assisted death.

Willems DL, Groenewoud JH, van der Wal G

Institute for Research in Extramural Medicine and Department of Social Medicine, Vrije Universiteit, Amsterdam, The Netherlands. d.willems.emgo@med.vu.nl

Epidemiological studies, case reports, and recommendations concerning the drugs used in physician-assisted death are reviewed in this paper. Using a MEDLINE and Cancerlit search, we found a total of 20 relevant publications. Recent research, mainly from the Netherlands, has shown that high doses of barbiturates are usually effective for physician-assisted suicide, while a combination of a barbiturate and a derivative of curare are effective for euthanasia. Opioids are less reliable drugs for physician-assisted death because of the unpredictable duration of the dying process even after high doses. The same applies to benzodiazepines. The most frequent undesired effect is an unexpectedly long dying process due to impaired uptake of the drugs. Although the evidence base is incomplete, the Dutch recommendations issued in 1994 and renewed in 1998 do not seem inappropriate.

7) Nurs N Z 1998 Nov;4(10):11-3

Caring for the dying.

Ladbrook J

Southland Hospice.

To provide the best possible care to dying patients, nurses must attend to their physical, emotional and spiritual needs. Nurses must also be aware of their own feelings towards death and dying.

8) Oncol Nurs Forum 1999 Nov-Dec;26(10):1683-7

Nurses' attitudes toward death and caring for dying patients.

Rooda LA, Clements R, Jordan ML

Division of Nursing, Indiana University Northwest, Gary, USA. lrooda@iunhaw1.iun.indiana.edu

PURPOSE/OBJECTIVES: To examine possible relationships among the demographic variables of nurses and their attitudes toward death and caring for dying patients. DESIGN: Descriptive. SETTING: A private hospital and Visiting Nurses Association office in an ethnically diverse metropolitan area in the Midwest. SAMPLE: 403 nurses, predominantly female (90%) and Caucasian (70%), with a mean age of 41.8 years. METHODS: Participants completed the Frommelt Attitude Toward Care of the Dying Scale, the Death Attitude Profile-Revised (DAP-R), and a demographic questionnaire. MAIN RESEARCH VARIABLES: Attitudes toward death and caring for dying people. FINDINGS: DAP-R scores were related to sex, religious affiliation, and current contact with terminally ill patients. Frommelt scale scores (e.g., showing acceptance of death) were positively related to current contact with dying patients, negatively correlated with two DAP-R subscales (Fear of Death and Death Avoidance), and positively correlated with two other DAP-R subscales (Approach Acceptance and Neutral Acceptance). CONCLUSIONS: Nurses' attitudes toward death and their current contact with terminally ill patients were predictive of their attitudes toward caring for terminally ill patients. IMPLICATIONS FOR NURSING PRACTICE: Professionals who are responsible for designing educational programs focused on nurses' attitudes toward caring for terminally ill patients may want to include an assessment of death attitudes and interventions aimed at decreasing negative attitudes and increasing positive attitudes toward death in such programs.

9) Fam Med 1999 Nov-Dec;31(10):691-6

Factors associated with residents' attitudes toward dying patients.

Kvale J, Berg L, Groff JY, Lange G

Department of Family Practice, University of Texas, Houston, USA. jkvale@fpcm.med.uth.tmc.edu

BACKGROUND AND OBJECTIVES: Management of the dying patient often elicits anxiety in physicians. This study identified the association of physicians' personal fear of death, tolerance of uncertainty, and attachment style with physician attitudes toward dying patients. METHODS: Four psychological scales were distributed to family practice residents located in Texas, Missouri, and Maine. The scales were "Death Anxiety," "Death Attitudes," "Physicians' Reactions to Uncertainty," and "Experiences in Close Relationships." The scores from the measures and demographic data were used to determine which factors were associated with physician attitudes toward caring for terminally ill patients. RESULTS: Completed surveys were received from 157 residents. Younger residents (< 30 years) reported more stress from uncertainty and were more uncomfortable with the care of dying patients. Residents who reported higher death anxiety were also more uncomfortable with caring for dying patients. In a multivariate analysis, uncertainty, death anxiety, and age predicted 26% of the total outcome variance of the death attitudes score. CONCLUSIONS: Physician tolerance of uncertainty plays a significant role in physician attitudes toward the dying patient. Our findings suggest that decreasing physicians' stress from uncertainty by educating them in the management of the dying patient may improve their attitude toward death and may better prepare them to provide end-of-life care.

10)Health Law J 1996;4:197-219

Dying with dignity and the death of dignity.

Pullman D

Centre for Society, Technology and Values, University of Waterloo, Ontario.

11) Int Nurs Rev 1999 Sep-Oct;46(5):135-9

Dying in the USA and Japan: selected legal and ethical issues.

Davis A, Mitoh T

University of California, San Francisco, USA.

While Japan and the USA are culturally different, they face many of the same ethical and legal issues in the area of death and dying. Facing these issues at different times and in different ways, both countries have sought solutions that fit their own social values and traditions.

12) CMAJ 1999 Nov 2;161(9):1109-13

Life support in the intensive care unit: a qualitative investigation of technological purposes. Canadian Critical Care Trials Group.

Cook DJ, Giacomini M, Johnson N, Willms D

Department of Medicine, McMaster University, Hamilton, Ont. debcook@fhs.csu.mcmaster.ca

BACKGROUND: The ability of many intensive care unit (ICU) technologies to prolong life has led to an outcomes-oriented approach to technology assessment, focusing on morbidity and mortality as clinically important end points. With advanced life support, however, the therapeutic goals sometimes shift from extending life to allowing life to end. The objective of this study was to understand the purposes for which advanced life support is withheld, provided, continued or withdrawn in the ICU. METHODS: In a 15-bed ICU in a university-affiliated hospital, the authors observed 25 rounds and 11 family meetings in which withdrawal or withholding of advanced life support was addressed. Semi-structured interviews were conducted with 7 intensivists, 5 consultants, 9 ICU nurses, the ICU nutritionist, the hospital ethicist and 3 pastoral services representatives, to discuss patients about whom life support decisions were made and to discuss life-support practices in general. Interview transcripts and field notes were analysed inductively to identify and corroborate emerging themes; data were coded following modified grounded theory techniques. Triangulation methods included corroboration among multiple sources of data, multidisciplinary team consensus, sharing of results with participants and theory triangulation. RESULTS: Although life-support technologies are traditionally deployed to treat morbidity and delay mortality in ICU patients, they are also used to orchestrate dying. Advanced life support can be withheld or withdrawn to help determine prognosis. The tempo of withdrawal influences the method and timing of death. Decisions to withhold, provide, continue or withdraw life support are socially negotiated to synchronize understanding and expectations among family members and clinicians. In discussions, one discrete life support technology is sometimes used as an archetype for the more general concept of technology. At other times, life-support technologies are discussed collectively to clarify the pursuit of appropriate goals of care. CONCLUSIONS: The orchestration of death involves process-oriented as well as outcome-oriented uses of technology. These uses should be considered in the assessment of life-support technologies and directives for their appropriate use in the ICU.

13) Death Stud 1999 Sep;23(6):495-519

Dying, mourning, and spirituality: a psychological perspective.

Marrone R

California State University, Sacramento, USA. Bobmarrone@aol.com.

Based in an unfortunate tradition that stretches back in time to Watson's behaviorism and Freud's psychoanalysis, psychology has tended to reject and to pathologize matters of the spirit. In the past 30 years, however, with the advent of what has been termed the cognitive revolution, psychology has greatly expanded the scope of its subject matter. Psychologists and thanatologists have begun to unravel the cognitive underpinnings of our assumptive world and the transformation of those underpinnings in times of crisis and stress. This article examines the cognitive basis of the spiritual experience and the use of cognitive assimilation, accommodation strategies during the process of mourning the death of a loved one, as well as during the process of living our own dying. Of special importance to mental health professionals and clergy, new research on dying, mourning, and spirituality suggests that the specific ways in which people rediscover meaning--such as belief in traditional religious doctrine, the afterlife, reincarnation, philanthropy, or a spiritual order to the universe--may be less important than the process itself. In other words, in the midst of dealing with profound loss in our lives, the ability to reascribe meaning to a changed world through spiritual transformation, religious conversion, or existential change may be more significant than the specific content by which that need is filled.

14) Crit Care Med 1999 Oct;27(10):2125-32

The influence of access to a private attending physician on the withdrawal of life-sustaining therapies in the intensive care unit.

Kollef MH, Ward S

Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.

OBJECTIVE: To assess the influence of patient access to a private attending physician on the withdrawal of life-sustaining therapies in a medical intensive care unit (ICU). DESIGN: Prospective cohort study. SETTING: A university-affiliated teaching hospital. PATIENTS: A total of 501 consecutive patients admitted to the medical ICU during a 5-month period. INTERVENTIONS: None MEASUREMENTS AND MAIN RESULTS: Among patients dying in the medical ICU, those without a private attending physician (n = 26) were statistically more likely to undergo the active withdrawal of life-sustaining therapies than patients with a private attending physician (n = 87) (80.8% vs. 29.9%; relative risk = 2.70; 95% confidence interval = 1.86-3.92; p < .001). Despite having similar predicted mortality rates by Acute Physiology and Chronic Health Evaluation II score (60.5% +/- 27.0% vs. 66.1% +/- 21.3%; p = .280), patients dying in the medical ICU without a private attending physician had statistically shorter hospital and ICU lengths of stay, a shorter duration of mechanical ventilation, and fewer total hospital costs and charges compared with patients with access to a private attending physician. Multiple logistic regression analysis, controlling for severity of illness, demographic characteristics, and patient diagnoses, demonstrated that lack of access to a private attending physician (adjusted odds ratio = 23.10; 95% confidence interval = 9.10-58.57; p < .001) and the presence of a do-not-resuscitate order while in the ICU (adjusted odds ratio = 7.33; 95% confidence interval = 3.69-14.54; p = .004) were the only variables independently associated with the withdrawal of life-sustaining therapies before death. CONCLUSIONS: Patients dying in a medical ICU setting without access to a private attending physician are more likely to undergo the active withdrawal of life-sustaining therapies before death than patients with a private attending physician. Health care providers should be aware of possible variations in the practice of withdrawal of life-sustaining therapies in their ICUs based on this patient characteristic.

15) Support Care Cancer 1999 Nov;7(6):437-8

General practitioners caring for terminally ill patients resident in a hospice.

Hermann I, Denekens J, Van den Eynden B, Van Royen P, Verrept H, Maes R

The goal of this study was to investigate why GPs have little or no involvement in the medical process relating to any of their patients when they are admitted to a palliative care unit (PCU) and what solutions they suggest. The study took the form of a descriptive pilot study based on a short questionnaire. It emerged that GPs felt their involvement was influenced by their job description, by practical factors (time investment, distance between practice and PCU, remuneration, referral) and personal issues (e.g. dealing with dying). It is concluded that GPs need education in palliative/supportive care and approved remuneration as well as knowledge about their task in the PCU.

16)J Cancer Educ 1999 Fall;14(3):144-7

Practicing physicians' assessments of the impact of their medical-school clinical hospice experience.

Seligman PA, Massey E, Fink RS, Nelson-Marten P, von Lobkowitz P

Department of Medicine of the University of Colorado School of Medicine, Lakewood, USA. Paul.Seligman@UCHSC.edu

BACKGROUND: The authors measured the impact of a clinical hospice experience in medical school on present medical practice by surveying former students after graduation. METHODS AND RESULTS: Of the graduates who apparently received anonymous questionnaires, 46 (71%) completed and returned them. Most were still in residency, and about a third were in private practice. Using a Likert scale, most gave the highest possible rankings in response to questions about how the experience had affected their present day-to-day communication with patients and their working knowledge of pain control, and the general question that asked about understanding quality-of-life issues. Written responses noted positive effects of the experience on the physicians' present practices, including improved knowledge of and attitudes towards dying patients, assessment of the effects of disease on patients and families, and quality-of-life. CONCLUSIONS: Although course work about death and dying is increasingly encountered in medical-school curricula, an intensive, focused clinical exposure is often lacking. This type of exposure has positive effects on physicians' self-assessments of their knowledge, attitudes, and skills in their present practices.

17) Crit Care Med 1999 Sep;27(9):2005-13

Incorporating palliative care into critical care education: principles, challenges, and opportunities.

Danis M, Federman D, Fins JJ, Fox E, Kastenbaum B, Lanken PN, Long K, Lowenstein E, Lynn J, Rouse F, Tulsky J

National Institutes of Health, Bethesda, MD 20892-1156, USA. mdanis@nih.gov

OBJECTIVE: To identify the goals and methods for medical education about end-of-life care in the intensive care unit (ICU). DATA SOURCES AND STUDY SELECTION: A status report on palliative care, a summary report of recent research on palliative care education, articles in the medical literature on end-of-life care and critical care, and expert opinion were considered. DATA EXTRACTION: A working group, including specialists in critical care, palliative care, medical ethics, consumer advocacy, and communications, was convened at the "Medical Education for Care Near the End of Life National Consensus Conference." A modified nominal group process was used to develop a consensus. DATA SYNTHESIS: In the ICU, life and death decisions are often made in a crisis mode or in the face of uncertainty, and may necessitate the withholding and withdrawal of life-supporting technologies. Because critical illness often diminishes the capacity of patients to make decisions, clinicians must often make decisions in conjunction with surrogates, rather than with patients. Discontinuity of care can threaten trusting relationships, and cultural diversity can have a particularly powerful impact on choices for care. In the face of these realities, it is possible and appropriate to give compassionate palliative care to dying patients and their families in the ICU. CONCLUSIONS: Teaching care of the dying in the ICU should emphasize the following: a) the goals of care should guide the use of technology; b) understanding of prognostication and treatment withholding and withdrawal is essential; c) effective communication and trusting relationships are crucial to good care; d) cultural differences should be acknowledged and respected; and e) the delivery of excellent palliative care is appropriate and necessary when patients die in the ICU.

18) Lijec Vjesn 1999 Jun;121(6):213-5

[Bioethics of dying].

Jusic A

Hrvatsko drustvo za hospicij/palijativnu skrb HLZ-a, Zagreb.

The bioethical problems related to the dying person might be classified in four groups: 1) those of the society the person is involved in, 2) those of physicians and other health professionals, 3) those of the nursing staff in the broadest sense and 4) those connected with the dying person himself. The society must consider the death as a part and natural end of life. One of the most delicate problems related to patient-physician relationship is adequate information concerning the diagnosis and prognosis of the condition. A very complex problem is stopping or not introducing the treatment which cannot influence significantly the quality and length of life. Palliative therapy, although risky, should be introduced if suffering is great. The duty to alleviate suffering is more important than life prolongation. The nursing staff and family should honour the wishes of the dying. Active euthanasia legalization is too risky, especially for nonautonomous persons unable to express their will. In autonomous persons even the possibility of its realization could be the cause of extreme disturbances in patient/physician relationship. Active euthanasia, due to the involvement of public opinion, is already becoming a sociopolitical problem.

19) Zentralbl Chir 1999;124(8):710-5

[Ethics of delivering the message of impending death].

[Article in German]

Splett J

Philosophisch-Theologische Hochschule Sankt Georgen, Frankfurt/M.

Two questions are discussed: 1. our relation to death. Contrary to the saying "shadows of the death" and to it's modern concealment this contribution states: death gives light: it enables to be conscious of one's self and to bow to the inevitable, it shows the valuables of earthly and mortal beings, and even allows us to hope. 2. Solidarity in the situation of death. This situation means the experience of being abandoned and in the same time the challenge to release the other (and to allow him to live [respectively to go]). Against the ego-centralizing power of pain and dread especially the dying needs aid--only to face to (the "hour of") truth. The decisive help is the helper: his being there and remaining by under the common fate.

20) Lancet 1999 Sep 4;354(9181):816-9

Will to live in the terminally ill.

Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D

Department of Psychiatry, University of Manitoba, Winnipeg, Canada. chochin@cc.umanitoba.ca

BACKGROUND: Complex biomedical and psychosocial considerations figure prominently in the debate about euthanasia and assisted suicide. No study to date, however, has examined the extent to which a dying patient's will to live fluctuates as death approaches. METHODS: This study examined patients with cancer in palliative care. Will to live was measured twice daily throughout the hospital stay on a self-report 100 mm visual analogue scale. This scale was incorporated into the Edmonton symptom assessment system, a series of visual analogue scales measuring pain, nausea, shortness of breath, appetite, drowsiness, depression, sense of well-being, anxiety, and activity. Maximum and median fluctuations in will-to-live ratings, separated by 12 h, 24 h, 7 days, and 30 days, were calculated for each patient. FINDINGS: Of 585 patients admitted to palliative care during the study period (November, 1993, to May, 1995), 168 (29%; aged 31-89 years) met criteria of cognitive and physical fitness and agreed to take part. The pattern of median changes in will-to-live score suggested that will to live was stable (median changes <10 mm on 100 mm scale for all time intervals). By contrast, the average maximum changes in will-to-live score were substantial (12 h 33.1 mm, 24 h 35.8 mm, 7 days 48.8 mm, 30 days 68.0 mm). In a series of stepwise regression models carried out at 12 h, 24 h, and 1-4 weeks after admission, the four main predictor variables of will to live were depression, anxiety, shortness of breath, and sense of well-being, with the prominence of these variables changing over time. INTERPRETATION: Among dying patients, will to live shows substantial fluctuation, with the explanation for these changes shifting as death approaches.

21) Arch Intern Med 1999 Aug 9-23;159(15):1741-4

Twenty years beyond medical school: physicians' attitudes toward death and terminally ill patients.

Dickinson GE, Tournier RE, Still BJ

Department of Sociology and Anthropology, College of Charleston, SC 29424, USA. dickinsong@cofc.edu

BACKGROUND: In response to consumer demands and recent changes in health care, the American Medical Association and the Association of American Medical Colleges have expressed concern about how physicians relate to patients, especially those who are seriously ill. OBJECTIVE: To determine the impact of 20 years of medical practice on the attitudes of physicians toward terminally ill patients and their families. METHODS: Data were gathered from questionnaires mailed in 1976 and again in 1996 to physicians who graduated from medical school between 1972 and 1975. RESULTS: Responses were received from 71% and 63% of the 1664 and 1109 physicians surveyed in 1976 and 1996, respectively. Using a t test for paired variables, statistically significant differences were noted for physicians' responses to all of the 11 Likert-type attitudinal statements on death and terminally ill patients and their families. Physicians in 1996 were more willing to inform terminally ill patients of their prognosis and in general seemed more confident with dying patients than they were in 1976. CONCLUSIONS: After 2 decades of practicing medicine, physicians' attitudes toward terminally ill patients seem to have changed; physicians appear to be more open to communicating with terminally ill patients and their families on issues concerning death and dying.

22) Hoitotiede 1998;10(4):207-15

[The nursing care of a dying patient on the health center ward--the relatives' point of view].

[Article in Finnish]

Mikkola-Salo V, Arve S, Lehtonen A, Routasalo P

The purposes of the study were to find out relatives' opinions about the care of dying patients as well as to find out how relatives assess the nursing care which was given to their nearest on the hospital wards. In order to collect the data for the study, the family members of patients (N = 628) who had died not more than one year before in the hospital, were interviewed. The interviewing was done by sending a questionnaire to every other relative (N = 314), 210 of which (62%) answered the questions. The answers to the structured questions were analyzed with the SAS-software and open-ended questions by the content analysis method. The relatives found that the hospital ward was quite a suitable environment for the nursing care of a dying patient. They found visiting hours flexible but they wished that they had the possibility to rest or stay over night in the hospital. The health care professionals responsible for the care of dying patients were considered to succeed in the field of the patient's rest and hygiene, but they took less well care of patient's physical exercise and dental hygiene. The relatives were satisfied with the pain relief the patient got. According to the relatives, examinations, medication, nursing interventions or the "futile" care given did not cause additional suffering. Although the nurses did not response to patients' spiritual well-being or needs of affections, they were able to make the patients happy with their kindness, presence and with good basic care. The relatives were best informed about patients' every day well-being, medication as well as practical matters concerning the time after the death of the patient. If the patient was transferred to another hospital for the terminal care, the relatives found, however, that they didn't get enough information of the situation. The health care professionals did not console the relatives for their grief and they had not been encouraged to participate in the care of their family members.

23) Neurology 1999 Jul 22;53(2):284-93

End-of-life care: a survey of US neurologists' attitudes, behavior, and knowledge.

Carver AC, Vickrey BG, Bernat JL, Keran C, Ringel SP, Foley KM

Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

OBJECTIVE: The American Academy of Neurology (AAN) surveyed the attitudes, behavior, and knowledge of its members regarding care at the end of life. Three groups of AAN members were surveyed: neuro-oncologists, ALS specialists, and a representative sample of US neurologists. METHODS: The survey presented two clinical scenarios involving end-of-life care. Neurologists were asked a series of questions to assess their knowledge of existing medical, ethical, and legal guidelines; their willingness to participate in physician-assisted suicide (PAS) or carry out voluntary euthanasia (VE); and their general attitudes regarding end-of-life care. RESULTS: Neurologists support a patient's right to refuse life-sustaining treatment, but many believe that they are killing their patients in supporting such refusals. Thirty-seven percent think it is illegal to administer analgesics in doses that risk respiratory depression to the point of death. Forty percent believe they should obtain legal counsel when considering stopping life-sustaining treatment. One half believe that PAS should be made explicitly legal by statute for terminally ill patients. Under current law, 13% would participate in PAS and 4% would carry out VE; if those procedures were legalized, 44% would participate in PAS and 28% in VE. Approximately one third believe that physicians have the same ethical duty to honor a terminally ill patient's request for PAS as they do to honor a such a patient's refusal of life-sustaining therapy. CONCLUSIONS: There is a gap between established medical, legal, and ethical guidelines for the care of dying patients and the beliefs and practices of many neurologists, suggesting a need for graduate and postgraduate education programs in the principles and practices of palliative care medicine. Many neurologists would participate in PAS and carry out VE if legalized.

24) Eur J Pediatr 1999 Jul;158(7):560-5

Circumstances of dying in hospitalized children.

van der Wal ME, Renfurm LN, van Vught AJ, Gemke RJ

Department of Paediatrics, University Children's Hospital Wilhelmina, Utrecht, The Netherlands.

Conditions of dying in a tertiary children's hospital were assessed in a retrospective cohort study. Non-survivors, excluding newborns and emergency room patients, were allocated to four groups: brain death (BD), failed cardiopulmonary resuscitation (failed CPR), death following a do-not-resuscitate (DNR) order and death following withholding or withdrawal of therapy (W/W). In a 4-year period 190 (1.3%) of 14,903 admitted patients died. Of these 134 (71%) died on the paediatric intensive care unit, 42 (22%) on the ward and 14 (7%) in the operating room. W/W was found in 75 (39%), failed CPR in 57 (30%), BD in 32 (17%), and death following a DNR order in 26 (14%). Justifications for restrictions of treatment (W/W or DNR) were imminent death in 41 (41%), lack of future relational potential in 13 (13%) and excessive burden of disease in 47 (47%). In non-survivors analgesics and sedatives were frequently used to relieve suffering in the terminal phase. General principles for the approach of terminally ill children in whom death may become an option instead of a fate are discussed. CONCLUSION: In the majority of children dying in hospital, death occurred following restrictions of life-sustaining treatment, comprising do-not-resuscitate or other forms of withholding or withdrawal of therapy.

25) Gan To Kagaku Ryoho 1999 Jun;26 Suppl 1:70-6

[Progress in palliative medicine].

[Article in Japanese]

Ishitani K

Higashi Sapporo Hospital.

The major factors in the progress in palliative medicine in Japan are the hospice movement, as represented by the activities of the Japanese Association for Clinical Research on Death and Dying, and interdisciplinary research on the quality of life (QOL), particularly in the field of clinical oncology. Palliative medicine as a new paradigm today encompasses the fields of biology, psychology, sociology, and ethics, all of which are making steady progress under the banner of evidence-based medicine. In recent years, the problems of euthanasia and physician-assisted suicide, subjects of great debate and public concern, especially in America and European countries, have been studied in the field of psycho-oncology and continue to attract considerable attention. The relationship between depression and social supports is said to be of particular importance. The American Society of Clinical Oncology (ASCO) has made a positive statement to the effect that it would not hesitate in confronting the so-called "end-of-life" issue. All of these global trends point to the increasing importance of palliative medicine.

26) Suicide Life Threat Behav 1999 Summer;29(2):97-104

Reasons for living versus reasons for dying: examining the internal debate of suicide.

Jobes DA, Mann RE

Department of Psychology, Catholic University of America, Washington, DC 20064, USA.

The Reasons for Living vs. Reasons for Dying (RFL/RFD) Assessment was used to obtain suicidal outpatients' top five reasons for living and for dying, respectively. Forty-nine suicidal university counseling center patients provided 173 RFL and 145 RFD responses. These responses were organized into eight RFL coding categories and nine RFD coding categories. Two coders trained in the RFL/RFD coding system showed high levels of interrater reliability (KRFL = .81; KRFD = .80). Chi-square results for RFL and RFD coding categories showed that the coding categories were not equally salient to these suicidal patients.

27) Psychosomatics 1999 Jul-Aug;40(4):309-13

Quality of life in hospice patients. A pilot study.

Bretscher M, Rummans T, Sloan J, Kaur J, Bartlett A, Borkenhagen L, Loprinzi C

Department of Psychiatry, Mayo Clinic, Rochester, Minnesota 55905, USA.

The general public and the medical community often perceive dying patients' quality of life (QOL) as rapidly deteriorating before death. However, with appropriate palliative services, this effect may be positively modified. Objective data are lacking on the true experience of dying from the point of view of the patient that this pilot study begins to address. Patients caregivers, and staff in our hospice program completed questionnaires evaluating the patient's QOL every 2 weeks until the patient's death. This pilot study found that patients QOL was relatively high and stable over time. Primary caregivers rated the patient's QOL lower than patient self-ratings, whereas the hospice staff evaluated the patient's QOL similarly to the patient. Many dying patients suffer and are perceived as having no QOL in the final days by their caregivers. This perception may be modified to maintain one's QOL with the help of palliative medical services, thereby relieving the suffering of those who are actively facing death.

28) Can Nurse 1998 Oct;94(9):40-4, 46

[Palliative care, a humanitarian way].

[Article in French]

Gendron C

This portion of a study, first published last month, examines the various aspects of dying (including the dying person's needs); looks introspectively at the spiritual aspect of death; and analyzes the behavior and attitudes of care-giving staff, their values, motivations and needs. While dying people may have unpredictable attitudes and behavior, nurses need to maintain an attitude of caring and communication in their interventions. Important to consider when nursing the dying are subjects such as: establishing a helping relationship; appropriate communication; and self-knowledge and preconceived notions. Criticism most often directed at palliative care suggests that curative and palliative care should be integrated; should abandon their reserved territories (such as care units); and should develop an association that goes beyond the terminal phase.

29) Oncol Nurs Forum 1999 Jun;26(5):869-76

Analysis of end-of-life content in nursing textbooks.

Ferrell B, Virani R, Grant M

City of Hope National Medical Center, Duarte, CA, USA.

PURPOSE/OBJECTIVES: To determine the amount and types of content regarding pain and end-of-life (EOL) care included in major textbooks used in nursing education. DESIGN: Descriptive. SAMPLE: 50 texts (45,683 pages) selected from a potential of more than 700 texts. METHODS: Content analysis and quantification of nine essential areas of EOL care content present in the texts. MAIN RESEARCH VARIABLES: Nine areas of EOL care: palliative care defined; quality of life, pain; other symptom assessment/management; communication with dying patients and families; role/needs of family caregivers in EOL care; death; issues of policy, ethics, and law; and bereavement. FINDINGS: Only 2% of the overall content and 1.4% of chapters in nursing texts were related to EOL care. Based on the analysis, many deficiencies were identified in the texts, including inaccurate information and a lack of information regarding critical EOL topics. CONCLUSIONS: Nursing texts contain limited content regarding EOL care. Increased attention to this area is essential in preparing nurses to care for patients at EOL. IMPLICATIONS FOR NURSING PRACTICE: Nursing practice is based on the foundation of nursing education. Changes in nursing school curriculum and provision of continuing education for practicing nurses are essential for improved EOL care.

30) J Prof Nurs 1999 May-Jun;15(3):151-9

Assisted suicide and nursing: possibly compatible?

White BC

Department of Philosophy, California State University, Chico 95929-0730, USA.

This article argues that the American Nurses Association's (ANA) prohibition of nurse-assisted suicide is misguided. The ANA's reasons for this policy do not provide the necessary conceptual or empirical support for the prohibition. In fact, arguments appear to lead to support for nurse-assisted suicide: (1) because the claim that death is always harmful may be false, the obligation to "do no harm" does not necessarily preclude assisted suicide (AS); (2) currently we have no evidence that AS would erode public trust in nurses; (3) AS may be compatible with the professional integrity of nursing, particularly the commitments to respecting autonomy, promoting patient welfare, and providing compassionate care; (4) nursing's participation would constrain, rather than contribute to, the potential for abuse to vulnerable patient populations; and (5) the professional has a responsibility to either embrace the public's increasing support of aid in dying or determine why AS is morally indefensible and educate the public.

1)Oncologist 2000;5(1):53-62
Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.

Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ Jr

Hematology-Oncology Department, Massachusetts General Hospital, Boston 02114-2617, USA.

Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded the Kenneth B. Schwartz Center at MGH. The Schwartz Center is a nonprofit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to caregivers, and encourages the healing process. The Center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. The case presented is of a young man dying of recurrent epithelioid hemangioendothelioma, distressed with stridor and severe pain, whose poorly controlled symptoms were successfully treated with an infusion of propofol, titrated to provide effective comfort in the last few hours of the patient's life. The tenet of double effect, which allows aggressive treatment of suffering in spite of foreseeable but unintended consequences, is reviewed. The patient's parents were invited and contributed to the Rounds, providing compelling testimony to the power of the presence of clinicians at the time of death and the importance of open communication about difficult ethical issues.

2)Perspect Biol Med 1999 Autumn;43(1):103-11
On dying with personhood: socratic death.

Potter VR

McArdle Laboratory for Cancer Research, Madison, WI 53706, USA.

 

3)J Palliat Care 1999 Winter;15(4):13-9
Age is not the crucial factor in determining how the palliative care needs of people who die from cancer differ from those of people who die from other causes.

Addington-Hall JM, Karlsen S

Department of Palliative Care and Policy, Guy's, King's and St Thomas' School of Medicine, London, UK.

A belief that the hospice philosophy is particularly applicable to younger people may account in part for the continued focus of palliative care on cancer patients, as it has been argued that age is the crucial factor in determining how cancer and non-cancer patients differ. We conducted a secondary analysis of the data from a UK population-based retrospective survey, the Regional Study of Care for the Dying, to critically examine this proposition. The sample comprised 2062 cancer and 1471 non-cancer deaths. On average cancer patients were younger. However, at all ages non-cancer and cancer patients differed significantly with, for example, different patterns of dependency and symptomatology. The cause of death--rather than age--is therefore the principal difference between cancer and non-cancer patients. The debate within palliative care on whether and how to provide services for non-cancer patients must move beyond a focus on group differences such as age between these and cancer patients and focus instead on understanding the varying problems non-cancer patients experience, and addressing how best to organize palliative care services to meet the individual needs of these patients.

4)Transfusion 2000 Feb;40(2):135-8
Apoptosis in transfusion medicine:of death and dying-is that all there is?

Snyder EL, Kuter DJ

Yale University School of Medicine, New Haven CT, Harvard Medical School, Boston, MA.

 

5)JAMA 2000 Feb 9;283(6):771-8
End-of-life care content in 50 textbooks from multiple specialties.

Rabow MW, Hardie GE, Fair JM, McPhee SJ

Division of General Internal Medicine, University of California, San Francisco 94115, USA. mrabow@medicine.ucsf.edu

CONTEXT: Prior reviews of small numbers of medical textbooks suggest that end-of-life care is not well covered in textbooks. No broad study of end-of-life care content analysis has been performed on textbooks across a wide range of medical, pediatric, psychiatric, and surgical specialties. OBJECTIVE: To determine the quantity and rate the adequacy of information on end-of-life care in textbooks from multiple medical disciplines. DESIGN AND SOURCES: A 1998 review of 50 top-selling textbooks from multiple specialties (cardiology, emergency medicine, family and primary care medicine, geriatrics, infectious disease and acquired immunodeficiency syndrome [AIDS], internal medicine, neurology, oncology and hematology, pediatrics, psychiatry, pulmonary medicine, and surgery) for the presence and adequacy of content in 13 end-of-life care domains. MAIN OUTCOME MEASURES: Chapters on diseases commonly causing death and those devoted to end-of-life care were identified, read, rated, and compared by textbook specialty, chapter, and domain for the presence of helpful information in the 13 domains. Content for each domain was rated as absent, minimally present, or helpful. Textbook indexes were analyzed for the number of pages relevant to end-of-life care. RESULTS: Overall, helpful information was provided in 24.1% (range, 8.7%-44.2%) of the expected end-of-life content domains; in 19.1% (range, 6.2%-38.5%), expected content received minimal attention; and in 56.9% (range, 23.1 %-77.9%), expected content was absent. As a group, the textbooks with the highest percentages of absent content were in surgery (71.8%), infectious diseases and AIDS (70%), and oncology and hematology (61.9%). Textbooks with the highest percentage of helpful end-of-life care content were in family medicine (34.4%), geriatrics (34.4%), and psychiatry (29.6%). In internal medicine textbooks, the content domains with the greatest amount of helpful information were epidemiology and natural history. Content domains covered least well were social, spiritual, ethical, and family issues, as well as physician after-death responsibilities. On average, textbook indexes cited 2% of their total pages as pertinent to end-of-life care. CONCLUSION: Top-selling textbooks generally offered little helpful information on caring for patients at the end of life. Most disease-oriented chapters had no or minimal end-of-life care content. Specialty textbooks with information about particular diseases often did not contain helpful information on caring for patients dying from those diseases.

6)Dtsch Med Wochenschr 2000 Jan 21;125(3):45-51
[Decubitus ulcer in the terminal phase: epidemiologic, medicolegal and ethical aspects].

Heinemann A, Lockemann U, Matschke J, Tsokos M, Puschel K

Institut fur Rechtsmedizin, Universitatsklinik Eppendorf, Hamburg. heineman@uke.uni-hamburg.de

BACKGROUND AND OBJECTIVES: Pressure sores usually result from insufficient preventive measures. They are particularly omnipresent among dying persons in geriatric care. This study deals with prevalence, risk factors and the significance of the nursing environment. PATIENTS AND METHODS: The prevalence of pressure sores among the dead was analysed in a prospective cross-sectional study based on 10,222 postmortem examinations in a crematorium in Hamburg. RESULTS: The overall prevalence of pressure sores from grades I to IV was 11.2% (grade I: 6.1%, grade II: 3%, grade III: 1.1%, grade IV: 0.9%). A final logistic regression model showed that pressure sores of Grade III or IV were associated with female gender, date of death in the summer, marasmus, stroke history, neurological disease in general, kidney disease, preceding traumatic events and nursery home residence at the time of death. More than half of all the grade IV cases were diagnosed among nursing home residents whereas those who had died in hospitals contributed to only 11.5% of all the grade IV cases (dead from private homes 34.4%). Nursing home residence was associated with female gender, marasmus and stroke history which predisposed to a higher rate of pressure sores. CONCLUSIONS: Nursing homes are confronted with the highest proportion of pressure sores among dying people when compared to hospitals or private home care. Failure to meet the standards of preventive action against pressure sores point to the shortfalls in the present public health sector and nursing home regulations as well as the medical responsibility for supervision of nursing care. Apart from established standards of care, medicolegal assessment of high-grade pressure sores should also take ethical considerations into account when considering maximum therapy goals among dying persons.

7)Health Place 1999 Mar;5(1):119-24
A death in our street.

Walter T

Department of Sociology, University of Reading, Whiteknights, UK.

How do neighbours relate to the dying, and what effect does a death have on a neighbourhood? After briefly reviewing related literature, the article explores the concepts of reciprocity and solidarity, using the recent work of Michael Young to highlight limitations in the work of Philip Abrams. The potential of suffering to generate neighbourhood solidarity in an increasingly affluent and private society is considered.

8)Palliat Med 1999 Jul;13(4):275-83
Lay carers' satisfaction with community palliative care: results of a postal survey. South Tyneside MAAG Palliative Care Study Group.

Lecouturier J, Jacoby A, Bradshaw C, Lovel T, Eccles M

Centre for Health Services Research, Newcastle upon Tyne, UK.

This paper reports the substantive findings of a study that examined the feasibility of using postal questionnaires to assess the satisfaction of lay caregivers with the care received in the community by those dying of cancer. The focus of the analysis was the quality of information provided by health professionals, health services used in the final year of the dying person's life and the lay carer's views about the quality of these services. The study was a retrospective survey of lay carers identified from death certificates over a 9-month period. Of the 355 people contacted, 156 completed the questionnaires, a 44% response rate. The results of the survey indicate that information provision was deemed unsatisfactory by a large proportion of respondents, and that dissatisfaction with care received from hospital, the district nursing service and the general practitioner was common. Levels of satisfaction with care were clearly related to a range of service factors. Our survey also highlighted clear differences in the perceived quality of specialist and generic services for those dying of cancer. A comparison of the findings from this postal study with those reported in earlier retrospective interview surveys of lay carers suggests that the use of the postal questionnaire is a valid and cost-effective approach for assessing quality of care. The data provide baseline information against which improvements in the quality of care can be measured.

9)Anticancer Res 1999 Sep-Oct;19(5C):4441-2
Fentanyl patches for the treatment of pain in dying cancer patients.

Jakobsson M, Strang P

Palliative Care Unit Linnea, Vrinnevi Hospital, Norrkoping, Sweden. Maria.Jakobsson@lio.se

It has been claimed that fentanyl patches are less suitable for elderly patients and for patients who are terminally ill and dying. In a retrospective survey of 205 cancer patients who died within the hospital-based home care in Norrkoping, Sweden between January 1997 and June 1998 we identified 34 patients who had used fentanyl patches. 30 patients were possible to evaluate for the analgesic efficacy of transdermal fentanyl. 18 out of 30 patients were treated with fentanyl until time of death. The estimated efficacy was good or moderate in 93% and 88%, respectively, of patients younger or older than 65 years of age.

CUIDADOS PALIATIVOS

1)Oncologist 2000;5(1):53-62
Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.

Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ Jr

Hematology-Oncology Department, Massachusetts General Hospital, Boston 02114-2617, USA.

Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded the Kenneth B. Schwartz Center at MGH. The Schwartz Center is a nonprofit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to caregivers, and encourages the healing process. The Center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. The case presented is of a young man dying of recurrent epithelioid hemangioendothelioma, distressed with stridor and severe pain, whose poorly controlled symptoms were successfully treated with an infusion of propofol, titrated to provide effective comfort in the last few hours of the patient's life. The tenet of double effect, which allows aggressive treatment of suffering in spite of foreseeable but unintended consequences, is reviewed. The patient's parents were invited and contributed to the Rounds, providing compelling testimony to the power of the presence of clinicians at the time of death and the importance of open communication about difficult ethical issues.

2)Perspect Biol Med 1999 Autumn;43(1):103-11
On dying with personhood: socratic death.

Potter VR

McArdle Laboratory for Cancer Research, Madison, WI 53706, USA.

3)J Palliat Care 1999 Winter;15(4):13-9
Age is not the crucial factor in determining how the palliative care needs of people who die from cancer differ from those of people who die from other causes.

Addington-Hall JM, Karlsen S

Department of Palliative Care and Policy, Guy's, King's and St Thomas' School of Medicine, London, UK.

A belief that the hospice philosophy is particularly applicable to younger people may account in part for the continued focus of palliative care on cancer patients, as it has been argued that age is the crucial factor in determining how cancer and non-cancer patients differ. We conducted a secondary analysis of the data from a UK population-based retrospective survey, the Regional Study of Care for the Dying, to critically examine this proposition. The sample comprised 2062 cancer and 1471 non-cancer deaths. On average cancer patients were younger. However, at all ages non-cancer and cancer patients differed significantly with, for example, different patterns of dependency and symptomatology. The cause of death--rather than age--is therefore the principal difference between cancer and non-cancer patients. The debate within palliative care on whether and how to provide services for non-cancer patients must move beyond a focus on group differences such as age between these and cancer patients and focus instead on understanding the varying problems non-cancer patients experience, and addressing how best to organize palliative care services to meet the individual needs of these patients.

4)Transfusion 2000 Feb;40(2):135-8
Apoptosis in transfusion medicine:of death and dying-is that all there is?

Snyder EL, Kuter DJ

Yale University School of Medicine, New Haven CT, Harvard Medical School, Boston, MA.

 

5)JAMA 2000 Feb 9;283(6):771-8
End-of-life care content in 50 textbooks from multiple specialties.

Rabow MW, Hardie GE, Fair JM, McPhee SJ

Division of General Internal Medicine, University of California, San Francisco 94115, USA. mrabow@medicine.ucsf.edu

CONTEXT: Prior reviews of small numbers of medical textbooks suggest that end-of-life care is not well covered in textbooks. No broad study of end-of-life care content analysis has been performed on textbooks across a wide range of medical, pediatric, psychiatric, and surgical specialties. OBJECTIVE: To determine the quantity and rate the adequacy of information on end-of-life care in textbooks from multiple medical disciplines. DESIGN AND SOURCES: A 1998 review of 50 top-selling textbooks from multiple specialties (cardiology, emergency medicine, family and primary care medicine, geriatrics, infectious disease and acquired immunodeficiency syndrome [AIDS], internal medicine, neurology, oncology and hematology, pediatrics, psychiatry, pulmonary medicine, and surgery) for the presence and adequacy of content in 13 end-of-life care domains. MAIN OUTCOME MEASURES: Chapters on diseases commonly causing death and those devoted to end-of-life care were identified, read, rated, and compared by textbook specialty, chapter, and domain for the presence of helpful information in the 13 domains. Content for each domain was rated as absent, minimally present, or helpful. Textbook indexes were analyzed for the number of pages relevant to end-of-life care. RESULTS: Overall, helpful information was provided in 24.1% (range, 8.7%-44.2%) of the expected end-of-life content domains; in 19.1% (range, 6.2%-38.5%), expected content received minimal attention; and in 56.9% (range, 23.1 %-77.9%), expected content was absent. As a group, the textbooks with the highest percentages of absent content were in surgery (71.8%), infectious diseases and AIDS (70%), and oncology and hematology (61.9%). Textbooks with the highest percentage of helpful end-of-life care content were in family medicine (34.4%), geriatrics (34.4%), and psychiatry (29.6%). In internal medicine textbooks, the content domains with the greatest amount of helpful information were epidemiology and natural history. Content domains covered least well were social, spiritual, ethical, and family issues, as well as physician after-death responsibilities. On average, textbook indexes cited 2% of their total pages as pertinent to end-of-life care. CONCLUSION: Top-selling textbooks generally offered little helpful information on caring for patients at the end of life. Most disease-oriented chapters had no or minimal end-of-life care content. Specialty textbooks with information about particular diseases often did not contain helpful information on caring for patients dying from those diseases.

6)Dtsch Med Wochenschr 2000 Jan 21;125(3):45-51
[Decubitus ulcer in the terminal phase: epidemiologic, medicolegal and ethical aspects].

Heinemann A, Lockemann U, Matschke J, Tsokos M, Puschel K

Institut fur Rechtsmedizin, Universitatsklinik Eppendorf, Hamburg. heineman@uke.uni-hamburg.de

BACKGROUND AND OBJECTIVES: Pressure sores usually result from insufficient preventive measures. They are particularly omnipresent among dying persons in geriatric care. This study deals with prevalence, risk factors and the significance of the nursing environment. PATIENTS AND METHODS: The prevalence of pressure sores among the dead was analysed in a prospective cross-sectional study based on 10,222 postmortem examinations in a crematorium in Hamburg. RESULTS: The overall prevalence of pressure sores from grades I to IV was 11.2% (grade I: 6.1%, grade II: 3%, grade III: 1.1%, grade IV: 0.9%). A final logistic regression model showed that pressure sores of Grade III or IV were associated with female gender, date of death in the summer, marasmus, stroke history, neurological disease in general, kidney disease, preceding traumatic events and nursery home residence at the time of death. More than half of all the grade IV cases were diagnosed among nursing home residents whereas those who had died in hospitals contributed to only 11.5% of all the grade IV cases (dead from private homes 34.4%). Nursing home residence was associated with female gender, marasmus and stroke history which predisposed to a higher rate of pressure sores. CONCLUSIONS: Nursing homes are confronted with the highest proportion of pressure sores among dying people when compared to hospitals or private home care. Failure to meet the standards of preventive action against pressure sores point to the shortfalls in the present public health sector and nursing home regulations as well as the medical responsibility for supervision of nursing care. Apart from established standards of care, medicolegal assessment of high-grade pressure sores should also take ethical considerations into account when considering maximum therapy goals among dying persons.

7)Health Place 1999 Mar;5(1):119-24
A death in our street.

Walter T

Department of Sociology, University of Reading, Whiteknights, UK.

How do neighbours relate to the dying, and what effect does a death have on a neighbourhood? After briefly reviewing related literature, the article explores the concepts of reciprocity and solidarity, using the recent work of Michael Young to highlight limitations in the work of Philip Abrams. The potential of suffering to generate neighbourhood solidarity in an increasingly affluent and private society is considered.

 

8)Palliat Med 1999 Jul;13(4):275-83
Lay carers' satisfaction with community palliative care: results of a postal survey. South Tyneside MAAG Palliative Care Study Group.

Lecouturier J, Jacoby A, Bradshaw C, Lovel T, Eccles M

Centre for Health Services Research, Newcastle upon Tyne, UK.

This paper reports the substantive findings of a study that examined the feasibility of using postal questionnaires to assess the satisfaction of lay caregivers with the care received in the community by those dying of cancer. The focus of the analysis was the quality of information provided by health professionals, health services used in the final year of the dying person's life and the lay carer's views about the quality of these services. The study was a retrospective survey of lay carers identified from death certificates over a 9-month period. Of the 355 people contacted, 156 completed the questionnaires, a 44% response rate. The results of the survey indicate that information provision was deemed unsatisfactory by a large proportion of respondents, and that dissatisfaction with care received from hospital, the district nursing service and the general practitioner was common. Levels of satisfaction with care were clearly related to a range of service factors. Our survey also highlighted clear differences in the perceived quality of specialist and generic services for those dying of cancer. A comparison of the findings from this postal study with those reported in earlier retrospective interview surveys of lay carers suggests that the use of the postal questionnaire is a valid and cost-effective approach for assessing quality of care. The data provide baseline information against which improvements in the quality of care can be measured.

9)Anticancer Res 1999 Sep-Oct;19(5C):4441-2
Fentanyl patches for the treatment of pain in dying cancer patients.

Jakobsson M, Strang P

Palliative Care Unit Linnea, Vrinnevi Hospital, Norrkoping, Sweden. Maria.Jakobsson@lio.se

It has been claimed that fentanyl patches are less suitable for elderly patients and for patients who are terminally ill and dying. In a retrospective survey of 205 cancer patients who died within the hospital-based home care in Norrkoping, Sweden between January 1997 and June 1998 we identified 34 patients who had used fentanyl patches. 30 patients were possible to evaluate for the analgesic efficacy of transdermal fentanyl. 18 out of 30 patients were treated with fentanyl until time of death. The estimated efficacy was good or moderate in 93% and 88%, respectively, of patients younger or older than 65 years of age.

Volver


Equidad y Salud

EQUIDAD Y BIOETICA

Tittle
Equity is out of fashion? An essay on autonomy and health policy in the individualized society.
Author
Lindbladh E; Lyttkens CH; Hanson BS; Ostergren PO
Address
Department of Community Medicine, MalmÂo University Hospital, Sweden.
Source
Soc Sci Med, 1998 Apr, 46:8, 1017-25
Abstract
It is widely recognized that there is a discrepancy between principle and practice with respect to the health equity aim of public policy. This discrepancy is analyzed from two theoretical perspectives: the individualization of society and the fact that individual beliefs and values are connected to one's position in the social structure. These mechanisms influence both the choice of health policy measures and the normative judgements of preventive efforts, both of which tend to be consonant with the views of dominant social groups. In particular, we focus on the treatment of the ethical principle of autonomy and how this is reflected in health policy aimed at influencing health-related behaviour. We examine the current trend towards targeting health information campaigns on certain socio-economic groups and argue that it entails an ethical dilemma. The dominant discourse of the welfare state is contemplated as a means to understand why there tend to be a lack of emphasis on measures that are targeted at socio-economic inequalities. It is argued that there is no substantive basis in the individualized society for perceiving health equity as an independent moral principle and that the driving force behind the professed health equity goal may be in essence utilitarian.
Title
Data needs in studies on equity in health and access to care--ethical considerations.
Author
Rosén M
Address
Centre for Epidemiology, National Board of Health and Welfare, Stockholm, Sweden. mans.rosen@sos.se
Source
Acta Oncol, 1999, 38:1, 71-5
Abstract
In order to study equity in health and access to care in an appropriate way, data are needed on an individual level and must include information about health, mortality, morbidity, utilization of care, age, sex, residential area, family situation and the social and economic circumstances of each individual. These data must be collected at several points of time during a life cycle. This is a demanding task requiring many resources and methodological and ethical considerations. The ethical and political trade-off is between our demand for knowledge and a fair distribution of resources in order to achieve equity in health and access to care and the need to administrate sensitive data without threatening personal integrity. In presenting results from Swedish studies, it is argued that the benefits of using registers for this kind of epidemiological research by far outweigh the risk of using registers.
Title
[What should medical decision be based on?]
Author
Grenier B
Address
 
Source
Rev Med Interne, 1997, 18:3, 250-4
Abstract
Medical decision making is basically related to three criteria: 1) estimated effectiveness in terms of objective and subjective results: 2) equity related to the concept of justice in the societal context; 3) legitimacy according to the willingness to pay of the society, its resource availability and the fraction of its income that is allowed to be spent for health care. A worsening dilemma is unescapable between a utilitarian medical project, and the traditional hippocratic rule of rescue no matter what the cost may be. Every care taker should be involved to give a clear account of medical decision in order to generate and adopt some acceptable view for a reliable implementation with respect to equity and justice.
Title
Consent, equity and ethics in new nursing.
Author
Furlong S; Glover D
Address
Nursing Developments Programme, King's Fund, London.
Source
Nurs Times, 1998 Sep, 94:38, 52-3
Abstract
The development of new nursing roles is set to continue. Patients may not always be aware that the person giving them care is a nurse. This paper explores some of the issues of ethics, equity and consent as nursing becomes involved in more invasive and independent areas of practice.
Title
Ethical considerations related to outcome studies-based clinical practice guidelines.
Author
Panek WC
Address
 
Source
J Glaucoma, 1999 Aug, 8:4, 267-72
Abstract
Expanding demand for health services is occurring in the face of diminishing resources. Root causes for this phenomenon include advancing expensive new technology and marked variations in quality of care and patterns of practice. Practice guidelines resulting from valid and appropriate outcome studies have the potential to promote consistency and quality. Perceived drawbacks to such guidelines include over-regulation and loss of autonomy for both physicians and patients. Clinical practice guidelines are discussed in the context of major ethical theories, including deontology, utilitarianism, and contractarianism. The conflicting needs and motivations of physicians, patients, third-party carriers, and society as a whole are discussed relative to these different ethical perspectives. Although contrasting ethical foundations likely will lead to significantly different solutions to the healthcare resource problem, it is only through educated and reasoned discussion that this difficult problem can be tackled. Sound ethical discipline is imperative when considering the related issues of equity, justice, and autonomy in a society with progressively decreasing resources.
Title
Ethical considerations in contemporary medicine [editorial]
Author
Stulhofer M
Address
 
Source
Acta Med Croatica, 1998, 52:1, 1-5
Abstract
Numerous benefits brought along by the impressive technological progress of the contemporary world are also accompanied by potential hazards of dehumanization of life. As neither medicine has been skipped over by the technological progress, there is a risk for the physician to become dependent on it rather than master it. Therefore, there is the risk of deprivation of medical ethics norms, ever more frequently transforming the patient's position of the subject of medical activities into the position of an object. This pending risk is especially present in surgery, a medical discipline characterized by the highest technological and technical differentiation. If the surgeon is to preserve high ethical standards in his work, he should strictly follow the basic medical ethics norm, that proclaim full respect of the patient's will, forbid doing harm to the patient, and point to equity and compassion on providing medical aid. These ethical norms should be respected not only on performing surgical procedures, but also on making indications for the procedure. The future development of medicine and surgery, with a substantial impact of new, technical and technological advances, will open new, presently unknown ethical issues. All this will require through sociophilosophical and humane-ethical considerations in order to preserve the basic medical ethics norms warranting humaneness and ethics of medicine.
Title
Assumptions and practice in clinical medical ethics.
Author
Baker AB
Address
Department of Anaesthesia, University of Sydney, N.S.W.
Source
Anaesth Intensive Care, 1997 Oct, 25:5, 528-34
Abstract
An orderly scheme of action is proposed to allow for the practical solution of clinical ethical problems. This scheme depends on understanding and discussion, between patient and doctor, of the ethical assumptions involved in any dilemma. Instead of the more usual ethical principles, arguments are presented for six basic ethical assumptions (and their associated corollaries) in favour of Life, Autonomy, Beneficence, Equity, Truth, and Law. Because these assumptions are dependent on the different personal viewpoints of the people involved and not immutable principles, such ethical assumptions are able to be set in different hierachical orders on different occasions permitting in most cases a particular solution specific for that dilemma.
Title
Ethical issues in radiation protection.
Author
Shrader Frechette K; Persson L
Address
Environmental Sciences and Policy Program and Philosophy Department, University of South Florida, Tampa 33620-5550, USA.
Source
Health Phys, 1997 Aug, 73:2, 378-82
Abstract
In this note the authors survey existing international radiation-protection recommendations of the ICRP, the IAEA, and the ILO. After outlining previous work on the ethics of radiation protection and risk assessment/management, the authors review ethical thinking on five key issues related to radiation protection and ethics. They formulate each of these five issues in terms of alternative ethical stances: (1) Equity vs. Efficiency, (2) Health vs. Economics, (3) Individual Rights vs. Societal Benefits, (4) Due Process vs. Necessary Sacrifice, and (5) Stakeholder Consent vs. Management Decisions.

Title

Ethical policy guidelines development for general hospital nurses.
Author
Commons L; Baldwin S
Address
Department of Nursing, Faculty of Health and Human Sciences Edith Cowan University, Bunbury, Western Australia.
Source
Int J Nurs Stud, 1997 Feb, 34:1, 1-8
Abstract
The purpose of this position paper is to examine ethical situations involving nurses, and provide suggestions about how to work through ethical problems they may encounter. Ethics in the nursing profession is ubiquitous. Nurses need to be aware of the provided codes so any ambiguity regarding ethical dilemmas can be resolved. Ethical situations which call for such judgements include: equity, confidentiality, honesty and justice. Resolution of such situations requires consistent education to ensure full awareness of societal values which are projected through the care of clients. This will aid in the provision of quality care and ensure that a holistic approach is achieved to maintain high standards of care.
Title
Screening for early detection of cancer--ethical aspects.
Author
Törnberg SA
Address
Oncologic Centre, M8, Karolinska Hospital, Stockholm, Sweden.
Source
Acta Oncol, 1999, 38:1, 77-81
Abstract
Ethical principles to be followed in cancer screening programmes are intended mainly to minimize unnecessary harm for the participating individuals. The principles that have been recommended by the Council of Europe, Committee of Ministers are: 1) Effectiveness is a necessary prerequisite for a screening activity to be ethical. 2) The need for a balance between the advantages and disadvantages of screening for a target population and an individual, between social and economic costs, equity and individual rights and freedoms. 3) The need for information about both the positive and the negative aspects of a screening programme. 4) The decision to participate in a screening programme or in research should be taken freely. 5) The right to integrity, i.e., the results of the tests are not communicated to those who do not wish to be informed, and the need to have laws and regulations on any communication of personal data derived from screening to third parties.
Title
Ethical issues in radiation protection, continued.
Author
Schwarz D
Address
VEW ENERGIE AG, Dortmund, Germany.
Source
Health Phys, 1998 Aug, 75:2, 183-6
Abstract
Shrader-Frechette and Persson (1997) reviewed ethical thinking on (1) Equity vs. Efficiency, (2) Health vs. Economics, (3) Individual Rights vs. Societal Benefits, (4) Due Process vs. Necessary Sacrifice, and (5) Stakeholder Consent vs. Management Decisions. This discussion offers reasoned conclusions pertaining to these five topics. In addition, ethical aspects are discussed as to (6) Psychological Harm Through Fear of Radiation, (7) Economical-ecological Harm Through Fear of Radiation, and (8) Science: the Question of Truth.
Title
Ethical issues in genetic screening for cancer.
Author
Vineis P
Address
Unit of Cancer Epidemiology, Main Hospital and University of Torino, Italy.
Source
Ann Oncol, 1997 Oct, 8:10, 945-9
Abstract
Genetically-based diseases with a late onset, such as BRCA1-dependent breast cancer or Huntington's disease, can be predicted by the screening of relevant mutations in members of high-risk families. Genetic screening is characterized by a conflict between respect for autonomy--e.g., the 'right not to know'--and responsibility toward future generations (the 'duty to know' for the sake of one's descendants). Other ethical conflicts are related to uncertainty as to benefits deriving from screening for mutations, since for most conditions no clearly effective therapeutical strategy has as yet been defined. In addition to monogenic high-penetrance conditions, polygenic low-penetrance susceptibility is attracting increasing attention, in particular with respect to environmental-genetic interactions (metabolic polymorphisms). A simple approach to genetic screening would be to weigh the benefits and costs of genetic screening against those of primary prevention, and a superficial conclusion might be that genetic screening is less expensive and, overall, more practicable than restriction of toxic exposures or other known risk factors for the disease. Economic advantage notwithstanding, however, giving precedence to screening over primary prevention would be unacceptable. A serious hazard of genetic screening is the implicit limitation of research efforts aimed at primary prevention, and a serious drawback is its potential application for selection of nonsusceptible employees. The principle of equity is easily violated by genetic screening of workers in view of the fact that genetically-based metabolic polymorphisms are distributed unevenly among different ethnic groups.
Title
Ethics and allocation of health resources--the influence of poverty on health.
Author
Taipale V
Address
National Research and Development Centre for Welfare and Health, Stakes, Helsinki, Finland. vappu.taipale@stakes.fi
Source
Acta Oncol, 1999, 38:1, 51-5
Abstract
Poverty and health are examined from the global and Nordic perspectives. The data from global social policy research, Nordic comparisons and equity in health research provide a basis for the discussion. At the global level the consequences of poverty are growing and the resultant problems posed are becoming increasingly evident. Poverty and sickness are interwoven; poverty aggravates mental problems, a situation regarding which we have seen steady deterioration. Research suggests that social cohesion, the factor that creates social capital and empowerment in societies, is a major factor that promotes health and the economy. Structural measures to combat poverty would require a global social policy: global redistribution, global regulation and global provision. However, the international community is not yet fully prepared for this discussion. At the Nordic level, Finland is a laboratory in which the viability of the welfare state has been tested in the worst recession ever to hit an OECD country. On the whole, it seems that income disparity has not grown during the recession and that services have functioned moderately well despite budget cuts. However, during that period the correlation between unemployment and sickness became apparent, and the challenges to healthcare more evident. We must make headway in untangling these relationships, because the tendency towards greater income disparity is growing in the post-recession boom. At the social welfare and health service level even the Nordic welfare states are not in full command of the means to alleviate poverty and its related health problems. Has the time come to dispel our Nordic arrogance and look at how the present services may in fact be generating inequity
Title
[Equity in health, between ethics and economy]
Author
Berlinguer G
Address
UniversitÄa La Sapienza, Rome.
Source
Rev Med Suisse Romande, 1998 Dec, 118:12, 989-93
Abstract
Abstract unavailable online.
Title
[The relativity and geodiversity of medico-economic realities]
Author
Piérard GE
Address
Service de Dermatopathologie, UniversitÆe de LiÄege.
Source
Rev Med Liege, 1998 May, 53:5, 252-4
Abstract
The economic gestion of health care is difficult to handle. It covers several aspects which cannot pride to be accurate sciences. It strikes difficulties such as the geodiversity of problems to be solved and the nuances in the application of principles of social equity and medical ethics. The health-care analysis is also exposed to some politician interpretations biased by doctrinal a priori. Most often, a confrontation ensues between the political cenacle and the professionals directly involved in health-care.
Title
Health for all: analyzing health status and determinants.
Author
Lerer LB; Lopez AD; Kjellstrom T; Yach D
Address
Programme on Substance Abuse, World Health Organization, Geneva.
Source
World Health Stat Q, 1998, 51:1, 7-20
Abstract
An analysis of health status and determinants is presented as a basis for health for all renewal and in order to provide a model linking the health for all vision with strategy and action. Equity and gender, at the core of health for all, directly concern health status and the distribution of health determinants. The role of the various transitions (demographic, epidemiological, health risk and technological) is described, the need to strengthen the link between data and decision-making for health is explained, and the range of health determinants--macroeconomic, demographic/nutritional, environmental, tobacco and alcohol and their implications for policy--is outlined.
Title
Population, ethics, and equity.
Author
Berlinguer G
Address
Scuola di Bioetica, UniversitÄa degli Studi di Roma "La Sapienza". Piazzale Aldo Moro 5, 00185, Roma. berlinguer@axrma.uniroma1.it
Source
Cad Saude Publica, 1999, 15 Suppl 1:, 111-22
Abstract
Demography is impregnated, more or less explicitly, with ethical contents. This is apparent in the words used to support data, which change over time (e.g., the term "illegitimate child" is no longer used). Ethical principles must be analyzed because demography concerns both public policies and individual choice. There is a conflict in this area between the idea of the ethical state, dictating personal behaviors to citizens, and that of decisions based on freedom, supported by three shared values: human rights, pluralism, and equity. This paper examines how these could be reinterpreted in the context of choices regarding population.
Title
In search of human dignity: gender equity, reproductive health and healthy aging.
Author
Diczfalusy E
Address
Karolinska Institutet, Stockholm, Sweden.
Source
Int J Gynaecol Obstet, 1997 Dec, 59:3, 195-206
Abstract
This paper analyzes the nine pillars of human dignity (sufficient food, potable water, shelter, sanitation, health services, healthy environment, education, employment and personal security), which humankind tries to establish by following nine approaches to reality (scientific, cultural, religious, ethical, economical, ecological, socio-critical, philosophical and political) in a world drastically changed by nine revolutions (demographic, scientific, technological, communication, global identity, environmental, contraceptive, reproductive health and gender equity). The author's generation participated in these revolutions and contributed to the global intellectual process by which gender equity and reproductive health assumed a central role in world affairs. A rapidly aging world population constitutes another major challenge. Its likely impact on the very fundaments of our future social, economical, health and even political infrastructures is--as yet--incompletely comprehended by the international community. The International Federation of Gynecology and Obstetrics (FIGO) has and will continue to have an indispensable role in assisting humankind to reach its ultimate goal : human dignity.
Title
Public spending on health care: how are different criteria related?
Author
Musgrove P
Address
World Bank Institute, World Bank, Washington, DC 20433, USA. pmusgrove@worldbank.org
Source
Health Policy, 1999 Jun, 47:3, 207-23
Abstract
At least nine different criteria are relevant for decisions about public spending for health care. These include economic efficiency criteria (public goods, externalities, catastrophic cost, and cost-effectiveness), ethical reasons (poverty, horizontal and vertical equity, and the rule of rescue), and political considerations (especially demands by the populace). Sometimes one criterion should be examined before another one is considered; that is, they are hierarchically related. Sometimes two criteria will not be compatible but will conflict, forcing difficult choices--particularly between efficiency and equity. Properly thought-out choices of which health care interventions to finance with public funds therefore depend not only on looking at all these criteria, but also on treating them in the appropriate sequence and taking account of their possible inconsistencies. Public funds should finance public and semi-public goods that are cost-effective and for which demand is inadequate; cost-effective interventions that preferentially benefit the poor; and catastrophically costly care, when contributory insurance will not work or there are good reasons to finance insurance publicly.
Title
Ethics, equity and health for all [letter]
Author
Banerji D
Address
 
Source
World Health Forum, 1998, 19:3, 298-9
Abstract
Title
Cooperation: the foundation of improvement.
Author
Clemmer TP; Spuhler VJ; Berwick DM; Nolan TW
Address
University of Utah School of Medicine and LDS Hospital, Salt Lake City 84143, USA. tclemme@ihc.com
Source
Ann Intern Med, 1998 Jun, 128:12 Pt 1, 1004-9
Abstract
Cooperation--working together to produce mutual benefit or attain a common purpose--is almost inseparable from the quest for improvement. Although the case for cooperation can be made on ethical grounds, neither the motivation for nor the effects of cooperation need to be interpreted solely in terms of altruism. Cooperation can be a shrewd and pragmatic strategy for accomplishing personal goals in an interdependent system. Earlier papers in this series have explored the conceptual roots of modern approaches to improvement, which lie in systems theory. To improve systems, we must usually attend first and foremost to interactions. Among humans, "better interaction" is almost synonymous with "better cooperation." Physicians have ample opportunities and, indeed, an obligation to cooperate with other physicians in the same or different specialties, with nurses and other clinical workers, with administrators, and with patients and families. Many intellectual disciplines have made cooperation an object of study. These include anthropology; social psychology; genetics; biology; mathematics; game theory; linguistics; operations research; economics; and, of course, moral and rational philosophy. Scientifically grounded methods to enhance cooperation include developing a shared purpose; creating an open, safe environment; including all who share a common purpose and encouraging diverse viewpoints; negotiating agreement; and insisting on fairness and equity in the application of rules. These methods apply at the organizational level and at the level of the individual physician. This paper describes the application of these methods at the organizational level and focuses on one especially successful example of system-level cooperation in a care delivery site where interactions matter a great deal: the modern intensive care unit.
Title
[Which graft for which patient? and when? II. Organ supply and allocation]
Author
Noury D; Claquin J; Romano P
Address
Praticien hospitalier d'anesthÆesie-rÆeanimation, l'EfG InterrÆegion Ouest CHRU Pontchaillou, Rennes.
Source
Rev Prat, 1997 Nov, 47:18 Spec No, S22-7
Abstract
Despite progress realised in transplantation and organ procurement, there is an increasing gap between the number of patients on the national waiting list and the number of harvested organs. As a result, the appropriate organs must be matched with the appropriate patient, with two constraints: equity and efficacy. In a context of lack of organs, another public health problematic is to conciliate both the interests of a given patient and the interests of those on the waiting lists. In 1996, the French secretary of state for health instituted a public consultation committee chaired by the vice-president of the Comité consultatif national d'éthique, Counsellor Jean Michaud, to study organ allocation rules and to plan recommendations for the future. Using, as a starting point, the allocation rules initiated in the past by France Transplant and transiently applied by l'Etablissement français des Greffes, the committee conducted a large audition of health care professionals concerned with transplantation, individuals qualified in ethics, laws, sociology or ethnology, politicians and a sample representation of the population. A new corpus of allocation rules and procedures was then defined according to the committee recommendations and the advice of all medico-surgical transplantation teams, and published as a ministerial order in the Journal officiel de la République française in november 1996. It specifies shared principles and organ by organ specific allocation rules.
Title
Global equity and disabilities: reflections of a mother from hell.
Author
Reed CM
Address
 
Source
Camb Q Healthc Ethics, 1997 Win, 6:1, 106-10
Abstract
Abstract unavailable online
Title
[Quality in public health. Deficits, concepts and political quality key issues from the ministerial viewpoint]
Author
Ruprecht TM
Address
BehÂorde fÂur Arbeit, Gesundheit und Soziales Hamburg.
Source
Z Arztl Fortbild Qualitatssich, 1997 Feb, 91:1, 75-81
Abstract
To preserve the quality of the German health care system as well as continuously optimize it towards the needs stated by ethics and law, an inter-professional and inter-institutional quality policy is required. It should be patient-centered, focus on process management and be based on EN ISO-Standards adapted to the specific needs of health care. The latter could provide internationally compatible models for quality management and quality improvement including economic efficiency. The 40 nation Council of Europe's 5th European Conference of Health Ministers in Warsaw as well as the 69th Conference of German Federal State Health Ministers (GMK) at Cottbus, who tackled the issue in November 1996, pointed out essential aspects. The GMK stated a lack of effective general concepts, quality control and patients' rights protection in Germany. Both conferences demanded equity, social justice and an active participation of patients in the setting of quality standards and the conception, functioning and control of health care. This includes rationalisations by using the limited funds in a most effective way.
Title
'Health-for-All' in the twenty-first century: a global perspective.
Author
Yach D
Address
World Health Organization, Geneva, Switzerland.
Source
Natl Med J India, 1997 Mar, 10:2, 82-9
Abstract
Changes in the broad determinants of health since the Alma Ata Conference in 1978 necessitate a renewed examination of the underlying principles and focus of the Primary Health Care (PHC) strategy. The PHC approach has been adopted by most countries and has led to improved access to certain basic health services. However, the health gains in other areas are less encouraging. Some elements of the PHC approach, for example, the effective implementation of equity-oriented health policies and the need to improve management principles within health services, have yet to be fully implemented. Moreover, to address the underlying determinants of health status, the World Health Organization's (WHO) renewed global health policy will have to include certain issues that were not considered at Alma Ata. For example, the health impacts of global recession and globalization and the need for human-centered sustainable development strategies were not considered at Alma Ata. A renewed global health policy will also have to consider demographic, epidemiological, environmental and technological changes that have emerged since 1978. It is important that WHO's renewed policy be based on sound evidence, a commitment to ethical principles and broad use of partnerships for health at global, national and local levels. One implication of this new context of health development for the renewed health policy will be that 'thinking globally and acting locally' will have to complemented by stronger global action to protect local and national health.
 

Volver


Engenería Genética

GENOMA HUMANO

 

1) Neth J Med 1999 Dec;55(6):287-9


Hepatology in the 21st century. Gene transfer, hepatocyte transplantation, DNA chips, cyberspace and ... a friendly hospital.

Jansen PL

Department of Gastrointestinal and Liver Diseases, University Hospital Groningen, The Netherlands. pl.m.jansen@int.azg.nl

What to expect for hepatology in the 21st century? If science is allowed to proceed at its current rate, expectations can hardly be underestimated. Bound by the present day's limitations we are only able to see a glimpse of what could be available 100 years from now. For the next few decades, the global eradication of viral hepatitis will be on the agenda. For the treatment of inherited and acquired metabolic, toxic and immune liver disease, targeted drugs, genes and antisense oligonucleotides will be added to our therapeutic repertoire. The completion of the human genome project in 2003 will have far-reaching consequences: the widespread use of prenatal diagnosis, using DNA chip technology, may be expected to cause a dramatic decrease in the incidence of inherited diseases. Liver cirrhosis, hepatocellular carcinoma and inborn errors of metabolism may be treated by gene transfer or gene repair therapy. Although eventually these developments may decrease the need for organ transplantation, this by no means is the case yet and no solution is available for an increased demand and a decreased supply of organs. In the long run, diseases caused by multi-drug-resistant infectious agents and diseases associated with the abuse of alcohol and drugs are expected to become major problems. The future of university-based research is uncertain. The staggering costs of research and limited career possibilities may force universities to the limited task of higher education, with as a result biotech companies, shareholders and corporate finance ruling the scientific waves in the next century. The 21st century patient will know the way in cyberspace and will go shopping for the best doctor, for the best treatment and for the best, or friendliest, hospital.

2) Science 1999 Dec 10;286(5447):2057;2059

Human genome research. German effort stuck in minor league.

Hagmann M

3) Hum Mutat 2000 Jan;15(1):62-67

Future vision of the GDB Human Genome Database.

Cuticchia AJ

Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.

In 1973, scientists assembled at the first Human Gene Mapping Workshop to discuss the 64 human genes mapped at that time. In 1989, the GDB Human Genome Database was created to store information on 1,700 mapped human genes. Ten years later, as the human genome project closes in on the release of the complete DNA sequence holding as many as 100,000 human genes, GDB is evolving to continue to meet the needs of the scientific community. Well known as a resource for data which has been stringently reviewed as part of the curation process, GDB prepares to continue to provide a compilation of the human genome including maps, map objects, polymorphisms, and mutations. As more sites across the Internet are established to share biological information, it becomes increasingly burdensome for the scientist to collect data from all sources of a particular domain. In an attempt to reduce this burden, GDB continues to load data from large genome centres and accept submissions from researchers around the world. Moreover, GDB looks to provide a mechanism to link gene-related information to the human reference sequence. In doing this, GDB plans to establish federated linkages with "boutique" databases around the world that could contain enormous amounts of valuable information about specific genes or chromosomes. Copyright 2000 Wiley-Liss, Inc.

4) Exp Dermatol 1999 Dec;8(6):439-52

Mapping complex traits in diseases of the hair and skin.

Aita VM, Christiano AM, Gilliam TC

Department of Genetics & Development, Columbia University, New York, NY 10032, USA. vma3@columbia.edu

The past decade has witnessed the ascendance of human genetics in modern medicine, and at the forefront of this movement is the identification of genetic factors underlying inherited diseases. The methods of genetic mapping and positional cloning have made the discovery of genes with alleles that cause simple Mendelian diseases commonplace. The elucidation of the genetic basis of such disorders has vitalized both human genetics and the entire medical community as the field has gained prominence. The fact remains, however, that diseases resulting from the action of alleles of a single gene comprise only a minor percentage of traits that are medically relevant to humanity. The majority of these are multifactorial "complex traits", which result from the aggregate contribution of an unknown number of genes interacting with each other and with the environment. The current challenge has become one of parlaying successes in the mapping of Mendelian diseases into the discovery of genes whose alleles predispose the development of a complex disease. In light of this challenge, this review summarizes the methods and addresses some of the central issues of complex trait mapping, while using examples from dermatologically-relevant complex traits such as psoriasis and alopecia. Additionally, current technical and theoretical advances as well as the potential impact of the Human Genome Project will be discussed.

5) Nippon Yakurigaku Zasshi 1999 Sep;114(3):126-30

[Impact of human genome analysis on the future medicine].

[Article in Japanese]

Nakamura Y

Human Genome Center, University of Tokyo, Japan.

The human genome project is considered to be the most important project in biology and medicine. The discovery of an entire human genes through this project should revolutionize biological medicine including molecular diagnosis of various diseases and development of novel treatment. The entire genome DNA sequence is expected to be completed by 2003, and 90% of the genes will be identified by 2001. The information will accelerate discovery of genes susceptible to or causing various diseases and contribute to screening of novel drugs that target these disease-gene products. In addition, the field of "phamacogenetics" will become more important. Phamacogenetic studies focusing on inherited variations in drug metabolism and polymorphisms in drug metabolisms of the genes encoding drug-metabolizing enzymes are also very important to determine an appropriate dose of certain drugs to obtain the maximum effect and avoid serious toxicity. In this regard, the recent world-wide effort of the SNP (single nucleotide polymorphism) project in which scientists attempt to discover 100,000 genetic variations in our genome will generate very variable resources. In this review, I will be describing the recent progress and future direction of human genome analysis and its impact on medicine and pharmacology.

6) Aust Fam Physician 1999 Oct;28(10):1011-6

Designing new drugs through DNA.

Foote S

BACKGROUND: The human genome project will sequence the human genome within the next 2 years. Tools have been created that allow the use of genetics to study inherited diseases in humans where the genetic component may be complex. Most human genes have been identified and tools exist to use this information to search for abnormal expression of genes in diseased tissues. Many medically important pathogens have already had their genomes sequenced. OBJECTIVE: Can this deluge of information be used effectively to design new drugs? Will it help in producing new therapies. Where are the bottlenecks in pharmacologic development and will the genome information revolution lift some of these blocks? This article addresses some of these issues and seeks to demonstrate that the genome project will inject an enthusiasm into the development of new pharmacologic agents against a large range of hitherto unknown target molecules. DISCUSSION: Pharmaceutical development is target limited. This is especially true in the microbiological arena where there have been no new targets used for the past decade or more. New genes will be uncovered that play a role in disease processes. These may not be the causative genes but will modulate the course of disease. These new target proteins will be identified either as a result of the large scale sequencing efforts, now underway in a small number of large laboratories in the USA and Europe or will be found as a result of applying this knowledge to find genes that are inappropriately expressed in diseased tissue.

7) Aust Fam Physician 1999 Oct;28(10):1005-9

Diagnosing disease through DNA. An exciting new frontier.

Trent R

Department of Molecular & Clinical Genetic, Royal Prince Alfred Hospital. rtrent@med.usyd.edu.au

BACKGROUND: The family physician is at the forefront of the modern genetics (DNA) revolution. Advances in genetics will continue to escalate as the human genome project reaches its conclusion. The result will be a vast compendium of newly discovered genes and demand from both patients and doctors for more information about them. OBJECTIVE: To describe the role of DNA testing in diagnosing and predicting disease. DISCUSSION: DNA is an ideal medium to search for gene mutations. The DNA content of our cells does not age, thereby expanding the scope for DNA testing. The general practitioner will often be the first contact for those with a genetic disorder. Following DNA diagnosis, ongoing support may be required. To do this effectively will require a new approach to continuing education, as well as active participation in the 'molecular medicine' team. Sourcing reliable and accurate information may be a problem with many turning to the Internet for this.

8) Aust Fam Physician 1999 Oct;28(10):995-9

The new genetics. What are the everyday clinical applications?

Williamson R, Robertson S

Murdoch Institute, Royal Children's Hospital, Victoria.

BACKGROUND: Our understanding of human genetics has changed exponentially in recent years, but genetic research is sometimes perceived as an esoteric and expensive pursuit with few practical implications for the majority of the population. As the human genome project nears completion, we need to assess how we can use this vast knowledge effectively. OBJECTIVE: To focus on the role of new genetics in the understanding of both single gene disorders and the inheritance of complex traits (which have genetic and environmental components) and to discuss the role of the general practitioner (GP) utilising this knowledge in daily practice. DISCUSSION: Genetic data is often best used to understand and modify environmental causes of disease in regard to the susceptibility of an individual or family. This article discusses the role of GPs in identifying those at high risk of disease by history, prenatal diagnostic techniques and appropriate genetic testing and providing practical, cost effective strategies for individuals and the community to minimise risk of illness.

9) Nucleic Acids Res 2000 Jan 1;28(1):37-40

MIPS: a database for genomes and protein sequences.

Mewes HW, Frishman D, Gruber C, Geier B, Haase D, Kaps A, Lemcke K, Mannhaupt G, Pfeiffer F, Schuller C, Stocker S, Weil B

GSF-Forschungszentrum fur Umwelt und Gesundheit, Munich Information Center for Protein Sequences, am Max-Planck-Institut fur Biochemie, Am Klopferspitz 18, D-82152 Martinsried, Germany

The Munich Information Center for Protein Sequences (MIPS-GSF), Martinsried, near Munich, Germany, continues its longstanding tradition to develop and maintain high quality curated genome databases. In addition, efforts have been intensified to cover the wealth of complete genome sequences in a systematic, comprehensive form. Bioinformatics, supporting national as well as European sequencing and functional analysis projects, has resulted in several up-to-date genome-oriented databases. This report describes growing databases reflecting the progress of sequencing the Arabidopsis thaliana (MATDB) and Neurospora crassa genomes (MNCDB), the yeast genome database (MYGD) extended by functional analysis data, the database of annotated human EST-clusters (HIB) and the database of the complete cDNA sequences from the DHGP (German Human Genome Project). It also contains information on the up-to-date database of complete genomes (PEDANT), the classification of protein sequences (ProtFam) and the collection of protein sequence data within the framework of the PIR-International Protein Sequence Database. These databases can be accessed through the MIPS WWW server (http://www. mips.biochem.mpg.de ).

10) Nature 1999 Dec 2;402(6761):489-95

The DNA sequence of human chromosome 22.

Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al

The Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. id1@sanger.ac.uk

Knowledge of the complete genomic DNA sequence of an organism allows a systematic approach to defining its genetic components. The genomic sequence provides access to the complete structures of all genes, including those without known function, their control elements, and, by inference, the proteins they encode, as well as all other biologically important sequences. Furthermore, the sequence is a rich and permanent source of information for the design of further biological studies of the organism and for the study of evolution through cross-species sequence comparison. The power of this approach has been amply demonstrated by the determination of the sequences of a number of microbial and model organisms. The next step is to obtain the complete sequence of the entire human genome. Here we report the sequence of the euchromatic part of human chromosome 22. The sequence obtained consists of 12 contiguous segments spanning 33.4 megabases, contains at least 545 genes and 134 pseudogenes, and provides the first view of the complex chromosomal landscapes that will be found in the rest of the genome.

11) Nature 1999 Dec 2;402(6761):445

Human chromosome 22 and the virtues of collaboration.

12) Arch Pathol Lab Med 1999 Dec;123(12):1151-3

DNA technology in the clinical laboratory.

Kiechle FL

Department of Clinical Pathology, William Beaumont Hospital, Royal Oak, MI 48073-6769, USA.

OBJECTIVES: To review the advances in clinically useful molecular biological techniques and to identify their applications in clinical practice, as presented at the Eighth Annual William Beaumont Hospital Symposium. DATA SOURCES: The 10 manuscripts submitted were reviewed, and their major findings were compared with literature on the same topic. STUDY SELECTION: Two manuscripts addressed specimen (nucleic acid) stability, 2 described novel analytic approaches, 3 discussed detection of B- or T-cell clonality in lymphoproliferative disorders, and 3 reported the frequency of a variety of genetic polymorphisms found in cardiac disorders. DATA SYNTHESIS: DNA from dried blood spots is stable and may be purified rapidly for amplification and mutation analysis. RNA is much less stable, and a variety of methods may be used to reduce ribonuclease degradation of enteroviral RNA. False-negative reactions may be reduced by genomic amplification of ligated padlock probes by cascade rolling circle or polymerase chain reaction. A multiplex polymerase chain method using fluorescence-labeled products that separate both the wild-type and mutant hemochromatosis gene alleles by capillary gel electrophoresis represents another approach for detecting the 2 major missense mutations (C282Y and H63D) in hemochromatosis. Southern blotting and polymerase chain reaction have been used to detect B- and T-cell clonality in lymphoproliferative diseases, including mantle cell lymphoma and lymphoma of the breast. Genetic polymorphisms in a variety of coagulation factors and platelet glycoprotein IIIa are associated with ischemic heart disease. CONCLUSIONS: As the Human Genome Project continues to define disease-associated mutations, the number of clinically useful molecular pathologic techniques and assays will expand. Clinical outcome analysis is still required to document a decrease in the patient's length of stay to offset the cost of introducing molecular biological assays in the routine clinical pathology laboratory.

13) J Am Diet Assoc 1999 Nov;99(11):1421-7

Human Genome Project and cystic fibrosis--a symbiotic relationship.

Tolstoi LG, Smith CL

Department of Biomedical Engineering, Boston University, Mass., USA.

When Watson and Crick determined the structure of DNA in 1953, a biological revolution began. One result of this revolution is the Human Genome Project. The primary goal of this international project is to obtain the complete nucleotide sequence of the human genome by the year 2005. Although molecular biologists and geneticists are most enthusiastic about the Human Genome Project, all areas of clinical medicine and fields of biology will be affected. Cystic fibrosis is the most common, inherited, lethal disease of white persons. In 1989, researchers located the cystic fibrosis gene on the long arm of chromosome 7 by a technique known as positional cloning. The most common mutation (a 3-base pair deletion) of the cystic fibrosis gene occurs in 70% of patients with cystic fibrosis. The knowledge gained from genetic research on cystic fibrosis will help researchers develop new therapies (e.g., gene) and improve standard therapies (e.g., pharmacologic) so that a patient's life span is increased and quality of life is improved. The purpose of this review is twofold. First, the article provides an overview of the Human Genome Project and its clinical significance in advancing interdisciplinary care for patients with cystic fibrosis. Second, the article includes a discussion of the genetic basis, pathophysiology, and management of cystic fibrosis.

14) J Am Diet Assoc 1999 Nov;99(11):1412-20

The genetic revolution: change and challenge for the dietetics profession.

Patterson RE, Eaton DL, Potter JD

Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.

Advances in genetics are occurring at a pace that challenges our ability to understand and respond to the implications. Soon we will be able to define more precisely the molecular mechanisms underlying human health and disease; subdivide diseases and conditions (e.g., obesity) that are clinically indistinguishable into more distinct entities, thereby improving our ability to choose rational preventive and treatment measures; identify genotypic markers that predict metabolic responses to dietary interventions; stratify the population into groups at higher or lower risk for chronic diseases such as cancer, thus allowing dietary intervention to be appropriately targeted; and develop dietary recommendations that take into account genetically determined taste preferences. Dietetics leaders, teachers, practitioners, and researchers must act now to ensure that dietetics professionals are prepared for practice in this new era. In this article we introduce the Human Genome Project, review the fundamentals of molecular genetics, discuss genetics and disease risk, and define and give examples of diet-gene interactions. We also discuss issues relevant to dietary counseling of healthy people with genetic susceptibility to chronic disease. To foster the growth of knowledge regarding this new biology among dietitians, The American Dietetic Association should take the following steps: require course work on diet-gene interactions and include human genetics as a topic area on dietetic registration examinations, form a practice group on this topic, develop an Internet-based communication and information hub for dietetics professionals, sponsor a session on human genetics at annual meetings, begin a dialogue regarding a new practice specialty in diet and genetic counseling, and encourage a health care system in which personal counseling on diet-gene interactions is valued and reimbursed.

15) Clin Genet 1999 Sep;56(3):179-85

Internet resources for the clinical geneticist.

Ouellette F

CMMT Bioinformatics Core Facility, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. francis@cmmt.ubc.ca

The Internet offers a number of resources to clinical geneticists. This review outlines some of these with special emphasis on sites present at the National Center for Biotechnology Information (NCBI) at the National Library of Medicine at the National Institutes of Health. Special attention is presented on how these various resources make use of PubMed, the premiere source of MEDLINE information on the Internet. Three NCBI resources are presented here. 1) 'Genes and diseases': a general curated series of web pages outlining various references to known genetic diseases with links to relevant on-line resources. 2) The Online Mendelian Inheritance in Man (OMIM) from Victor A. McKusick at Johns Hopkins University presents our current knowledge of all known human genetic diseases. 3) Human genome resources describe our current knowledge on the human genome project (HGP). A list of relevant uniform resource locators (URLs) is also included.

16) Arch Surg 1999 Nov;134(11):1209-15

Functional genomics: clinical effect and the evolving role of the surgeon.

Hernandez A, Evers BM

Department of Surgery, The University of Texas Medical Branch, Galveston 77555, USA.

The genetic and molecular revolution that has occurred over the last 2 decades has dramatically increased our understanding of basic disease processes and will undoubtedly lead to improved detection methods and treatment. This will occur at an even more rapid rate after the completion of the Human Genome Project in the next 2 to 3 years. While these remarkable technological advances offer great hopes for novel therapeutic modalities, complicated medical, ethical, and legal issues will need to be addressed. This article briefly describes the advances that have occurred and their future ramifications for the field of surgery. Most assuredly, we will all be affected by these changes. Surgeons have the opportunity to be active participants and real leaders in the research and complex decisions regarding the optimal treatment of patients. However, formal training in these techniques and their potential applications will be required. Surgeons, as well as all physicians, must rise to the occasion or, otherwise, we will be relegated to a bystander status with clinical and moral decisions being made by nonclinicians.

17) Hum Hered 2000 Jan-Feb;50(1):76-84

Mapping in the sequencing Era.

Collins A

University of Southampton, Wessex Human Genetics Institute, Southampton General Hospital, Southampton, UK.

[Medline record in process]

The present phase of the Human Genome Project is concerned with sequencing. The shift of emphasis has left an impression that mapping is in some sense complete or finished. On the contrary, faced with the challenges of mapping genes for complex traits and efforts to understand recombination and other biological processes, the need for accurate integrated metric maps is greater than ever. Furthermore, sequencing could be regarded as merely a way of improving the map, since the most useful 'end product' of the sequencing effort must be the annotated sequence that gives precise physical coordinates for markers and expressed sequences. Integration of both location and functional information, the latter provided by homology, expression and other functional studies, is the main target for the future.

18) J Health Soc Policy 1999;10(4):51-66

Whose genes are they? The Human Genome Diversity Project.

Lone Dog L

The Human Genome Diversity Project (HGDP) has targeted several hundred indigenous peoples worldwide as their source of genetic material. Proponents for this project claim that information derived by analyzing these materials may be used for a variety of purposes ranging from finding a cure for diabetes to resolving debates about human origins. However, the HGDP plan raises many issues for indigenous people. This paper describes the project as well as the possible ethical and policy implications for Native communities.

19) Nat Genet 1999 Oct;23(2):151-7

Structural genomics: beyond the human genome project.

Burley SK, Almo SC, Bonanno JB, Capel M, Chance MR, Gaasterland T, Lin D, Sali A, Studier FW, Swaminathan S

Howard Hughes Medical Institute, 1230 York Avenue, New York, New York 10021, USA. burley@rockvax.rockefeller.edu

With access to whole genome sequences for various organisms and imminent completion of the Human Genome Project, the entire process of discovery in molecular and cellular biology is poised to change. Massively parallel measurement strategies promise to revolutionize how we study and ultimately understand the complex biochemical circuitry responsible for controlling normal development, physiologic homeostasis and disease processes. This information explosion is also providing the foundation for an important new initiative in structural biology. We are about to embark on a program of high-throughput X-ray crystallography aimed at developing a comprehensive mechanistic understanding of normal and abnormal human and microbial physiology at the molecular level. We present the rationale for creation of a structural genomics initiative, recount the efforts of ongoing structural genomics pilot studies, and detail the lofty goals, technical challenges and pitfalls facing structural biologists.

20) J Hered 1999 Jul-Aug;90(4):477-84

A human genome map of comparative anchor tagged sequences.

Chen ZQ, Lautenberger JA, Lyons LA, McKenzie L, O'Brien SJ

Intramural Research Support Program, SAIC Frederick, National Cancer Institute, Maryland, USA.

Effective comparative mapping inference utilizing developing gene maps of animal species requires the inclusion of anchored reference loci that are homologous to genes mapped in the more "gene-dense" mouse and human maps. Nominated anchor loci, termed comparative anchor tagged sequences (CATS), have been ordered in the mouse linkage map, but due to the dearth of common polymorphisms among human coding genes have not been well represented in human linkage maps. We present here an ordered framework map of 314 comparative anchor markers in humans based on mapping analysis in the Genebridge 4 panel of radiation hybrid cell lines, plus empirically optimized CATS PCR primers which detect these markers. The ordering of these homologous gene markers in human and mouse maps provides a framework for comparative gene mapping of representative mammalian species.

21) Lakartidningen 1999 Aug 11;96(32-33):3426-8

[A harvest time for genomic research].

[Article in Swedish]

Landegren U

Institutionerna for genetik, Uppsala universitet.

The article consists in a review of the human genome project, launched a decade ago to characterise the entire human genome. The project has proved highly successful, due both to the economy of so large scale an endeavour and to the value of gaining access to such an abundance of biological information. Accordingly, similar approaches have also been adopted in efforts to characterise the entire range of genes expressed as mRNA and as protein. Genomic information has become an invaluable asset to biomedical research, and both the information obtained and the methodology developed are now important adjuncts of pharmaceutical research. Applications in clinical medicine follow, albeit at a slower rate.

22) Clin Genet 1999 Jul;56(1):28-34

Family physicians' perspectives on genetics and the human genome project.

Fetters MD, Doukas DJ, Phan KL

Department of Family Medicine, University of Michigan Medical Center, University of Michigan, Ann Arbor 48109-0708, USA. mfetters@umich.edu

The objective of the study was to determine family physicians' attitudes and beliefs about human genetics research and the human genome project (HGP). The design of the study involved qualitative, semi-structured interviews. Primary variables of interest included family physicians' training; their attitudes about the HGP; requests for genetics counseling; and their approaches to counseling requests. The setting was a medium-sized, Midwest, US city. The participants were 16 university-affiliated, community-based family physicians. For contents analysis, we used a coding scheme to identify illustrative themes and subthemes. While most of the family physicians reported familiarity with genetics and the HGP, and experiences with counseling requests, nearly all (15) reported little training in genetics counseling. Four major themes were identified: 1) impact on clinical care; 2) educational issues relevant to genetics and the HGP; 3) ethical concerns; and 4) family medicine responsibilities. These family physicians do not perceive genetics as having a substantial impact on their practice, but do expect major clinical changes in the future. Many feel there have been inadequate educational opportunities to learn about genetics, and some indicate reluctance to invest in self-education until genetic problems become more clinically relevant. These practitioners envision a role for family medicine the specialty to shape priorities in genetics research.

23) MD Comput 1999 May-Jun;16(3):40-2

Transforming the cancer center in the 21st century.

Lowe HJ

University of Pittsburgh School of Medicine, Pennsylvania, USA.

Academic cancer centers will be hit, simultaneously, by all three of the technology tidal waves outlined above within the next five years. In preparing for this impact one should note the central role that Internet technologies will play in providing solutions in all three areas. In addition, as the volume and size of data objects increases dramatically, having an adequate networking infrastructure in place will be crucial. So what do we do now to prepare for the future? The following five steps are suggested: (1) Establish an oncology informatics group within the cancer center to provide the necessary expertise and begin the planning process. (2) Begin implementing a secure intranet based on standard Internet technologies. (3) Work with the host medical center and external agencies to determine who will pay for and implement a high-bandwidth networking infrastructure. (4) Recruit a bioinformatician who can help implement technologies to take advantage of the genomics data wave when it hits. (5) Ensure that the cancer center's EMR system can support cancer protocol data and facilitate the retrieval and delivery of the complex digital imaging data that are in our future.

24) Semin Nephrol 1999 Jul;19(4):319-26

Genetic testing for patients with renal disease: procedures, pitfalls, and ethical considerations.

Korf BR

Division of Genetics, Children's Hospital and Harvard Medical School, Boston, MA, USA. korf@hub.tch.harvard.edu

The Human Genome Project is rapidly producing insights into the molecular basis of human genetic disorders. The most immediate clinical benefit is the advent of new diagnostic methods. Molecular diagnostic tools are available for several genetic renal disorders and are in development for many more. Two general approaches to molecular diagnosis are linkage-based testing and direct mutation detection. The former is used when the gene has not been cloned but has been mapped in relation to polymorphic loci. Linkage-based testing is also helpful when a large diversity of mutations makes direct detection difficult. Limitations include the need to study multiple family members, the need for informative polymorphisms, and genetic heterogeneity. Direct mutation detection is limited by genetic heterogeneity and the need to distinguish nonpathogenic allelic variants from pathogenic mutations. Molecular testing raises a number of complex ethical issues, including those associated with prenatal or presymptomatic diagnosis. In addition, there are concerns about informed consent, privacy, genetic discrimination, and technology transfer for newly developed tests. Health professionals need to be aware of the technical and ethical implications of these new methods of testing, as well as the complexities in test interpretation, as molecular approaches are increasingly integrated into medical practice.

25) Semin Nephrol 1999 Jul;19(4):312-8

Overview: the genetics of renal disease.

Guay-Woodford LM

Department of Medicine, University of Alabama at Birmingham, USA. lgw@uab.edu

Disease susceptibility and, to a certain extent, disease progression, in many renal disorders are determined by specific genetic factors. The Human Genome Project has generated an explosion of gene discovery tools and strategies. These new technologies are being applied to a wide range of renal disorders. The most significant impact to date has been the identification of disease-susceptibility genes for more than 20 monogenic renal disorders. This review summarizes the role of genetics in renal disease, the different modes of inheritance of disease-susceptibility genes, the strategies for gene discovery, and the clinical impact of disease gene identification.

26)Neonatal Netw 1999 Apr;18(3):7-12

Implications for nursing of the Human Genome Project.

Munro CL

Department of Adult Health Nursing, Virginia Commonwealth University, USA. CMUNRO@vcu.edu

Information obtained from the Human Genome Project, initiated in 1990 and targeted for completion in 2005, will influence both health care and nursing practice. It will substantially revise our understanding of disease susceptibility and causation. Additional genetic tests will be developed and gene therapies explored. The project has implications for both nursing research and nursing practice. This article reviews the establishment of the Human Genome Project, reports on current progress of the project, and identifies some implications of the project for health care generally and nursing specifically.

27)Genome Res 1999 Jul;9(7):597-607

The involvement of genome researchers in high school science education.

Munn M, Skinner PO, Conn L, Horsma HG, Gregory P

Department of Molecular Biotechnology, University of Washington, Seattle, Washington 98195, USA. mmunn@u.washington.edu

The rapid accumulation of genetic information generated by the Human Genome Project and related research has heightened public awareness of genetics issues. Education in genome science is needed at all levels in our society by specific audiences and the general public so that individuals can make well-informed decisions related to public policy and issues such as genetic testing. Many scientists have found that an effective vehicle for reaching a broad sector of society is through high school biology courses. From an educational perspective, genome science offers many ways to meet emerging science learning goals, which are influencing science teaching nationally. To effectively meet the goals of the science and education communities, genome education needs to include several major components-accurate and current information about genomics, hands-on experience with DNA techniques, education in ethical decision-making, and career counseling and preparation. To be most successful, we have found that genome education programs require the collaborative efforts of science teachers, genome researchers, ethicists, genetic counselors, and business partners. This report is intended as a guide for genome researchers with an interest in participating in pre-college education, providing rationale for their involvement and recommendations for ways they can contribute, and highlighting a few exemplary programs. World Wide Web addresses for all of the programs discussed in this report are given in Table 1. We are developing a database of outreach programs offering genetics education () and request that readers submit an entry describing their programs. We invite researchers to contact us for more information about activities in their local area.

28) Gan To Kagaku Ryoho 1999 Jun;26 Suppl 1:3-7

[Advances in cancer research. Cancer research and clinical oncology in the 21st century].

[Article in Japanese]

Kanamaru R

Dept. of Clinical Oncology, Aging and Cancer Tohoku University.

It is my great pleasure to congradulate the Japanese Journal of Cancer and Chemotherapy on its 25 th anniversary. During this period, great progress has been made in cancer research, mainly owing to the advances in technology in molecular biology. Recently, not only researchers, but lay people as well have come to understand that cancer is mainly a genetic disease. Advances in the human genome project, DNA chip technology and gene technology; including gene targeting and cloning techniques, will enable us to accelerate progress forward the final goal of cancer research in the coming century. Major changes are coming in both cancer research and clinical oncology, which will completely transform the human social environment.

 

Volver


Consentimiento Informada

1) Acta Otorrinolaringol Esp 1999 Sep 1;50(7):505-511

[Informed consent in ear, nose and throat practice].

[Article in Spanish]

Cajade Frias J, Castro Vilas C, Perez-Carro A, Labella Caballero T

Servicio de ORL, Complejo Hospitalario de Santiago de Compostela, La Coruna, Espana. jcajade@yahoo.com

Changes in society's mentality have made health professionals get involved in legal aspects. In order to perform a correct medical proceeding, two premises must be fulfilled (Spanish Health General Law, 25th April 1986). First that it is carried out according to lex artis and second patient's consent. Consent needs as a prerequisite the adequate information; it is temporal, it can be revoked and it must be freely given and in writing (although it can be guaranteed by other means). Consent includes, on the patient's side, his/her acceptation of those risks inherent to the treatment. Nevertheless, it does not assure its results since doctor-patient's agreement is just related to means. If it were necessary, it is the doctor the one responsible to prove the consent was appropriately given. This would not be necessary when there is any kind of risk for public health or when the urgency allows no delay. Likewise, the assumption of the patient being under age or not able to take any decision will also be analysed. Features to be fulfilled by informed consent models are also analysed and a prototype is proposed.

2) Pediatr Int 1999 Dec;41(6):733-6

Ethical issues and decision-making in fetal cardiology.

Kawataki M

Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Japan. m-kawata@yha.ne.jp

BACKGROUND: As the technique of fetal ultrasound has developed, we have more opportunities to perform fetal echocardiography. Our knowledge about fetal diagnosis has been rapidly expanded. It is essential for the pediatricians to understand the ethical issues surrounding the fetal diagnosis. METHODS: We discussed these ethical issues at the 5th Annual Meeting of the Japanese Society of Fetal Cardiology in Fukuoka, Japan, 1999. I have reviewed the ethical issues brought up in the discussions. RESULTS: We have discussed many aspects of ethical issues. We should explain to parents before the fetal scan how and why the fetus is examined. It is very important to get written informed consent from the parents. It seems very difficult to inform of fetal diagnosis and support parents appropriately. We have to establish a system where obstetricians, neonatologists, cardiologists, nurses, midwives and medical social workers are cooperating in the perinatal center. CONCLUSION: We have many problems in the field of ethical issues. We have to keep discussing them. It is necessary to establish a team for fetal medicine in every perinatal hospital.

3) Psychol Med 1999 Nov;29(6):1367-75

Assessing the ability of people with a learning disability to give informed consent to treatment.

Arscott K, Dagnan D, Kroese BS

Tizard Centre, University of Kent at Canterbury.

BACKGROUND: People with a learning disability are increasingly being encouraged to take a more active role in decisions about their psychological and medical treatment, raising complex questions concerning their ability to consent. This study investigates the capacity of people with a learning disability to consent in the context of three treatment vignettes, and the influence of verbal and memory ability on this capacity. METHODS: Measures of verbal ability, memory ability and ability to consent to treatment (ACQ) were administered to 40 people with a learning disability. The ACQ consisted of three vignettes depicting a restraint, psychiatric or surgical intervention. These were followed by questions addressing people's ability to understand the presenting problem; the nature of the proposed intervention; the alternatives, risks and benefits; their involvement in the decision-making process; and their ability to express a clear decision with a rationale for treatment. RESULTS: Five people (12.5%) could be construed as able to consent to all three vignettes; 26 (65%) could be construed as able to consent to at least one. The questions that were most difficult to answer concerned a participants' rights, options and the impact of their choices. Verbal and memory ability both influenced ability to consent. CONCLUSIONS: This study introduces a measure that may enable clinicians to make more systematic assessments of people's capacity to consent. A number of issues surrounding the complex area of consent to treatment are also raised.

4) Nurs Manage 1999 Sep;30(9):14

How to cover all the bases on informed consent.

Staten PA

Department of Standards, JCAHO, Oakbrook Terrace, Ill., USA.

Understand when to obtain informed consent and what structures you can put in place to ensure compliance.

5) JAMA 1999 Dec 22-29;282(24):2313-20

Informed decision making in outpatient practice: time to get back to basics.

Braddock CH 3rd, Edwards KA, Hasenberg NM, Laidley TL, Levinson W

Department of Medicine, VA Puget Sound Health Care System, Seattle 98108, USA. braddock@u.washington.edu

CONTEXT: Many clinicians have called for an increased emphasis on the patient's role in clinical decision making. However, little is known about the extent to which physicians foster patient involvement in decision making, particularly in routine office practice. OBJECTIVE: To characterize the nature and completeness of informed decision making in routine office visits of both primary care physicians and surgeons. DESIGN: Cross-sectional descriptive evaluation of audiotaped office visits during 1993. SETTING AND PARTICIPANTS: A total of 1057 encounters among 59 primary care physicians (general internists and family practitioners) and 65 general and orthopedic surgeons; 2 to 12 patients were recruited from each physician's community-based private office. MAIN OUTCOME MEASURES: Analysis of audiotaped patient-physician discussions for elements of informed decision making, using criteria that varied with the level of decision complexity: basic (eg, laboratory test), intermediate (eg, new medication), or complex (eg, procedure). Criteria for basic decisions included discussion of the nature of the decision and asking the patient to voice a preference; other categories had criteria that were progressively more stringent. RESULTS: The 1057 audiotaped encounters contained 3552 clinical decisions. Overall, 9.0% of decisions met our definition of completeness for informed decision making. Basic decisions were most often completely informed (17.2%), while no intermediate decisions were completely informed, and only 1 (0.5%) complex decision was completely informed. Among the elements of informed decision making, discussion of the nature of the intervention occurred most frequently (71 %) and assessment of patient understanding least frequently (1.5%). CONCLUSIONS: Informed decision making among this group of primary care physicians and surgeons was often incomplete. This deficit was present even when criteria for informed decision making were tailored to expect less extensive discussion for decisions of lower complexity. These findings signal the need for efforts to encourage informed decision making in clinical practice.

Comment in: JAMA 1999 Dec 22-29;282(24):2356-7

6) Acad Emerg Med 1999 Dec;6(12):1283-91

A proposed consent process in studies that use an exception to informed consent.

Sloan EP, Nagy K, Barrett J

Department of Emergency Medicine, University of Illinois at Chicago, 60612, USA. edsloan@uic.edu

Federal regulations allow an exception to informed consent when it is not feasible to obtain informed consent in certain emergency research circumstances. A multicenter, randomized, single-blinded, normal saline procedure-controlled efficacy trial of diaspirin cross-linked hemoglobin (DCLHb) in acute traumatic hemorrhagic shock was conducted. The study intended to include 850 of the most severely injured trauma patients with hemorrhage and persistent hypoperfusion as demonstrated by vital signs suggestive of vascular collapse or a base deficit that signified prolonged hypoperfusion. It was anticipated that some patients would be unable to provide informed consent, and that identification and availability of some patients' legally authorized representatives (LARs) would be unlikely within the therapeutic window of the intervention. Each participating institution therefore developed a process to implement exception to informed consent. Each hospital's proposed process was reviewed by the institutional review board, the sponsor, the FDA, and the study's data monitoring committee chair. The goal was the development of local implementation processes by which the best interests of patients and their families could be fulfilled using prospective informed consent, the exception to informed consent, and consent to continue in emergency research, as appropriate for each individual patient. This paper describes the proposed implementation method developed for Cook County Hospital. It includes several important features, 1) prospective informed consent by the patient, when feasible; 2) the ability of the patient to decline participation, even when deemed incompetent to provide prospective informed consent; 3) prospective consent by the family/LAR, when feasible; 4) the use of a scripted abbreviated consent by the patient family/ LAR in life-threatening situations when it is possible only to briefly discuss the research being conducted; 5) independent approval for the use of the consent exception by a second physician immediately prior to patient enrollment; 6) the repeated use of consent to continue (both for the family/LAR and by the patient) when an exception to consent has been utilized; and 7) ongoing review of the informed consent process on a case-by-case basis by the institution's scientific review committee. The authors believe this proposed informed consent process maximizes the communication between investigators, patients and their proxies, and the institution's scientific review committee. Multiple mechanisms exist that allow for consent to be provided or declined, both prior to and after enrollment in the research protocol. The ongoing immediate review of the process allows for process enhancements to be made as needed.

7) Acad Emerg Med 1999 Dec;6(12):1272-82

Implementing the Food and Drug Administration's final rule for waiver of informed consent in certain emergency research circumstances.

Biros MH, Fish SS, Lewis RJ

Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA. biros001@tc.umn.edu

ation released its Final Rule for Waiver of Informed Consent in Certain Emergency Research Circumstances (the Final Rule). The Department of Health and Human Services (DHHS) also released an update of its regulations related to waiver of informed consent in emergency research. These new regulations allow resuscitation research to proceed with a waiver of informed consent under very narrow and specific clinical research circumstances. Waiving informed consent for research participation has profound ethical and scientific implications. However, in unpredictable life-threatening clinical situations for which current therapy is unproven or unsatisfactory, patients usually are unable to consent on their own behalf to participate in clinical trials of potentially beneficial but experimental interventions. Because of the time-dependent nature of most resuscitation interventions, it is usually not feasible to identify and contact the legally authorized representative who can speak on behalf of the patient within the presumed therapeutic window of the intervention under investigation. For such clinical trials to proceed, a waiver of informed consent is usually necessary. Patients who are critically ill or injured and unable to provide meaningful prospective informed consent because of their current life-threatening condition are vulnerable and require additional protections beyond those for research subjects who can speak on their own behalf. The Final Rule and the DHHS-updated regulations incorporate a number of additional patient safeguards that must occur if a clinical trial is to proceed with waiver of informed consent. Specific means of adequately meeting these requirements are not described in the regulations. Although this was intentional on the part of the federal regulators so that individual protocols and research environments would direct the development of these patient safeguards, the lack of specific guidance has led to confusion on the appropriate implementation of the new regulations. This article reviews some of the key concepts of the Final Rule, with suggestions on their purpose and meaning. It also reviews the studies that have been approved to date to proceed with waiver of informed consent, and offers suggestions for the process of implementing the requirements of the Final Rule for research involving patients who are unable to give prospective informed consent.

8) Acad Emerg Med 1999 Dec;6(12):1210-5

An approach to community consultation prior to initiating an emergency research study incorporating a waiver of informed consent.

Baren JM, Anicetti JP, Ledesma S, Biros MH, Mahabee-Gittens M, Lewis RJ

Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA.

OBJECTIVES: In November 1996, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) enacted rules allowing a narrow exception to the requirement for prospective informed consent when enrolling critically ill patients in clinical research studies of emergency treatments. These rules require that, prior to initiation of the study, the applicable institutional review board (IRB) assess the acceptability of the proposed research study to members of the community in which the research will be conducted. Specifically, the IRB must perform community consultation-a process during which community members learn about the proposed research and communicate their opinions regarding its acceptability to investigators or IRB representatives. The FDA and DHHS rules do not define specific acceptable methods for performing this community consultation. The objective of this study is to demonstrate the feasibility and utility of one proposed method for performing such community consultation. METHODS: Parents of children being seen for minor traumatic injuries in three pediatric EDs were asked to participate in a study regarding informed consent. After consent, an instructor described to the parent a prospective, randomized, placebo-controlled trial of phenytoin for the prophylaxis of posttraumatic seizures in children with severe closed head trauma. All parents were then asked whether they would have consented for their own child's participation, if their child had suffered such head injury. The parents were further asked to explain the reason(s) for their responses. RESULTS: Parents of 227 children (children's mean +/- SD age 8.0 +/- 4.8 years, 57% male) were interviewed. Sixty-six percent of parents (149/227) stated they would give consent for their child's participation. Of the 149 consenting parents, 85% (126/149) cited potential benefit to their child, 72% (107/149) cited potential benefit to other children, and 60% (90/149) cited furthering medical knowledge. Of the 78 nonconsenting parents (34% of total), 54% (42/78) cited fear of adverse effects, 39% (30/78) did not want their child to be a research subject in general, 27% (21/78) believed they needed to discuss participation with family members who were unavailable, and 26% (20/78) stated they were unable to decide unless they were in the actual situation. Parental ethnicity and household income were found to influence the consent decision, while the parent's gender, religion, language, and educational level were not associated with the consent decision. CONCLUSIONS: Community consultation regarding the acceptability of an emergency research protocol can be obtained via interview techniques in the ED. This methodology may allow investigators to obtain data on opinion from a targeted community for IRB consideration during the review of emergency research studies proposing a waiver of informed consent.

9) Acad Emerg Med 1999 Dec;6(12):1203-9

The informed consent process and the use of the exception to informed consent in the clinical trial of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock. DCLHb Traumatic Hemorrhagic Shock study group.

Sloan EP, Koenigsberg M, Houghton J, Gens D, Cipolle M, Runge J, Mallory MN, Rodman G Jr

Department of Emergency Medicine, University of Illinois at Chicago, USA. edsloan@uic.edu

In the clinical trial of diaspirin cross-linked hemoglobin (DCLHb), optimal therapy required the immediate enrollment of patients with severe, uncompensated, traumatic hemorrhagic shock. When it was not feasible to obtain prospective consent, an exception to informed consent was used according to FDA regulation 21 CFR 50.24. OBJECTIVES: To examine the informed consent process and the use of the consent exception and consent to continue (CTC), and to describe the patients for whom this process was used. METHODS: This was a multicenter, randomized, controlled, single-blinded efficacy trial of DCLHb as an adjunct to standard therapy in the treatment of severe, traumatic hemorrhagic shock. Patients with unstable vital signs or a critical base deficit were treated, with a primary study endpoint of 28-day mortality. RESULTS: During the 11-month study period, 112 patients were randomized in 18 U.S. trauma centers, and data from 98 of the infused patients were analyzed. Prospective consent was obtained from two patients, three family members, and one legally authorized representative (LAR) (6%). Consent to continue was requested for 89 patients (89%), and full participation was granted for 87 of these patients (98%). Consent to continue was provided by 54 (98%) of the 55 patients approached. The mean number of days for family/LAR CTC was 1.1 +/-3.8 days, and 50% of the time it was obtained on the day of study enrollment. Patient CTC was obtained in an average of 13 +/- 23 days, with a median of four days. Patients treated in this protocol were more likely to have sustained penetrating trauma than the overall trauma patient population treated in these trauma centers (44% vs 21%, p = 0.002). CONCLUSIONS: Informed consent in this study of an emergent therapy most often involved the use of the consent exception and consent to continue, the latter of which occurred in a timely manner. Nearly all of those who were approached for CTC approved full participation in the study, suggesting acceptance of the process outlined in the new regulations. Patients treated in a hemorrhagic shock clinical trial may differ from the general trauma patient population.

10) Forum (Genova) 1999 Jul-Dec;9(3 Suppl 3):93-8

Ethical limitations in patenting biotechnological inventions.

Lugagnani V

Universit degli Studi di Milano Bicocca.

In order to connect ethical considerations with practical limits to patentability, the moral judgement should possibly move from the exploitation of the invention to the nature and/or objectives of Research and Development (R&D) projects which have produced it: in other words, it appears quite reasonable and logical that Society is not rewarding unethical R&D activities by granting intellectual property rights. As far as biotechnology R&D is concerned, ethical guidance can be derived from the 1996 Council of EuropeOs OConvention for the protection of human rights and dignity of the human being with regard to the application of biology and medicineO, whose Chapter V - Scientific research - provides guidelines on: i. protection of persons undergoing research (e.g. informed consent); ii. protection of persons not able to consent to research; iii. research on embryos in vitro. As far as the specific point of patenting biotechnology inventions is concerned, the four exclusions prescribed by Directive 98/44/EC (i.e. human cloning, human germ-line gene therapy, use of human embryos for commercial purposes, unjustified animal suffering for medical purposes) are all we have in Europe in terms of ethical guidance to patentability. In Italy, in particular, we certainly need far more comprehensive legislation, expressing SocietyOs demand to provide ethical control of modern biotechnology. However it is quite difficult to claim that ethical concerns are being raised by currently awarded biotechnology patents related to living organisms and material thereof; they largely deal with the results of genomic R&D, purposely and usefully oriented toward improving health-care and agri-food processes, products and services. ONo patents on lifeOO can be an appealing slogan of militants against modern biotechnology, but it is far too much of an over-simplified abstraction to become the Eleventh Commandment our Society.

11) Forum (Genova) 1999 Jul-Dec;9(3 Suppl 3):88-92

Biotechnologies and predictive medicine: legal aspects.

Fucci S

Consigliere della Corte di Appello, Milano.

Scientific progress in molecular biology and genetics is now providing the medical field with new OtoolsO for diagnosis of possible gene alterations which may be connected with the risk of disease later in life. The development of predictive medicine incurs novel problems in the relationship of the medical doctor and the individual at risk of disease, with particular reference to the identification of situations in which genetic testing may be relevant, the type of information which one should give the individual in order to have the informed consent for the diagnosis and the type of possible therapy taking into account the confidential aspect of using the data produced. These problems are exmined in the light of ethical citations and guidelines which are included in the National Comittee for Bioethics in Gene Therapy, 1991, the Italian privacy law, 1996, the European Convention on Bioethics, 1996, the 98/44/CE Directive on the Patentability of Biotechnological Inventions and the Deontological Medical Code, 1998.

12) Obstet Gynecol Surv 1999 Dec;54(12):766-77

Sterilization and its consequences.

Hendrix NW, Chauhan SP, Morrison JC

Spartanburg Regional Medical Center, South Carolina, USA.

The purpose of this review is to analyze critically the two techniques of sterilization (bilateral tubal ligation [BTL] and vasectomy) so that a physician may provide informed consent about methods of sterilization. A MEDLINE search and extensive review of published literature dating back to 1966 was undertaken to compare preoperative counseling, operative procedures, postoperative complications, procedure-related costs, psychosocial consequences, and feasibility of reversal between BTL and a vasectomy. Compared with a vasectomy, BTL is 20 times more likely to have major complications, 10 to 37 times more likely to fail, and cost three times as much. Moreover, the procedure-related mortality, although rare, is 12 times higher with sterilization of the woman than of the man. Despite these advantages, 300,000 more BTLs were done in 1987 than vasectomies. In 1987, there were 976,000 sterilizations (65 percent BTLs and 35 percent vasectomies) with an overall cost of $1.8 billion. Over $260 million could have been saved if equal numbers of vasectomies and BTLs had been performed, or more than $800 million if 80 percent had been vasectomies, as was the case in 1971. The safest, most efficacious, and least expensive method of sterilization is vasectomy. For these reasons, physicians should recommend vasectomy when providing counseling on sterilization, despite the popularity of BTL. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians LEARNING OBJECTIVES: After completion of this article, the reader will be able to predict the failure rates and likelihood of successful reversal of tubal ligation and vasectomy; to recall the difference in cost between the two sterilization procedures, and to describe the short-term and long-term complications associated with each of the two methods of sterilization.

13) Curr Opin Pediatr 1999 Dec;11(6):508-11

Ethical issues in neurodevelopmental disabilities.

Shevell M

Department of Neurology/Neurosurgery, McGill University, Montreal, Quebec, Canada.

Ethics concerns itself with the search for the good and right option when one faces a choice about a potential action. In persons with significant neurodevelopmental disabilities, clinical ethics has concentrated on such pragmatic issues as justice (the means and measures by which resources are allocated) and informed consent. However, recent papers relevant to this topic have addressed more fundamental issues that underlie our entire approach to the field as a whole. These issues include the moral status of the disabled, the concept of "quality of life," our attitudes toward the disabled, the elements of competence and its evaluation, and models for decision making. This review highlights recent papers on these topics and assesses their impact on ongoing ethical debates.

14) Am J Surg 1999 Oct;178(4):351-5

Assessing medical students' competence in obtaining informed consent.

Roberts LW, Mines J, Voss C, Koinis C, Mitchell S, Obenshain SS, McCarty T

Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque 87131, USA.

BACKGROUND: Medical schools increasingly place emphasis on preparing students to perform routine, ethically important clinical activities with sensitivity and acumen. A method for evaluating students' skills in obtaining informed consent that was created at our institution is described. METHODS: Formal assessment of medical students' professional attitudes, values, and ethics skills occurs in the context of three required and developmentally attuned comprehensive examinations. A videotaped station tested senior medical students' ability to obtain informed consent from a standardized patient who expresses concern about undergoing cardiac catheterization. Two checklists were completed by the patient. Videotapes were reviewed by a faculty member, and students' reactions to the assessment experience were documented. RESULTS: Seventy-one senior students participated, and all performed well. Mean scores of 6.3 out of 7 (range 5 to 7, SD = 0.5) on the informed consent checklist and 8.7 out of 9 (range 6 to 9, SD = 0.5) on the communication skills checklist were obtained. Students endorsed the importance of the skills tested. CONCLUSIONS: This method of examining medical students' abilities to obtain informed consent has several positive features and holds promise as an ethics competence assessment tool.

15) Med Clin North Am 1999 Nov;83(6):1423-42, vi

Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness.

Burack RC, Wood DP Jr

Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA.

Evidence demonstrating the burden of prostate cancer upon men in the United States is incontrovertible; less compelling, however, is proof of benefit from early detection efforts. Nevertheless, the absence of definitive evidence does not lessen the interest of men in prostate testing or the obligation of physicians to help interested men make well-informed decisions, which integrate personal circumstance and preference with the best available data. This article provides the counseling physician with the information required to frame the current prostate testing debate and an approach to support informed decision making by men who can benefit from their assistance.

16) JAMA 1999 Nov 24;282(20):1947-52

Challenges to human subject protections in US medical research.

Woodward B

Department of Philosophy, Brandeis University, Waltham, Mass 02454, USA.

United States regulations governing federally supported research with human subjects derive in part from 2 international codes, the Nuremberg Code and the Declaration of Helsinki. The Declaration of Helsinki states that "concern for the interests of the subject must always prevail over the interests of science and society." The concept of minimal risk and the principle of informed consent are the key means by which US federal regulations seek to protect the rights and welfare of the individual in the research setting. Current trends in medical research-including increased funding, ever-greater capabilities of computers, development of new clinical tools that can also be used in research, and new research tools developed through research itself are creating greater demand for human subjects, for easier recruitment and conscription of these subjects, and for unimpeded access to patient medical records and human biological materials. Nationally and internationally, there are new pressures to subordinate the interests of the subject to those of science and society. The National Bioethics Advisory Commission, which is about to undertake a comprehensive review of the US system of human subject protections, faces a daunting task.

Comment in: JAMA 1999 Nov 24;282(20):1963-5

17) J Clin Nurs 1999 May;8(3):291-8

The role of the paediatric nurse in promoting paediatric right to consent.

Orr FE

South Thames Paediatric Intensive Care, UK.

This article examines the processes involved in obtaining informed consent focusing on the abilities and legalities related to a child's right to consent. Most authors who have researched when a child may be considered competent to give a valid consent propose that the child must be 14 years old and thus able to think abstractly and consider the risks and benefits of the planned treatment. Qualitative research on this topic reveals that a child's previous life experiences can influence their ability to comprehend the intervention. This suggests children under 14 years of age may be regarded as competent. The confusion around the prevailing legal situation is examined. The role of the paediatric nurse is explored to distinguish areas in which the nurse could potentially make a contribution to the process of gaining consent from children. The paediatric nurse's role as an assessor, educator and evaluator are identified.

18) Ugeskr Laeger 1999 Oct 4;161(40):5531-6

[Informed consent in connection with autopsy and sending out discharge notes. A questionnaire study].

[Article in Danish]

Jensen RB, Thomsen OO

Medicinsk afdeling C, Amtssygehuset i Herlev.

The purpose of this study was to illustrate the attitude towards informed consent in connection with performing an autopsy and sending out discharge notes amongst a group of patients, doctors and nurses. A questionnaire was given to four different groups consisting of 75 patients, 20 nursing staff, 20 hospital doctors and 20 family doctors. The attitudes amongst the two groups of doctors were generally close to the attitudes amongst patients. The majority of doctors and patients in contrary to the nursing staff found it unnecessary to obtain informed consent before sending out discharge notes. More than half of all of the groups thought that patients should take part in the decision of performing autopsy, but still the family should be asked as well.

19) J Investig Med 1999 Nov;47(9):468-76

Effectiveness of a writing improvement intervention program on the readability of the research informed consent document.

Philipson SJ, Doyle MA, Nightingale C, Bow L, Mather J, Philipson EH

Department of Curriculum and Instruction, Kent State University, OH, USA.

BACKGROUND: Problems with the comprehensibility of human research informed consent have been documented since the 1970s, and efforts aimed at rewriting consents have not been successful in consistently producing more readable consents. This study employed researched principles of reading comprehension research to create writing intervention program designed to help the research writer produce more comprehensible informed consent documents. The purpose of this study was to determine if this intervention program was effective. METHOD: The key component of the writing improvement intervention packet was a newly formatted consent form that contained annotated instructions for researchers on how to write each section for optimum comprehension. The resulting consent forms were evaluated using a Readability and Processability Form (RPF). The RPF is based on reading research and includes the Fry Scale, which yields an approximate grade reading level. The RPF assigned points to each of the 20 areas of comprehension analysis according to strict scoring criteria, and target scores were established by the authors in consultation with the hospital institutional review board. RESULTS: We evaluated 66 post-intervention informed consents. The mean readability and processability score was 62, resulting in the RPF classification of "good." The established readability and processability target range was good to excellent or 61-100 points; 66% of the forms scored in this range. In our 1995 pre-intervention study, the corresponding score was 12%. The target range for grade reading level was 8th grade: 53% scored in that range as compared with 4% in 1995. A question-by-question analysis of each of the 20 checklist items on the RPF identified important aspects of the consent writing that improved and others that were still weak and needed improvement. CONCLUSIONS: The Hartford Hospital writing improvement intervention program was associated with the production of more comprehensible informed consent documents. Using the intervention materials, investigators from a variety of departments could function independently to produce readable consent forms. This program may help others who wish to assist their research departments in creating consents that are written for optimal reading comprehension.

20) Eur Psychiatry 1999 Apr;14(2):93-100

What are the reciprocal influences of randomized clinical trials and the patient-psychiatrist relationship?

Catteau J, Cyran C, Bordet R, Thomas CE, Dupuis BA

REPP (Reseau d'Experimentation en Psycho-Pharmacologie), Service de Pharmacologie, CHRU de Lille, 2 avenue Oscar-Lambret, 59045 Lillecedex, France.

The goal of this prospective investigation was to study the course and the quality of patient-psychiatrist relationships during phase II / phase III clinical trials of antidepressant medication prescribed for depressive disorders. All patients who participated in the clinical trials (and subsequently in this survey) signed written informed consent statements and were subject to random double blind treatment assignment. Retrospective analysis of 118 investigations was carried out, and the patients involved were questioned concerning their experiences and impressions during and after the study. Data show that the outcome of clinical trials of antidepressant drugs are not a function of pre-existing good patient-psychiatrist relationships. On the other hand, no effects on the patient-psychiatrist relationship were found as a result of the experimental procedure, and it can be concluded that no detrimental effects on future patient-psychiatrist relationships were incurred.

21) Proc AMIA Symp 1999;(1-2):731-5

Re-engineering the process of surgical informed consent.

Dierks MM, Sands DZ, Safran C

Center for Clinical Computing, Beth Israel Deaconess Medical Center Harvard Medical School, USA.

We have created a clinical performance support system that transforms surgical informed consent into an interactive process capable of evolving in response to institution-specified, provider-specified and patient-specified needs. The system functions in several capacities, including: (1) a source of standardized and comprehensive content and format the transmission of procedure-related risk and complications; (2) as expert critique, providing cues in an effort to reduce the effects of biased risk appraisal; (3) captures and archives clinician behavior relating to use, modification and disclosure of standardized knowledge sources; (4) provides just-in-time access to procedural descriptions information relating to risks and complications; (5) captures, archives and makes available to the clinician patient use of procedure-related knowledge resources. By design, the system will be used to assess the relationship between clinician perception and heuristics surrounding risk appraisal and disclosure and patient perceptions based on response to the disclosure process. The system prototype is currently being deployed in a breast surgery unit at the Beth Israel Deaconess Medical Center.

 

1)J Med Ethics 1999 Dec;25(6):463-8
Bioethics of the refusal of blood by Jehovah's Witnesses: Part 3. A proposal for a don't-ask-don't-tell policy.

Muramoto O

Kaiser Permanente Northwest Division, Oregon, USA.

Of growing concern over Jehovah's Witnesses' (JWs) refusal of blood is the intrusion of the religious organisation into its members' personal decision making about medical care. The organisation currently may apply severe religious sanctions to JWs who opt for certain forms of blood-based treatment. While the doctrine may be maintained as the unchangeable "law of God", the autonomy of individual JW patients could still be protected by the organisation modifying its current policy so that it strictly adheres to the right of privacy regarding personal medical information. The author proposes that the controlling religious organisation adopt a "don't-ask-don't-tell" policy, which assures JWs that they would neither be asked nor compelled to reveal personal medical information, either to one another or to the church organisation. This would relieve patients of the fear of breach of medical confidentiality and ensure a truly autonomous decision on blood-based treatments without fear of organisational control or sanction.

2)J Clin Ethics 1999 Summer;10(2):156-65
Legal trends in bioethics.

Forster HP

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

3)Vaccine 1999 Oct 29;17 Suppl 3:S14-7
Individual rights versus societal duties.

Vermeersch E

Rijksuniversiteit Gent, Huis van Oostenrijk, Wetteren, Belgium.

In 'bioethics', the rights to self-determination and to informed consent of the patient are prerequisites to every medical decision: paternalism is no longer a justifiable attitude. Hence, it seems that compulsory vaccination is an unacceptable praxis. Even John Stuart Mill. however, took into account other values: e.g. the duty not to harm others. This article is dedicated to the analysis of the historical development of these values and to their relevance for the ethics of vaccination. The acceptability of coercion is upheld, but no clear-cut answers are given in general: in every case the pros and cons of coercion are to be weighed carefully against each other.

4)Hum Mutat 2000;15(1):30-5
Ethical guideposts for allelic variation databases.

Knoppers BM, Laberge CM

University of Montreal, Montreal, Quebec, Canada.

Basically, a mutation database (MDB) is a repository where allelic variations are described and assigned within a specific gene locus. The purposes of an MDB may vary greatly and have different content and structure. The curator of an electronic and computer-based MDB will provide expert feedback (clinical and research). This requires ethical guideposts. Going to direct on-line public access for the content of an MDB or to interactive communication also raises other considerations. Currently, HUGO's MDI (Mutation Database Initiative) is the only integrated effort supporting and guiding the coordinated deployment of MDBs devoted to genetic diversity. Thus, HUGO's ethical "Statements" are applicable. Among the ethical principles, the obligation of preserving the confidentiality of information transferred by a collaborator to the curator is particularly important. Thus, anonymization of such data prior to transmission is essential. The 1997 Universal Declaration on the Human Genome and Human Rights of UNESCO addresses the participation of vulnerable persons. Researchers in charge of MDBs should ensure that information received on the testing of children or incompetent adults is subject to ethical review and approval in the country of origin. Caution should be taken against the involuntary consequences of public disclosure of results without complete explanation. Clear and enforceable regulations must be developed to protect the public against misuse of genetic databanks. Interaction with a databank could be seen as creating a "virtual" physician-patient relationship. However, interactive public MDBs should not give medical advice. We have identified new social ethical principles to govern different levels of complexity of genetic information. They are: reciprocity, mutuality, solidarity, and universality. Finally, precaution and prudence at this early stage of the MDI may not only avoid ethically inextricable conundrums but also provide for the respect for the rights and interests of all those involved. Copyright 2000 Wiley-Liss, Inc.

5)Forum (Genova) 1999 Jul-Dec;9(3 Suppl 3):88-92
Biotechnologies and predictive medicine: legal aspects.

Fucci S

Consigliere della Corte di Appello, Milano.

Scientific progress in molecular biology and genetics is now providing the medical field with new OtoolsO for diagnosis of possible gene alterations which may be connected with the risk of disease later in life. The development of predictive medicine incurs novel problems in the relationship of the medical doctor and the individual at risk of disease, with particular reference to the identification of situations in which genetic testing may be relevant, the type of information which one should give the individual in order to have the informed consent for the diagnosis and the type of possible therapy taking into account the confidential aspect of using the data produced. These problems are exmined in the light of ethical citations and guidelines which are included in the National Comittee for Bioethics in Gene Therapy, 1991, the Italian privacy law, 1996, the European Convention on Bioethics, 1996, the 98/44/CE Directive on the Patentability of Biotechnological Inventions and the Deontological Medical Code, 1998.

6)JAMA 1999 Nov 24;282(20):1947-52
Challenges to human subject protections in US medical research.

Woodward B

Department of Philosophy, Brandeis University, Waltham, Mass 02454, USA.

United States regulations governing federally supported research with human subjects derive in part from 2 international codes, the Nuremberg Code and the Declaration of Helsinki. The Declaration of Helsinki states that "concern for the interests of the subject must always prevail over the interests of science and society." The concept of minimal risk and the principle of informed consent are the key means by which US federal regulations seek to protect the rights and welfare of the individual in the research setting. Current trends in medical research-including increased funding, ever-greater capabilities of computers, development of new clinical tools that can also be used in research, and new research tools developed through research itself are creating greater demand for human subjects, for easier recruitment and conscription of these subjects, and for unimpeded access to patient medical records and human biological materials. Nationally and internationally, there are new pressures to subordinate the interests of the subject to those of science and society. The National Bioethics Advisory Commission, which is about to undertake a comprehensive review of the US system of human subject protections, faces a daunting task.

7)Health Law J 1996;4:259-82
Roles and fictions in clinical and research ethics.

Weisstub DN

Faculte de medicine, Universite de Montreal, Quebec.

8)Nat Genet 1999 Nov;23(3):275-80
Protecting communities in research: current guidelines and limits of extrapolation.

Weijer C, Goldsand G, Emanuel EJ

Department of Bioethics, Dalhousie University, Halifax, Nova Scotia, Canada. Charles.Weijer@dal.ca

As genetic research increasingly focuses on communities, there have been calls for extending research protections to them. We critically examine guidelines developed to protect aboriginal communities and consider their applicability to other communities. These guidelines are based on a model of researcher-community partnership and span the phases of a research project, from protocol development to publication. The complete list of 23 protections may apply to those few non-aboriginal communities, such as the Amish, that are highly cohesive. Although some protections may be applicable to less-cohesive communities, such as Ashkenazi Jews, analysis suggests substantial problems in extending these guidelines in toto beyond the aboriginal communities for which they were developed.

9)J Med Ethics 1999 Oct;25(5):404-7
Bioethics regulations in Turkey.

Aydin E

Department of Medical Ethics, Hacettepe University, Ankara, Turkey.

Although modern technical and scientific developments in medicine are followed closely in Turkey, it cannot be claimed that the same is true in the field of bioethics. Yet, more and more attention is now being paid to bioethics and ethics training in health sciences. In addition, there are also legal regulations in bioethics, some of which are not so new. The objective of these regulations is to provide technical and administrative control. Ethical concerns are rather few. What attracts our attention most in these regulations is the presence of the idea of "consent".

10)Biol Psychiatry 1999 Oct 15;46(8):1106-19
Ethical dimensions of psychiatric research: a constructive, criterion-based approach to protocol preparation. The Research Protocol Ethics Assessment Tool (RePEAT).

Roberts LW

Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque 87131, USA.

Preparing experimental protocols that are ethically sound, possess scientific merit, and meet institutional and national standards for human subject protections is a key responsibility of psychiatric investigators. This task has become increasingly complex due to developments in biomedical science, bioethics, and society at large. Practical and constructive approaches to help investigators in their efforts to create protocols that are ethically acceptable have nevertheless received little attention. To better address this gap, the Research Protocol Ethics Assessment Tool (RePEAT) was developed as an educational instrument to help assure that ethically important elements, including scientific design features, are explicitly addressed by investigators in their work with protocols involving human participants. The RePEAT is a brief evaluative checklist that reflects rigorous ethical standards, particularly with respect to criteria for studies that may involve individuals with compromised decisional abilities. For this reason, it may be especially beneficial as a self-assessment tool for investigators and protocol reviewers in psychiatry. To stimulate education and dialogue, this report presents the RePEAT and outlines its content, format, use, and limitations.

11)Science 1999 Aug 27;285(5432):1359-61
Privacy in genetics research.

Fuller BP, Kahn MJ, Barr PA, Biesecker L, Crowley E, Garber J, Mansoura MK, Murphy P, Murray J, Phillips J, Rothenberg K, Rothstein M, Stopfer J, Swergold G, Weber B, Collins FK, Hudson KL

12)Zentralbl Chir 1999;124(7):636-40
[Xenotransplantation from the ethical viewpoint. An outline].

Beckmann JP

Institut fur Philosophie, Fern-Universitat Hagen.

The duty to save and to preserve lives on one hand, and the scarcity of human donor organs on the other hand call for a search for new organ sources, including xenogenic ones. Xenotransplantation, however, is not only in need of medical research, but also of ethical analysis. The latter is not to be considered a substitute for moral intuition, but rather a foundation of it by way of a critical evaluation of the ethical principles and reasons involved. This basically demands an analysis of the legitimacy of the aims and of the acceptability of the means for xenotransplantation. It includes safeguarding informed consent; risk assessment and the protection of not only the recipient, but also others; the question of limitation of personal rights; allocation problems; and last but not least animal protection. The aim is to clarify the ethical status of xenotransplantation in general and the question of a moratorium regarding clinical trials due to unsolved problems of infectivity and immunosuppression in particular by way of an integrative approach to both scientific developments and ethical analysis.

13)J Clin Pathol 1999 Apr;52(4):254-6
Supplying commercial biomedical companies from a human tissue bank in an NHS hospital--a view from personal experience.

Gray N, Womack C, Jack SJ

Department of Histopathology, Peterborough District Hospital, UK.

NHS histopathology laboratories are well placed to develop banks of surgically removed surplus human tissues to meet the increasing demands of commercial biomedical companies. The ultimate aim could be national network of non-profit making NHS tissue banks conforming to national minimum ethical, legal, and quality standards which could be monitored by local research ethics committees. The Nuffield report on bioethics provides ethical and legal guidance but we believe that the patient should be fully informed and the consent given explicit. Setting up a tissue bank requires enthusiasm, hard work, and determination as well as coordination between professionals in the NHS trust and in the commercial sector. The rewards are exiting new collaborations with commercial biomedical companies which could help secure our future.

14)Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Jul;34(7):396-401
[Informing the patient--but how? Ethics and theory of patient information].

Maio G

Institut fur Medizin- und Wissenschaftsgeschichte, Medizinische Universitat zu Lubeck. maio@imwg.mu-luebeck.de

Informed consent is one of the most discussed topics of bioethics. This new emphasis on seeking patient's consent is due to the fact that since the 1960s there has been a considerable change in the ideal of patient-physician relationship. There has been an important shift from a physician-based commitment of promoting well-being to a patient-based right of information arising from individual autonomy instead of a Hippocratic paternalism. Consent requirement is ethically derived from the duty to treat persons as ends, not merely as means. So the physician has a special moral obligation to assure the patient's moral agency by reducing the inequality in information between patient and physician. Therefore a morally valid consent has to be a continuing process rather than a singular event.

15)J Med Ethics 1999 Aug;25(4):293-5
Bioethics in and from Asia.

Macer D

16)Nature 1999 Jul 22;400(6742):307-8
Ethics of population genomics research.

Gulcher JR, Stefansson K

17)Emerg Med Clin North Am 1999 May;17(2):283-306, ix
Principles of biomedical ethics.

Iserson KV

Department of Surgery, University of Arizona College of Medicine, Tucson, USA.

Ethics is the application of values and moral rules to human activities. Bioethics is a subsection of ethics, actually a part of applied ethics, that uses ethical principles and decision making to solve actual or anticipated dilemmas in medicine and biology. This article focuses on the primary principles of biomedical ethics and their implications for physicians in the ED.

18)Pediatrics 1999 Aug;104(2 Pt 1):337-40
Sterilization of minors with developmental disabilities. American Academy of Pediatrics. Committee on Bioethics.

Sterilization of persons with developmental disabilities has often been performed without appropriate regard for their decision-making capacities, abilities to care for children, feelings, or interests. In addition, sterilization sometimes has been performed with the mistaken belief that it will prevent expressions of sexuality, diminish the chances of sexual exploitation, or reduce the likelihood of acquiring sexually transmitted diseases. A decision to pursue sterilization of someone with developmental disabilities requires a careful assessment of the individual's capacity to make decisions, the consequences of reproduction for the person and any child that might be born, the alternative means available to address the consequences of sexual maturation, and the applicable local, state, and federal laws. Pediatricians can facilitate good decision-making by raising these issues at the onset of puberty.

19)J Clin Ethics 1999 Spring;10(1):66-75
Legal trends in bioethics.

Forster HP

Case Western Reserve University School of Medicine and School of Law, Cleveland, Ohio, USA.

20)P R Health Sci J 1999 Mar;18(1):31-7
Bioethics committees--a health communication approach.

Fabregas SM, Kreps GL

School of Pharmacy, Medical Sciences Campus, University of Puerto Rico. S_FABREGAS@RCMACA.UPR.CLU.EDU

The modern health care system is being transformed as a consequence of scarce resources and better informed consumers. In this transformed health care system human communication has become a crucially important process. This essay examines the health communication functions performed by bioethics committees in health care delivery and makes recommendations for promoting the effective use of these groups within the modern health care system. The essay describes how bioethics committee can help establish a climate in which physicians and other committee members can share relevant health information, learn about patient and family concerns, promote health education and informed consent, and facilitate effective decision making about complex health care practice issues. It is argued that clear recognition and attention to the central role of effective communication within the bioethics committee is essential for the survival of the modern health care system since ethics committees depend on sharing relevant information to diagnose health problems, provide health care, promote health education, help in the formulation of new health care policies, and provide much-needed decision-making support to health care providers and consumers. The role that health communication expertise can perform in the effective operation and utilization of bioethics committees is described. We conclude that in order to provide needed support in addressing the many complexities of modern health care, bioethics committees must develop clear communication processes, norms, and roles.

Volver


Transplantación de Organoss

1) Presse Med 1999 Sep 25;28(28):1522-4

[Re-examination of the bioethics law of 1999: reflections and propositions. Group on Ethical Aspects of Transplantation].

[Article in French]

THE FRENCH LAW ON BIO-ETHICS BEING REVISITED: The GRET (Group on ethical aspects of transplantation) makes a series of proposals in order to update some articles of the law, this being considered as a considerable progress. BONE MARROW GRAF: The new concept of graft of "Hematopoietic stern cells" including their different sources, better reflects the current practice, remaining considered basically as an organ. ORGAN TRANSPLANTATION, WITH LIVING DONOR: The extension to new categories of donors is proposed, with, however, the creation of a multidisciplinary committee of experts and representatives of the society in charge of the evaluation of the motivations, with objective criteria. ORGAN TRANSPLANTATION, DECEASED DONOR: A better information of the public, together with the help of Associations is proposed, and the creation of help units in order to provide support for family members, who come in emergency as witnesses and greatly need support and help.

2) Theor Med Bioeth 1999 Jun;20(3):261-73

The dream of consensus: finding common ground in a bioethical context.

Koch T, Rowell M

Hospital for Sick Children, Department of Bioethics, Toronto, Ontario, Canada.

Consensus is the holy grail of bioethics, the lynch pin of the assumption that well informed, well intentioned people may reach generally acceptable positions on ethically contentious issues. It has been especially important in bioethics, where advancing technology has assured an increasing field of complex medical dilemmas. This paper results on the use of a multicriterion decision making system (MCDM) analyzing group process in an attempt to better define hospital policy. In a pilot program at The Hospital for Sick Children, Toronto, a series of small scale focus groups was constituted to examine criteria defining organ transplant eligibility. Criteria were organized hierarchically using the Analytic Hierarchy Process, an MCDM approach, and the resulting data was analyzed using Expert Choice 9.0, software designed to facilitate AHP analysis. Qualitative and quantitative analysis map barriers to practical consensus in a way not previously possible.

3) Presse Med 1999 Jul 3-10;28(24):1296-301

[Organ procurement and transplantation: a public health mission for the year 2000].

[Article in French]

Vallee JP

Organ procurement is the limiting factor in cadaver organ transplantation in France. The number of organs currently available is insufficient to meet demands while there are a sufficient number of potential donors. This critical situation has created difficult problems at all levels of the transplantation process: long waiting lists, discouraged patients, use of grafts of limited quality, selection of candidates on the basis of uncertain scientific criteria due to the lack of choice. This unsatisfactory situation after 30 years of successful transplantation raises many unanswered questions for decision makers including political leaders (the 1994 bioethics law will be revisited in this summer's session of parliament), health professionals (selection of candidates), hospital administrators (planning hospital structures) and ordinary individuals who are called upon to think about their own death. According to the data from the French graft control center, organs are not procured from approximately half of subjects in a state of brain death, because of refusal in 1 out of 3 cases. What is the meaning of this refusal? Solutions are available, what is lacking appears to be the will to solve the problem.

4) J Clin Ethics 1999 Spring;10(1):66-75

Legal trends in bioethics.

Forster HP

Case Western Reserve University School of Medicine and School of Law, Cleveland, Ohio, USA.

5) Ann Transplant 1998;3(3):59-61

Xenotransplantation. Ethics and rights: an interaction.

Aluwihare AP

University of Peradeniya, Sri Lanka. aluwihare@hantana.pdn.ac.lk

6) Ann Transplant 1998;3(3):55-8

Organ transplantation and brain-death in Japan. Cultural, legal and bioethical background.

Kimura R

Waseda University, Tokyo, Japan. rihitok@mxy.meshnet.or.jp

7) Ann Transplant 1998;3(3):38-41

Rights and ethics in transplantation: perspectives.

Aluwihare AP, Sheriffdeen AH

University of Peradeniya, Peradeniya, Sri Lanka. aluwihare@hantana.pdn.ac.lk

8) Transplant Proc 1999 Feb-Mar;31(1-2):1349-51

Professional attitudes to bioethical issues ration the supply of "marginal living donor" kidneys for transplantation.

Donnelly PK, Henderson R, Price D

EUROTOLD Secretariat, University of Leicester, UK.

9) Transplant Proc 1999 Feb-Mar;31(1-2):1342-4

Ethical issues in pediatric liver transplantation.

Superina RA, Harrison C, Alonso EM, Whitington PF

Liver Transplant Program, Children's Memorial Hospital, Chicago, Illinois 60614, USA.

10) Transplant Proc 1999 Feb-Mar;31(1-2):1322-3

Living renal donor health eligibility: a European "best practice" protocol?

Donnelly PK, Henderson R, Price D

EUROTOLD Secretariat, University of Leicester, UK.

11) Transplant Proc 1999 Feb-Mar;31(1-2):1317-9

Organ transplantation and the human revolution.

Awaya T

Tokuyama University, Sociology of Medical Law Office, Department of Economics, Japan.

12) J Clin Ethics 1998 Winter;9(4):421-30

Legal trends in bioethics.

Forster HP

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

13) Ann Transplant 1998;3(2):38-45

Attitudes to xenotransplantation: scientific enthusiasm, assumptions and evidence.

Mohacsi PJ, Thompson JF, Quine S

Department of Public Health & Community Medicine, University of Sydney, Australia.

The use of xenografts could relieve the chronically inadequate supply of human organs for transplantation, but doubts have been expressed about the general acceptability of transplanting animal organs into human. Some researchers and clinicians have chosen to ignore negative attitudes towards clinical xenotransplantation, assuming that people will automatically embrace this new technology when it becomes available. A review of eight studies of attitudes to xenotransplantation did not reveal overwhelming support for it. Particularly negative views were expressed by acute care nurses. Primates have been the donors of choice in clinical xenotransplantation to date, but their continued use is a highly contentious option; the preferred animal donor is now clearly the pig. Animal farming for xenotransplantation is generally regarded as acceptable since animals provide food for man and are an accepted source of items for human use such as heart valves and insulin. Open debate about xenotransplantation must now take place, and present attitudes may change as a result of this. However, it remains to be seen whether xenografts will be widely accepted and used, and the extent to which the chronic shortage of organs for transplantation will thereby be alleviated.

14) Transplant Proc 1998 Aug;30(5):2463-4

Ethical aspects in xenotransplantation.

Cortesini R

Universita di Roma La Sapienza, Italy.

15) Nature 1998 Aug 6;394(6693):513

Xenotransplant experts face good and bad news.

Masood E

16) Wiad Lek 1995 Jan-Jun;48(1-12):75-8

industrialized society].[Bioethical aspects of ecology and medicine in an

[Article in Polish]

Grabski J

Ambulatorium Medycznego w Lengenfeld, Dusseldorfu.

17) J Med Ethics 1998 Apr;24(2):127-33

An anthropological exploration of contemporary bioethics: the varieties of common sense.

Turner L

Hastings Center, New York, USA.

Patients and physicians can inhabit distinctive social worlds where they are guided by diverse understandings of moral practice. Despite the contemporary presence of multiple moral traditions, religious communities and ethnic backgrounds, two of the major methodological approaches in bioethics, casuistry and principlism, rely upon the notion of a common morality. However, the heterogeneity of ethnic, moral, and religious traditions raises questions concerning the singularity of common sense. Indeed, it might be more appropriate to consider plural traditions of moral reasoning. This poses a considerable challenge for bioethicists because the existence of plural moral traditions can lead to difficulties regarding "closure" in moral reasoning. The topics of truth-telling, informed consent, euthanasia, and brain death and organ transplantation reveal the presence of different understandings of common sense. With regard to these subjects, plural accounts of "common sense" moral reasoning exist.

Comment in: J Med Ethics 1998 Dec;24(6):414

18) Tijdschr Diergeneeskd 1997 Nov 15;122(22):628-30

[Pigs as source animals for humans].

[Article in Dutch]

Sybesma W

Afdeling biotechnologische vraagstukken, Raad voor Dierenaangelgenheden.

This article reviews the current status of animal-to-human organ transplantation (xenotransplantion). In addition to immunological problems and the risk of disease, ethical issues with regard to both donor animals and humans make this technique not yet practicable. From further progress of this essentially veterinary development veterinary medicine and research will benefit.

19) Nippon Hoigaku Zasshi 1997 Oct;51(5):356-66

[The research and practice of legal medicine in human society].

[Article in Japanese]

Katsumata Y

Department of Legal Medicine, Nagoya University School of Medicine, Japan.

Researchers in legal medicine have often been asked to solve legal problems specifically related to medicine. Recently, breakthrough medical techniques such as organ transplantation from brain dead patients or gene therapy have attracted much attention, and their practice requires interaction with society. Since most universities do not have a department of medical ethics, the role of legal medicine for the dialogue between medicine and society is becoming more and more important. This paper seeks to address some specific issues and to review some of my research in an attempt to have an ongoing dialogue with society. It covers the following four points. 1) Two methods for forensic practice established in our laboratory were introduced. One is a simple spectrophotometric determination of carboxyhemoglobin, very accurate even at low concentration. This method is especially useful for the examination of fire victims. Another is a method for the identification of human urinary stains using uric acid/urea nitrogen quotients, and is useful for the diagnosis of asphyxia. 2) Various approaches of DNA analysis for personal identification or paternity testing established in our laboratory were described. They include DNA typing of HLA class II antigens, microsatellites, and minisatellite variant repeat mapping by polymerase chain reaction (MVR-PCR). 3) Various efforts describing the reliability of DNA testing for court cases in Europe and the United States were presented. Methods proving the reliability of the population data for DNA analysis were also described. Unfortunately, research in this field remains insufficient in Japan. 4) The important role of legal medicine from the standpoint of medical ethics in modern medicine is described, and my research related to medical ethics were reviewed.

Volver


Bioética y Salud Pública

Bailey R.           [
Warning! Bioethics can be hazardous to health.
Med Econ. 1999 Oct 25;76(20):113, 117-8, 120. No abstract available.
Smaglik P.         
As panel seeks help for trial host nations.
Nature. 2000 Jan 20;403(6767):237. No abstract available.
Reynolds T.          
Gene patent race speeds ahead amid controversy, concern.
J Natl Cancer Inst. 2000 Feb 2;92(3):184-6. No abstract available.
Pastoret PP.          
Veterinary vaccinology.
C R Acad Sci III. 1999 Nov;322(11):967-72. Review.
Strauch D.        
[Environmental and animal hygiene--an indispensable subject for veterinary education]?
Berl Munch Tierarztl Wochenschr. 1999 Dec;112(12):418-21. German.
Fetters MD, et al.         
The epidemiology of bioethics.
J Clin Ethics. 1999 Summer;10(2):107-15. Review. No abstract available.
Polkinghorne JC.           
Ethical issues in biotechnology.
Trends Biotechnol. 2000 Jan;18(1):8-10.
Schwarz JK.          
Assisted dying and nursing practice.
Image J Nurs Sch. 1999;31(4):367-73. Review.
Vermeersch E.           
Individual rights versus societal duties.
Vaccine. 1999 Oct 29;17 Suppl 3:S14-7.
Matsuda I.           
Bioethical issues in newborn mass screening: experiences in Japan.
Acta Paediatr Suppl. 1999 Dec;88(432):104-5. Review. No abstract available.
Kenny N.           
One of the best minds of our times.
Hosp Q. 1999 Summer;2(4):45-54. No abstract available.
[No authors listed]          
Renewed violence by animal rights activists who target research labs.
Hosp Secur Saf Manage. 1999 Aug;20(4):13-4. No abstract available.
Gibbs N.           [
If we have it, do we use it?
Time. 1999 Sep 13;154(11):59-60. No abstract available.
Lemonick MD.          
Smart genes?
Time. 1999 Sep 13;154(11):54-8. No abstract available.
Nielen M, et al.          
Spatial and stochastic simulation to evaluate the impact of events and control measures on the 1997-1998 classical swine fever epidemic in The Netherlands. II. Comparison of control strategies.
Prev Vet Med. 1999 Dec 1;42(3-4):297-317.
Stegeman A, et al.          
Quantification of the transmission of classical swine fever virus between herds during the 1997-1998 epidemic in The Netherlands.
Prev Vet Med. 1999 Dec 1;42(3-4):219-34.
Gol-Freixa JM, et al.          
[The phenomenon of "evidence-based medicine"].
Med Clin (Barc). 1999;112 Suppl 1:3-8. Review. Spanish.
Gall C.         
Opinion on use of prerace inspection.
J Am Vet Med Assoc. 1999 Oct 15;215(8):1092-3. No abstract available.
Siegler M.          
Ethical aspects of biotechnology applications.
Forum (Genova). 1999 Jul-Dec;9(3 Suppl 3):106-12.
Fucci S.          
Biotechnologies and predictive medicine: legal aspects.
Forum (Genova). 1999 Jul-Dec;9(3 Suppl 3):88-92.
Woodward B.           
Challenges to human subject protections in US medical research.
JAMA. 1999 Nov 24;282(20):1947-52.
Browner CH, et al.           
Ethnicity, bioethics, and prenatal diagnosis: the amniocentesis decisions of Mexican-origin women and their partners.
Am J Public Health. 1999 Nov;89(11):1658-66.
Dixon RM, et al.           
UK screening programme for canine autoimmune thyroiditis.
Vet Rec. 1999 Oct 16;145(16):472. No abstract available.
Winsnes R, et al.          
Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use.
Dev Biol Stand. 1999;101:277-88.
Gaines Das RE, et al.         
Validation of in vitro assays for botulinum toxin: a case study.
Dev Biol Stand. 1999;101:267-76.
Redhead K, et al.          
Veterinary vaccines: In-VITRO--International Veterinary Industry Test Replacement Organisation.
Dev Biol Stand. 1999;101:261-6.
Morton DB.          
Refinement of in vivo tests.
Dev Biol Stand. 1999;101:187-93.
Lemercinier X, et al.        
New methods for the characterisation of biopharmaceuticals: conjugate vaccines against Haemophilus influenzae type b.
Dev Biol Stand. 1999;101:177-83.
Mire-Sluis AR.          
The development of non-animal-based bioassays for cytokines and growth factors.
Dev Biol Stand. 1999;101:169-75.
Cussler K.          
A 4R concept for the safety testing of immunobiologicals.
Dev Biol Stand. 1999;101:121-6. Review.
Kreeftenberg JG.           
Developments in the reduction refinement and replacement of animal tests in the quality control of immunobiologicals.
Dev Biol Stand. 1999;101:13-7. Review. No abstract available.
[No authors listed]          
National Institute of Environmental Health Sciences (NIEHS); the Murine Local Lymph Node Assay: a Test Method for Assessing the Allergic Contact Dermatitis Potential of Chemicals/Compounds, report now available. Public Health Service.
Fed Regist. 1999 Mar 23;64(55):14006-7.
Backlar P.          
Public bioethics and research involving persons with mental disorders.
Community Ment Health J. 1999 Oct;35(5):389-99. No abstract available..
Neel JV.           
Some ethical issues at the population level raised by 'soft' eugenics, euphenics, and isogenics.
Hum Hered. 2000 Jan-Feb;50(1):14-21.
Roberts LW.           
Ethical dimensions of psychiatric research: a constructive, criterion-based approach to protocol preparation. The Research Protocol Ethics Assessment Tool (RePEAT).
Biol Psychiatry. 1999 Oct 15;46(8):1106-19. Review.
Wyatt RJ, et al.          
The long-term effects of placebo in patients with chronic schizophrenia.
Biol Psychiatry. 1999 Oct 15;46(8):1092-105.
Carpenter WT Jr.          
The schizophrenia ketamine challenge study debate.
Biol Psychiatry. 1999 Oct 15;46(8):1081-91.
Jeste DV, et al.          
Neuroleptic discontinuation in clinical and research settings: scientific issues and ethical dilemmas.
Biol Psychiatry. 1999 Oct 15;46(8):1050-9. Review.
Vitiello B, et al.        
Integrating science and ethics in child and adolescent psychiatry research.
Biol Psychiatry. 1999 Oct 15;46(8):1044-9.
Nardell EA, et al.           [
Air sampling for tuberculosis- homage to the lowly guinea pig.
Chest. 1999 Oct;116(4):1143-5. No abstract available.
[No authors listed]           
[Re-examination of the bioethics law of 1999: reflections and propositions. Group on Ethical Aspects of Transplantation].
Presse Med. 1999 Sep 25;28(28):1522-4. French.
Lederberg MS.           
Disentangling ethical and psychological issues--a guide for oncologists.
Acta Oncol. 1999;38(6):771-9.
Derenge S, et al.         
Issues surrounding xenotransplantation.
AORN J. 1999 Sep;70(3):428-32.
Margetts B, et al.           
Who or what sets the international agenda for research and public health action?
Public Health Nutr. 1999 Sep;2(3):235-6. No abstract available.
Jayaraman KS.           
Court compensates over activist delay.
Nat Med. 1999 Oct;5(10):1098. No abstract available.
Beckmann JP.        
[Xenotransplantation from the ethical viewpoint. An outline].
Zentralbl Chir. 1999;124(7):636-40. Review. German.
Koch T, et al.          
The dream of consensus: finding common ground in a bioethical context.
Theor Med Bioeth. 1999 Jun;20(3):261-73.
Morris RS.          
The application of economics in animal health programmes: a practical guide.
Rev Sci Tech. 1999 Aug;18(2):305-14. Review.
Dove A.         
Indecision over human pesticide data.
Nat Med. 1999 Sep;5(9):972. No abstract available.
Oxenham GJ.         
Tuberculosis in cattle and badgers.
Vet Rec. 1999 Jul 31;145(5):146-7. No abstract available.
Capner CA, et al.          
Current British veterinary attitudes to perioperative analgesia for dogs.
Vet Rec. 1999 Jul 24;145(4):95-9.
Nys H.           
The difficult search for an equilibrium between data protection and (public) health protection.
Acta Clin Belg. 1999 Jun;54(3):137-40. No abstract available.
Frank MW, et al.         
Virginity examinations in Turkey: role of forensic physicians in controlling female sexuality.
JAMA. 1999 Aug 4;282(5):485-90.
Vallee JP.        
[Organ procurement and transplantation: a public health mission for the year 2000].
Presse Med. 1999 Jul 3-10;28(24):1296-301. French.
Kirby M.         
The right to health fifty years on: still skeptical?
Health Hum Rights. 1999;4(1):6-25.
Miller FG, et al.           
Protecting vulnerable research subjects without unduly constraining neuropsychiatric research.
Arch Gen Psychiatry. 1999 Aug;56(8):701-2; discussion 703-4. No abstract available.
Charney DS.           
The National Bioethics Advisory Commission report: the response of the psychiatric research community is critical to restoring public trust.
Arch Gen Psychiatry. 1999 Aug;56(8):699-700. No abstract available.

Childress JF, et al.          
Almost persuaded: reactions to Oldham et al.
Arch Gen Psychiatry. 1999 Aug;56(8):697-8. No abstract available.
Oldham JM, et al.           
Protection of persons with mental disorders from research risk: a response to the report of the National Bioethics Advisory Commission.
Arch Gen Psychiatry. 1999 Aug;56(8):688-93.
Landau RE.        
A survey of teaching and implementation: the veterinarian's role in recognizing and reporting abuse.
J Am Vet Med Assoc. 1999 Aug 1;215(3):328-31.
.
Gulcher JR, et al.         
Ethics of population genomics research.
Nature. 1999 Jul 22;400(6742):307-8. No abstract available.
Asch DA.           
From boardroom to bedside: bioethical implications of policy research for clinical practice. J Investig Med. 1999 Jul;47(6):273-7. No abstract available.
Schmut O, et al.          
[Quantifying the damage to conjunctival and corneal cell cultures caused by uv light using CASY (Cell Analysis System). A method for reducing animal experiments].
Ophthalmologe. 1999 Jun;96(6):375-81. German.
Marshall E.
Beryllium screening raises ethical issues.
Science. 1999 Jul 9;285(5425):178-9. No abstract available.
[No authors listed]           
Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis.
Arch Intern Med. 1999 Jul 26;159(14):1529-39. Review.
Inch C, et al.        
[Report on the state of animal sanitation in Canada].
Can Vet J. 1999 Jul;40(7):509-13. French. No abstract available.
Gulcher J, et al.           
An Icelandic saga on a centralized healthcare database and democratic decision making.
Nat Biotechnol. 1999 Jul;17(7):620. No abstract available.
[No authors listed]         
Weighing the benefits against the costs: the welfare implications of biotechnology.
Vet Rec. 1999 Jun 12;144(24):655-7. No abstract available.
Mouttotou N, et al.         
Foot lesions in finishing pigs and their associations with the type of floor.
Vet Rec. 1999 Jun 5;144(23):629-32.
Forster HP.          
Legal trends in bioethics.
J Clin Ethics. 1999 Spring;10(1):66-75. Review. No abstract available.
Ross JW.         
The Task Force report: comprehensible forest or unknown beetles?
J Clin Ethics. 1999 Spring;10(1):26-33. No abstract available.
Edwards DS, et al.
Welfare implications of sheep ear tags.
Vet Rec. 1999 May 29;144(22):603-6.
Marshall E.
Shutdown of research at Duke sends a message.
Science. 1999 May 21;284(5418):1246. No abstract available.
Rochlitz I.
Welfare of animals in quarantine.
Vet Rec. 1999 May 15;144(20):568. No abstract available.
Kaushik A, et al.
Need for research in companion animal vaccinology.
Can Vet J. 1999 Jun;40(6):381-2. No abstract available.
Bessant C.
Welfare of animals in quarantine.
Vet Rec. 1999 May 1;144(18):512. No abstract available.
Heusser P.
[Problems of study designs with randomization, blinding and placebos].
Forsch Komplementarmed. 1999 Apr;6(2):89-102. German.
Paxton A.
How regulatory agencies are addressing genetic testing.
CAP Today. 1999 Feb;13(2):44. No abstract available.
Goody S.
Welfare of animals in quarantine.
Vet Rec. 1999 Apr 17;144(16):456. No abstract available.
Grandin T, et al.
Prevalence of severe welfare problems in horses that arrive at slaughter plants.
J Am Vet Med Assoc. 1999 May 15;214(10):1531-3.
[No authors listed]       
Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services (Part II). World Health Organization, Human Genetics Programme.
Law Hum Genome Rev. 1998 Jul-Dec;(9):239-51. No abstract available.
Sebatier S.  
Ethical questions raised by human genetics. A personal contribution to the preparation of a legal instrument of the Council of Europe on human genetics (Part II).
Law Hum Genome Rev. 1998 Jul-Dec;(9):211-32. No abstract available.
Palsson B, et al.  
Genetic databases. Decoding developments in Iceland.
Nat Biotechnol. 1999 May;17(5):407. No abstract available.
Arluke A.
Uneasiness among laboratory technicians.
Occup Med. 1999 Apr-Jun;14(2):305-16.
Morrow WE.
Euthanasia hazards.
Occup Med. 1999 Apr-Jun;14(2):235-46. Review.
Boinski S, et al.  
Environmental enrichment of brown capuchins (Cebus apella): behavioral and plasma and fecal cortisol measures of effectiveness.
Am J Primatol. 1999;48(1):49-68.
Patronek GJ.    
Hoarding of animals: an under-recognized public health problem in a difficult-to-study population.
Public Health Rep. 1999 Jan-Feb;114(1):81-7.
Fears R, et al.    
Policy forum: health care delivery. Building populations genetics resources using the U.K. NHS.
Science. 1999 Apr 9;284(5412):267-8. No abstract available.
Larkin GL.         
Evaluating professionalism in emergency medicine: clinical ethical competence.
Acad Emerg Med. 1999 Apr;6(4):302-11. Review.
[No authors listed]   
Fetal therapy-ethical considerations. American Academy of Pediatrics. Committee on Bioethics.
Pediatrics. 1999 May;103(5 Pt 1):1061-3.
Greenberg DS.         
Hidden data and abuse in research come to light in the USA.
Lancet. 1997 Oct 11;350(9084):1083. No abstract available.
Gulland FM.   
Stranded seals: important sentinels.
J Am Vet Med Assoc. 1999 Apr 15;214(8):1191-2. Review. No abstract available.
Bossart GD.  
The Florida manatee: on the verge of extinction?
J Am Vet Med Assoc. 1999 Apr 15;214(8):1178-83. Review. No abstract available.
Nuwaysir EF, et al.        
Microarrays and toxicology: the advent of toxicogenomics.
Mol Carcinog. 1999 Mar;24(3):153-9. Review.
Harding D.
Health of dogs purchased from animal rescue centres.
Vet Rec. 1999 Feb 27;144(9):243. No abstract available.
Smith GP 2nd, et al.  
Genetic determinism or genetic discrimination?
J Contemp Health Law Policy. 1994 Fall;11(1):23-61. No abstract available.
Kirby M.  
The Human Genome Project--promise and problems.
J Contemp Health Law Policy. 1994 Fall;11(1):1-21. No abstract available.
Swanson JC.  
What are animal science departments doing to address contemporary issues?
J Anim Sci. 1999 Feb;77(2):354-60.
Lichtman AH.  
The up-and-down method substantially reduces the number of animals required to determine antinociceptive ED50 values.
J Pharmacol Toxicol Methods. 1998 Aug;40(2):81-5.
Schlegel PN.  
Debate: is ICSI a genetic time bomb? No: ICSI is safe and effective.
J Androl. 1999 Jan-Feb;20(1):18-22. No abstract available.

Volver